Pharmacokinetics and Therapeutic Uses of Mesna by Cutler, Murray J
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
November 2010 
Pharmacokinetics and Therapeutic Uses of Mesna 
Murray J. Cutler 
The University of Western Ontario 
Supervisor 
Dr. David J. Freeman 
The University of Western Ontario 
Graduate Program in Pharmacology and Toxicology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Murray J. Cutler 2010 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Pharmacology Commons 
Recommended Citation 
Cutler, Murray J., "Pharmacokinetics and Therapeutic Uses of Mesna" (2010). Electronic Thesis and 
Dissertation Repository. 28. 
https://ir.lib.uwo.ca/etd/28 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
PHARMACOKINETICS AND  
THERAPEUTIC USES OF MESNA 
(Spine Title: Pharmacokinetics and Therapeutic Uses of Mesna) 
(Thesis Format: Integrated-Article) 
By 
Murray J. Cutler 
 
Department of Physiology and Pharmacology 
Graduate Program 
In 
Pharmacology and Toxicology 
Submitted in partial fulfillment 
of the requirement for the degree of 
Doctor of Philosophy 
 
 
School of Graduate and Postdoctoral Studies  
The University of Western Ontario 
London, Ontario 
November, 2010 
 
 
 © Murray J. Cutler, 2010 
ii 
THE UNIVERSITY OF WESTERN ONTARIO 
 SCHOOL OF GRADUATE AND POSTDOCTORAL STUDIES 
 
 
CERTIFICATE OF EXAMINATION 
 
 
Supervisor 
 
______________________________  
Dr. David Freeman  
 
 
Supervisory Committee 
 
______________________________  
 
______________________________  
 
Examiners 
 
______________________________  
Dr. Timothy Renault 
 
______________________________  
Dr. James Koropatnick 
 
______________________________  
Dr. Subrata Chakrabarti 
 
______________________________  
Dr. Andrea Edginton 
 
 
 
 
The thesis by 
 
 
Murray John Cutler 
 
entitled: 
 
Pharmacokinetics and Therapeutic Uses of Mesna 
 
is accepted in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy 
  
 
 
Date__________________________ _______________________________ 
Chair of the Thesis Examination Board 
  
 
 
 
iii 
ABSTRACT 
In the early 1980s, significant advancement in the safety of ifosfamide therapy 
was achieved by co-administrating mesna (sodium 2-mercaptoethane sulfonate) to 
prevent dose-limiting hemorrhagic cystitis. Mesna exerts its protective effect within the 
urine, where its free sulfhydryl group is able to conjugate cytotoxic metabolites. Within 
the circulation, however, mesna exists primarily as its inactive disulfide, dimesna. 
Dimesna is currently undergoing clinical development as a prodrug (BNP7787) to treat 
cisplatin-induced nephrotoxicity. Remarkably, chemoprotection is achieved without 
attenuation of efficacy of co-administered anti-cancer agents. This is widely attributed to 
the kidney-specific disposition and stability of dimesna. 
We sought to evaluate the role of drug transporters in the disposition of dimesna. 
In vitro screens of uptake and efflux transporters identified putative mechanisms of apical 
and basolateral uptake of dimesna and subsequent secretion of mesna into renal tubules. 
Administration of the renal drug transporter inhibitor probenecid to healthy subjects 
significantly increased combined mesna and dimesna plasma exposure while decreasing 
the renal clearance due to secretion and steady-state volume of distribution.  
Chemical reduction of dimesna to mesna is essential for the mitigation of 
ifosfamide- and cisplatin-induced toxicities. In vitro, reduction of dimesna was facilitated 
by redox enzymes of the thioredoxin and glutaredoxin systems and also by non-
enzymatic thiol-disulfide exchange with cysteine and glutathione. These findings 
supported the further investigation of mesna as a thiol exchange agent to lower the toxic 
endogenous thiol amino acid homocysteine (Hcy). 
iv 
Increased plasma total homocysteine (tHcy) is a graded, independent risk factor 
for the development of atherosclerosis and thrombosis. Over 90% of patients with end-
stage renal disease (ESRD) have elevated plasma tHcy. Previous studies have expanded 
the use of mesna to exchange with albumin-bound Hcy, thereby enhancing its dialytic 
clearance. Although an initial pilot study of 12 mg/kg intravenous mesna administered 
predialysis caused a significant decrease in plasma tHcy compared to placebo, prolonged 
treatment had no effect on plasma tHcy. 
Successful therapeutic uses of mesna and dimesna are likely due to their unique 
disposition by renal drug transporters and thiol-disulfide redox equilibrium. Loss of renal 
transporter function due to disease, drug-drug interactions, or genetic variability may 
decrease their therapeutic efficacy. 
 
KEYWORDS 
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CHAPTER 1: INTRODUCTION 
1.1 Mesna Background 
Mesna (sodium 2-mercaptoethane sulfonate, Mistabron®) amongst other thiolate 
compounds N-acetylcysteine (NAC) and S-carboxymethylcysteine, was first developed as 
a potential mucolytic for treatment of impaired mucociliary clearance in diseases such as 
asthma, chronic bronchitis, and cystic fibrosis. As a low molecular weight compound 
with a free sulfhydryl group, it was believed that mesna could reduce disulfide bonds of 
glycoproteins that constituted mucus, thereby reducing its viscosity and easing 
expectoration by patients (Houtmeyers et al., 1999). Despite promising in vitro results 
showing significant sputum-thinning (i.e. mucolytic) activity (Hirsch et al., 1966; Hirsch 
et al., 1969), and case reports of application in intensive care (Van De Walle et al., 1976), 
a clinical trial of aerosolized mesna failed to improve sputum clearance in patients with 
chronic bronchitis compared to isotonic saline aerosol (Clarke et al., 1979). In 
comparison, NAC remains the well-tolerated mucolytic of choice for management of 
sputum in asthma, cystic fibrosis, chronic obstructive pulmonary disease (Rogers, 2007). 
Only after its chemical synthesis was mesna identified as coenzyme M in the 
methanogenic archaea methanobacterium hermoautotrophicum (Taylor & Wolfe, 1974). 
Methylated coenzyme M (2-(methylthio)ethanesulfonic acid) is a cofactor for the 
methylcoenzyme M methylreductase system which acts to reduce carbon dioxide (CO2) 
to methane (CH4) (Rouviere & Wolfe, 1988; Balch & Wolfe, 1979). Coenzyme M is 
essential to this hallmark process allowing methanogens to use CO2 as an electron 
acceptor during metabolism (Fahey, 2001). Later screening revealed that the gram-
negative bacterium Xanthobacter strain Py2 and gram-positive bacterium Rhodococcus 
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rhodochrous strain B276 also possess coenzyme M, where it functions as a cofactors in 
short-chain alkene metabolism (Allen et al., 1999; Krum & Ensign, 2000). Thus, it would 
seem that through their own endogenous production, the methanogens and their recent 
evolutionary prokaryotic relatives were the first to exploit the nucleophilicity and redox 
properties of mesna as coenzyme M. 
 
1.2 Mesna for Cancer Chemotherapy 
1.2.1 Mesna 
Cancer treatment requires effective management of not only the disease but also 
the cancer therapy itself.  Chemotherapy-induced toxicities frequently prohibit effective 
quantity and duration of administered doses. Various drugs have been developed to 
control side effects associated with chemotherapy, including erythropoietics for anemia 
(epogen, darbepoetin), antiemetics for nausea and vomiting (e.g. ondansetron, 
aprepitant), and immunostimulators for neutropenia (pegfilgrastim). Failure to provide 
adequate chemoprotection during regimen initiation may mandate withdrawal and 
postponement of treatment (i.e. dose delay), lowering the probability of curative therapy. 
In addition, sustained toxicity can lessen both short- and long-term quality of life of 
cancer survivors (Hensley et al., 1999; Hogle, 2007). 
Ifosfamide is a broad spectrum antineoplastic agent approved for first line 
treatment of cervical cancer, soft tissue sarcomas and second line treatment of pancreatic 
cancer.  In addition, ifosfamide has been widely used in the treatment of refractory germ 
cell tumors and malignant lymphomas (Higgs et al., 1989; Wagner, 1994). Although 
effective against a variety of sarcomas, the initial use of ifosfamide was limited by 
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hemorrhagic cystitis (Brade et al., 1985; Brock et al., 1979b; Cox, 1979), a severe 
urotoxic complication characterized by edema and hematoma of the bladder epithelium 
potentially leading to death (Gray et al., 1986; Watson & Notley, 1973; Philips et al., 
1961). 
Significant advancement in oxazaphosphorine therapy was achieved by the 
introduction of mesna as a chemoprotectant in the late 1970s and early 1980s.  
Concurrent mesna dosing significantly reduced the incidence of hemorrhagic cystitis, the 
previously dose-limiting side effect of the oxazaphosphorines, ifosfamide and 
cyclophosphamide (Andriole et al., 1987; Antman et al., 1985; Fukuoka et al., 1991; 
Kemeny et al., 1987; Scheef et al., 1979; Scheulen et al., 1983; Stuart-Harris et al., 
1983). 
1.2.2 Mesna Preclinical Development 
Development of mesna for uroprotection was undertaken by the Pharmacology 
Department of the German Bielefeld-based Asta-Werke A.G. (now Frankfurt-based 
ASTA Medica A.G.) in the late 1970s, concurrently with an ongoing research program to 
synthesize new alkylating nitrogen mustards (Brock et al., 1981b; Brock, 1989). With 
little success in improving the tumor-specific targeting of new nitrogen mustard 
phosphoramide esters (i.e. oxazaphosphorines), an alternate strategy of combating 
undesired toxicity with adjuvant pharmacological therapies was pursued (Brock et al., 
1981b; Brock, 1989). Mesna emerged as a potent bladder-specific chemoprotectant 
without detriment to the activity of concomitant anticancer drugs (Brock et al., 1982; 
Brock et al., 1979a; Brock, 1978). The successful preclinical development of this 
“pharmacologically unremarkable” compound led to Asta-Werke A.G. becoming wholly 
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acquired by one of Germany’s largest chemical companies, Degussa-Hüls A.G. in 1983 
(now Degussa GmbH of Evonik Industries A.G.) (Brock et al., 1982; Brock, 1989; Wolf, 
1989). 
A variety of pharmacological and ambulatory measures have been used for the 
prophylaxis of renal toxicities. Forced diuresis by intravenous hydration, administration 
of diuretics, and alkalinization remains in practice today (Hensley et al., 2008), while 
organ-specific chemical inactivation of toxic metabolites proved more difficult (Brock et 
al., 1981b). Compounds possessing nucleophilic free sulfhydryl functional groups rapidly 
covalently bind to hydroxylated oxazaphosphorine rings, similar to endogenous thiols 
cysteine (Cys) and glutathione (GSH) (Brock et al., 1988; Hospers et al., 1999; Kurowski 
& Wagner, 1997). However, like these endogenous thiols, early thiol-containing 
compounds such as NAC showed wide tissue distribution (Connors, 1966). As a result, 
not only was renal toxicity attenuated, so too was the effectiveness of anticancer therapy 
(Brock et al., 1979a; Connors, 1966; ISHIDATE et al., 1953). Direct instillation of NAC 
to the bladder via catheterization protected against bladder toxicity, but was clinically 
impractical and was ineffective at protecting the remaining urinary tract (Creaven et al., 
1976; Primack, 1971). 
1.2.2.1 Pharmacodynamics 
 During their work to develop new alkylating agents with greater anticancer 
efficacy and lower toxicity, the Pharmacology Department of Asta-Werke catalogued the 
urotoxicity observed following dosing of each new compound to Sprague-Dawley rats. 
This meticulous work helped determine whether the active alkylating metabolites or other 
breakdown products were responsible for urotoxicity. Direct administration of alkylating 
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agents (e.g. mustards) did not induce renal or urothelial damage, whereas 
oxazaphosphorines capable of forming acrolein (e.g. ifosfamide) induced swelling and 
hemorrhagic foci. Furthermore, direct instillation of metabolites showed only 4-
hydroxyifosfamide and acrolein to be potently urotoxic, providing theoretical targets for 
covalent binding and inactivation by thiols (Brock et al., 1981b; Brock et al., 1979b). 
Through the use of modern enzyme overexpression systems the complete metabolic fate 
of ifosfamide has since been identified (Kerbusch et al., 2001a). 
Ifosfamide is a chiral prodrug that undergoes autoinducible hepatic cytochrome P-
450 (CYP) metabolism to its active mustard (Figure 1.1) (Kerbusch et al., 2001a; Lind et 
al., 1989). Ifosfamide may be metabolized by CYP2B6 to isomers (S)-2-
dechloroethylifosfamide or (S)-3-dechloroethylifosfamide along with the nephrotoxin 
chloroacetaldehyde (Granvil et al., 1999). However, ifosfamide is believed to 
predominantly undergo CYP3A4-mediated metabolism, yielding the reactive metabolite 
4-hydroxyifosfamide. 4-Hydroxyifosfamide spontaneously forms its isomer 
aldoifosfamide which subsequently breaks-down to active ifosfamide mustard and the 
potent urotoxin acrolein (Chang et al., 1993; Walker et al., 1994). 
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Figure 1.1   Metabolism of ifosfamide and mesna. Ifosfamide is a chiral prodrug that 
predominantly undergoes autoinducible CYP3A4-mediated metabolism, yielding the 
reactive metabolite 4-hydroxyifosfamide. 4-Hydroxyifosfamide spontaneously forms its 
isomer aldoifosfamide, which subsequently breaks-down to active ifosfamide mustard 
and the potent urotoxin acrolein. Alternatively, ifosfamide may be metabolized by 
CYP2B6 to isomers (S)-2-dechloroethylifosfamide or (S)-3-dechloroethylifosfamide 
along with the nephrotoxin chloroacetaldehyde. Mesna exerts its protective effect within 
the urine, where its free sulfhydryl group covalently binds 4-hydroxyifosfamide forming 
inactive 4-sulfoethylthioifosfamide. Upon entering the circulation mesna undergoes 
metal-catalyzed autooxidation to dimesna which may be reduced to mesna via thiol 
exchange. 
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Using previously established methods of quantitation of urotoxicity in the rat, the 
ability of an average of three doses of 29 compounds to lower ifosfamide-induced 
urotoxicity was examined. From this screen, only mesna demonstrated the desired 
pharmacological and pharmacokinetic properties. Doses of 6.81 to 21.5 mg/kg IV mesna 
provided significant uroprotection, rapid renal excretion (t1/2 = 1.4 h in rats ), and little 
extra-renal tissue distribution (Brock et al., 1981c), consistent with prior observations of 
[35S]mesna during its development as a mucolytic (Gobert et al., 1971). Mesna exerts its 
protective effect within the urine, where its free sulfhydryl group covalently binds 4-
hydroxyifosfamide forming inactive 4-sulfoethylthioifosfamide. Conjugation with mesna 
may therefore prevent not only the spontaneous formation of urotoxic acrolein, but also 
active ifosfamide mustard (Figure 1.1) (Kurowski & Wagner, 1997; Manz et al., 1985). 
1.2.2.2 Pharmacodynamic Drug Interactions 
To ensure mesna would not interfere with the efficacy of ifosfamide and 
cyclophosphamide at doses required for adequate uroprotection in the rat and mouse, the 
drugs were tested in combination in a variety of tumour models. When used in molar 
ratios of 0.5:1 up to 21.5:1 (mesna:oxazaphosphorine) and given either simultaneously or 
one hour after oxazaphosphorine administration, mesna unequivocally had no effect on 
the survival time of leukaemia L5222, Yoshida’s sarcoma (colorectal cancer), and solid 
DS carcinosarcoma bearing rats or leukaemia L1210 bearing mice. With the increase in 
use of combination chemotherapy, the effect of systemic mesna was also tested against 
other anticancer drugs to ensure it would not reduce their antineoplastic effects. Mesna 
(100 mg/kg administered simultaneously) did not affect survival times conferred by 5-
fluorouracil, cisplatin, doxorubicin, methotrexate or vincristine (Brock et al., 1982). 
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Brock et al. hypothesized that this unique pharmacological profile may be due to its 
hydrophilicity and rapid oxidation to its dimer, dimesna (Brock et al., 1981a; Brock et 
al., 1981c). However the underlying mechanisms of mesna’s disposition remained to be 
investigated. 
1.2.2.3 Safety 
Following promising preclinical pharmacodynamic results establishing mesna as a 
lead compound, more time consuming and expensive toxicological studies of mesna were 
completed. Mesna demonstrated very low toxicity in mice (LD50 = 1968 mg/kg IV), rats 
(LD50 = 1891 mg/kg IV), and beagle dogs (only vomiting and diarrhea at doses 100 - 316 
mg/kg IV). No evidence of embryotoxicity was found in either rats given oral doses up to 
2000 mg/kg or rabbits with oral doses up to 1000 mg/kg. Mesna did not induce reversion 
of growth of Salmonella typhimurium in histidine-free medium (Ames’ test) and thus has 
no detectable mutagenic potential (Brock et al., 1982). Most importantly, the dose 
required for complete prophylaxis of urotoxicity in the rat (21.5 mg/kg,(Brock et al., 
1981c)) is approximately only 1% of the LD50 (1891 mg/kg (Brock et al., 1982)) and 
indicative of a wide therapeutic index. 
1.2.3 Clinical Development 
The clinical efficacy of mesna (ASTA D-7093 now branded Uromitexan™ and 
Mitexan™) and favourable toxicity profile quickly became apparent in a series of clinical 
trials evaluating ifosfamide therapy with mesna. Prior to the addition of mesna to 
ifosfamide therapy, hematuria (blood in the urine; a useful marker of urotoxicity) 
occurred in almost all patients and dose-limiting hemorrhagic cystitis occurred in 18 – 
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40% of patients (Teufel & Pfleiderer, 1976; Czownicki & Utracka-Hutka, 1981; Van Dyk 
et al., 1972; Creaven et al., 1976). 
1.2.3.1 Efficacy 
The efficacy of mesna to significantly lower the incidence of hematuria was first 
demonstrated in a randomized, open-label phase II study of IV mesna alone versus 
standard prophylaxis (approximately 4 L/d IV fluids, furosemide, alkalinization of the 
urine). Although mesna had previously been used as an aerosol for its mucolytic 
properties (Clarke et al., 1979; Van De Walle et al., 1976), the safe limit of systemic 
exposure in humans was unknown. In the absence of FDA guidelines for first-dose in 
human trials, mesna doses were arbitrarily initiated at 66% of total oxazaphosphorine 
dose and decreased to 33% and 17% in subsequent chemotherapy cycles until severe 
hematuria (> 50 rbs/µL urine) appeared. Three mesna doses of 17% and 33% were 
required to eliminate the occurrence of severe hematuria in two separate groups of four 
patients. One patient required three mesna doses of 66%. All nine patients receiving 
standard prophylaxis experienced severe hematuria. Although a dose greater than 17% 
was required in 5 of 9 patients to eliminate severe ifosfamide-induced hematuria, the 
authors concluded by recommending that mesna be administered in three doses of 20% of 
the daily oxazaphosphorine dose (equal to 60% of the daily oxazaphosphorine dose); 
immediately prior and at two and four hours after the start of oxazaphosphorine dosing. 
No differences in tumor response rates were observed between groups (Scheef et al., 
1979). Although this trial design effectively identified the minimally effective dose (51% 
of daily oxazaphosphorine dose) such “dose-reduction” protocols would be considered 
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unethical today, and have subsequently been replaced by pharmacokinetic and allometric 
estimation of the minimally effective dose followed by dose-escalation. 
A daily mesna dose of 60% of the daily oxazaphosphorine dose (administered in 
three equal doses at 0, 4, and 8 hours) recommended by the previous study (Scheef et al., 
1979), was tested again in a small single-blind crossover trial of eight patients with 
bronchogenic carcinoma. Seven of eight patients receiving 2 g/m2/day ifosfamide alone 
experienced hematuria or symptoms of bladder irritation. Only one patient had hematuria 
during concomitant mesna administration. Five patients also completed fifteen courses of 
increased ifosfamide doses of 4 to 8 g/m2/day with mesna. Remarkably, hematuria was 
not seen until after three courses of ifosfamide, at doses known to cause severe toxicity in 
18 of 25 patients and 25% mortality (Bryant et al., 1980; Van Dyk et al., 1972). This 
finding suggested mesna may greatly enhance the feasibility of “high-dose” ifosfamide 
(>2.5 mg/m2/day) (Bryant et al., 1980). Concurrent plasma concentration-time analysis 
revealed mesna had no effect on ifosfamide or mustard pharmacokinetics (Bryant et al., 
1980), consistent with animal studies (Brock et al., 1982). 
 An early retrospective study of 748 patients who received 50 mg/kg/day 
ifosfamide for five days provided a well-powered comparison of mesna (administered at 
60% of the ifosfamide dose divided between 0, 4, and 8 hours) versus standard 
prophylaxis of IV hydration, diuretics and alkalinization. Amongst patients receiving 
mesna, only 3.5% experienced urotoxicity compared to 38% of patients receiving 
standard care (Scheef & Soemer, 1980). Since this study, numerous phase I/II studies 
have consistently demonstrated decreased incidence of oxazaphosphorine-induced 
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urotoxicity with the use of mesna (Andriole et al., 1987; Antman et al., 1985; Kemeny et 
al., 1987; Scheulen et al., 1983; Stuart-Harris et al., 1983). 
Most convincingly, the efficacy of this mesna dosing regimen in addition to 
standard prophylaxis has also been demonstrated in a large double-blind randomized, 
placebo-controlled study involving 91 patients receiving 2 g/m2/day dose ifosfamide. All 
patients received 2 L/day IV fluid and forty-five patients received IV mesna (20% of the 
ifosfamide dose administered at 0, 4, and 8 hours). The incidence of hematuria was 
significantly lower in the mesna group compared to placebo (6.7% with mesna versus 
32.6% with placebo). In a blinded survey of patients, 80% judged receiving mesna to be 
“useful” compared to 34.8% of patients that believed receiving placebo to be beneficial 
(Fukuoka et al., 1991). 
1.2.3.2 Standard Ifosfamide-Mesna IV Therapy 
In light of current research, the American Society of Clinical Oncology (ASCO) 
has recommended guidelines for the use of intravenous mesna with ifosfamide therapy.  
Today mesna and ifosfamide are administered as bolus doses or together in either short 
(0.5 – 8 hours) or continuous (>24 hours) infusions, typically as a five day regimen or 
“cycle”. During bolus dosing, mesna is administered 15 minutes prior to the start of 
ifosfamide infusion, and again 4 and 8 hours following ifosfamide (Hensley et al., 2008). 
Numerous clinical trials over the past three decades have empirically set the total daily 
intravenous mesna dose to 60% of the daily ifosfamide dose. Despite clinically effective 
dosing protocols, the incidence of moderate (hematuria) to severe (renal failure) 
ifosfamide-induced urotoxicity remains 3.5% to 6.7% per chemotherapy cycle, resulting 
in 19.2% to 34.0% of patients experiencing dose-limiting toxicity over the course of 
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treatment of six cycles (Hensley et al., 1999; Hensley et al., 2008; Schuchter et al., 
2002).  
Given the typical ifosfamide dose of 1 to 2.5 g/m2, a single IV bolus dose of 
mesna at 20% of the ifosfamide dose would equate to 0.2 to 0.5 g/m2 or roughly 5 to 12 
mg/kg (Links & Lewis, 1999; Kerbusch et al., 2001a). Mesna doses may safely be 
increased. In humans, doses of 70 to 100 mg/kg IV were free of bone marrow, hepatic, 
and renal toxicities and did not impair CNS functions (Brade, 1987). Vomiting and 
diarrhea were only seen following IV doses greater than 80 mg/kg (Klein et al., 1983). 
Although higher doses and various dosing intervals have been suggested (Brock et al., 
1988), the efficacy of mesna doses in excess of 66% (16 to 40 mg/kg) at a frequency 
greater than four hours remains unknown, and thus optimal dosing schedules remain to be 
determined. 
1.2.3.3  High-Dose Ifosfamide IV Therapy 
The antineoplastic potency of ifosfamide is maintained by dosages up to 16 
g/m2/day (Cerny et al., 1999; Frei, III et al., 1985; Verweij, 1998). To take advantage of 
the steep dose-response relationship high-dose continuous infusion regimens of 
ifosfamide are of growing interest (Kerbusch et al., 2001a; Anderson et al., 2008).  
Continuous infusion avoids “spikes” in plasma concentrations, offering patients lower 
haematological toxicity with less nausea and emesis, compared to short infusions or bolus 
doses. It has been theorized that continuous infusion therapy may also increase efficacy 
of ifosfamide, by virtue of its autoinduction of metabolism to its active mustard 
(Kerbusch et al., 2000; Kerbusch et al., 2001b; Lewis et al., 1990). 
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Evaluation of the standard mesna dosing regimen for ifosfamide doses of 4 – 16 
g/m2/day yielded urotoxicity in 10 – 27% of patients; much higher despite maintaining 
the daily mesna dose proportionality of 60% per day (Elias et al., 1990; Le Cesne et al., 
1995; Sakurai et al., 1986).  As previously highlighted in Figure 1.1, ifosfamide is 
activated to its cytostatic mustard and urotoxic metabolites through a combination of 
spontaneous and autoinducible enzymatic reactions (Kurowski & Wagner, 1993; Lind et 
al., 1989; Wagner, 1994).  Whereas the proportion of toxic metabolites increases during 
the chemotherapeutic cycle (Kerbusch et al., 2001b), the amount of mesna administered 
remains a fixed percentage of the original ifosfamide dose.  This divergence from 
linearity may account for the increased incidence of urotoxicity observed during “high-
dose” continuous infusion ifosfamide (Elias et al., 1990; Le Cesne et al., 1995; Sakurai et 
al., 1986). However, as of yet, no guidelines for mesna doses or dosing schedules to 
accompany continuous infusion of ifosfamide doses in excess of 2.5 g/m2/day have been 
provided by the ASCO, stating insufficient research (Hensley et al., 2008). 
The appropriateness of providing mesna as a percentage of daily ifosfamide 
depends on the assumption that the metabolism and disposition of ifosfamide and mesna 
are proportional, yet ifosfamide and mesna follow different biological fates. 
Unfortunately, there is a dearth of data regarding the mechanisms of mesna disposition, 
and so clinical administration of mesna remains heuristic (Hensley et al., 1999; Hensley 
et al., 2008; Schuchter et al., 2002). 
1.2.3.4 Oral MesnaTherapy 
To facilitate outpatient care during short-infusion chemotherapy, the intravenous 
solution of mesna can be administered orally in Canada, the United States, Germany, and 
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the United Kingdom (Goren, 1996). The development of both continuous infusion and 
oral dosing regimens would enable mesna to be provided as outpatient care, allowing 
patients to spend more time at home, alleviating not only patient stresses of 
hospitalization, but also associated costs of prolonged patient monitoring in clinics. Since 
their approval by the Food and Drug Administration (FDA) in 2002, mesna tablets have 
provide increased patient convenience, with the same bioavailability as IV solution 
(Goren et al., 1998b), while circumventing the poor palatability of the IV solution, likely 
increasing compliance during outpatient care (Cohen et al., 2002). Despite administering 
mesna orally since the early 1980’s (Araujo & Tessler, 1983; Bryant et al., 1980), it is 
widely recognized that an optimal oral mesna dosing regime has yet to be established 
(Cohen et al., 2002; Goren, 1996; Goren et al., 1997; Goren et al., 1998a; Links & Lewis, 
1999; Olver et al., 2005). As a result, in its most recent clinical practice guidelines, the 
ASCO does not provide dosing recommendations for oral mesna in combination with 
ifosfamide infusions exceeding four hours (Hensley et al., 2008). 
 
1.3 Dimesna for Cancer Chemotherapy 
1.3.1  Dimesna 
Similar to the nucleophilic sulfhydryls GSH and NAC, mesna may theoretically 
be beneficial for the mitigation of renal toxicities associated with other anticancer agents. 
Platinum-based anticancer drugs cisplatin (cis-diamminedichloroplatinum), carboplatin 
(cis-diammine(1,1-cylclobutane-dicarboxylato)platinum), and oxaliplatin (1,2-
cyclohexane-1,2-diamine(ethanedioato)platinum) are broad spectrum DNA cross-linking 
agents approved for use against colorectal, non-small-cell lung, ovarian, prostate, and 
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testicular cancers. Although newer platinum-based drugs exhibit some nephrotoxicity, 
cisplatin is the most potent platinum-containing cytostatic agent and hence remains in use 
today despite its dose-limiting nephrotoxicity (Kelland, 2007; Rosell et al., 2002). 
Aggressive prehydration techniques have been developed to combat the nephrotoxicity 
associated with cisplatin, however it remains a significant cause of dose delay (Cvitkovic 
et al., 1977; Kelland, 2007). 
So-called “first-generation” chemoprotectants sodium thiosulfate, 
diethyldithiocarbamate and amifostine, readily conjugate nephrotoxic monohydroxy- and 
monaquo-monochloro species of cisplatin. However, the thiolate of each of these 
chemoprotectants may also covalently bind cisplatin, rendering it inactive prior to tumor 
penetration (Berry et al., 1990; Hausheer et al., 1998; Hospers et al., 1999; Qazi et al., 
1988; Schuchter et al., 1992; Wagner et al., 1988). For this reason cisplatin is 
incompatible with sulfhydryls and must be administered separately, unlike ifosfamide 
and mesna which can be easily infused from the same IV drip (Brock et al., 1988). Mesna 
has previously been used to lessen cisplatin-induced nephrotoxicity in mice with mixed 
results (Kempf & Ivankovic, 1987; Millar et al., 1985). 
 To circumvent conjugation of parental cisplatin and lessen the gastrointestinal 
side effects associated with sulfhydryl compounds, mesna may be instead administered as 
its dimer, dimesna. As a disulfide, dimesna cannot conjugate cisplatin or its hydrated 
reactive metabolites monohydroxo- and monoaqua-cisplatin. Upon entry to organ 
parenchyma, dimesna may be chemically reduced by endogenous thiols (i.e. thiol 
exchange) to active mesna which may form an inactive adduct with intracellular cisplatin 
or its metabolites (Figure 1.2). 
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Figure 1.2   Conjugation of cisplatin and metabolites by mesna. Cisplatin is readily 
hydrated by displacement of chlorine with water to form active monohydroxo and 
monoaqua metabolites. As a disulfide, dimesna cannot conjugate cisplatin or its hydrated 
reactive metabolites. Upon entry to organ parenchyma, dimesna undergoes thiol 
exchange with GSH and Cys yielding active mesna which may form an inactive adduct 
with intracellular cisplatin or its metabolites. 
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1.3.2 Dimesna Preclinical Development 
BioNumerik Pharmaceuticals, Inc. in collaboration with the Vrije Universiteit 
Medical Centre in Amsterdam, Holland have led the development of dimesna (disodium-
2’,2’-dithio-bis-ethane sulfonate) as BNP7787, Tavocept™, for the mitigation of 
cisplatin-associated toxicities. The ongoing goal of their project is to find a patentable 
method to prevent or mitigate common toxicities of anticancer agents without preventing 
their efficacy thereby increasing the therapeutic index of chemotherapy (Hausheer et al., 
2003). 
 Dimesna exerts significantly less toxicity than its reduced sulfhydryl moieties. 
Dimesna doses of up to 4000 mg/kg were nonlethal to rats and dogs. When compared to 
established LD50s of mesna, dimesna demonstrates dose safety ratios in rats and dogs of > 
2.7-fold and > 10-fold, respectively (Brock et al., 1982; Hausheer et al., 1998). 
1.3.2.1 Pharmacodynamic Drug Interactions 
In vitro measurements of the degradation half-lives of cisplatin with dimesna and 
mesna revealed dimesna reacted 5.5-fold slower than mesna. To ensure dimesna would 
not interfere with the efficacy of platinum-based drugs in vivo, dimesna was administered 
in combination with cisplatin and its analogue carboplatin to xenograft-bearing nude 
mice, a standard preclinical model of efficacy in cancer research. Efficacy of bi-weekly 
doses of cisplatin and carboplatin to slow human ovarian cancer cell-derived (OVCAR-3) 
xenografts were unaffected by 1000 mg/kg IV dimesna administered 5 min prior to 
platinum drugs (dimesna:cisplatin molar ratio of 184:1). Cisplatin administered with 
1000 mg/kg IV mesna (mesna:cisplatin molar ratio of 368:1) was slightly, but not 
significantly less effective at slowing tumour growth, however animals receiving mesna 
18 
experienced greater weight loss than those receiving dimesna (Boven et al., 2002). Mixed 
results of previous studies evaluating the effect of mesna on cisplatin activity in tumour-
bearing rodents have also been observed (Brock et al., 1982; Kempf & Ivankovic, 1987; 
Millar et al., 1985). Half of the mice receiving mesna and cisplatin suffered toxicity-
associated death, whereas no death occurred in mice receiving dimesna (Boven et al., 
2002). The corollary of this finding suggests dimesna may facilitate increased cisplatin 
dosing, consistent with observations that cisplatin dose may be safely increased from 6 to 
9 mg/kg when preceded by 750 or 1500 mg/kg dimesna in rats bearing WARD colon 
tumours (Hausheer et al., 1998). 
1.3.2.2 Mechanism of Action 
Cisplatin exerts its nephrotoxic effects through toxification by the γ-
glutamyltranspeptidase (GGT) xenobiotic metabolism pathway. Extensive work by 
Hanigan et al. has determined that cisplatin is glutathionylated both non-enzymatically by 
GSH and enzymatically by glutathione-S-transferase. Glutamate, glycine, and Cys 
residues are then sequentially hydrolyzed from cisplatin-GSH conjugates by GGT, 
aminopeptidase (APN), and finally cysteine-S-conjugate-β-lyase (CCBL) to form 
reactive thiolate-platinum species (Hanigan et al., 1994; Hanigan et al., 1996; Hanigan et 
al., 2001; Townsend et al., 2003). Recent in vitro work by BioNumerik has presented 
multiple mechanisms by which dimesna may prevent formation of these reactive 
nephrotoxins. Mesna, formed by the intracellular reduction of dimesna, may directly bind 
to cisplatin and hydrated metabolites forming conjugates that are unsusceptible to 
metabolism by either GGT or APN. In addition to direct conjugation, findings indicate 
that mesna-disulfide hetero conjugates that contain a terminal γ-glutamate moiety, such 
19 
as mesna-GSH and mesna-cysteinylglutamate, inhibit GGT and APN preventing the 
toxification of cisplatin leading to nephrotoxicity (Hausheer et al., 2010a; Hausheer et al., 
2010b). 
 In addition to dimesna’s application in treating cisplatin-induced nephrotoxicity, 
dimesna may also be useful in the treatment of taxane-induced neurotoxicity. Dimesna 
has been shown to normalize tubulin hyperpolymerization induced by paclitaxel in vitro, 
suggesting dimesna may be useful in preventing unwanted microtubulin dysfunction 
(Hausheer et al., 2000), believed to be a major cause of taxane-induced neuropathy (Lee 
& Swain, 2006). 
1.3.3 Dimesna Clinical Development 
1.3.3.1 Phase I/II 
 In a phase I study dimesna was administered in escalating doses of 4.1 – 41 g/m2 
to 25 patients prior to cisplatin treatment for advance solid tumors. Side effects of 
dimesna were only observed at the highest dose (41 g/m2) and included nausea, vomiting, 
and dysgeusia. Cisplatin pharmacokinetics were not altered by dimesna. Although this 
was a relatively small study, patients receiving > 18.4 g/m2 dimesna required 
significantly less IV hydration, suggesting dimesna may be chemoprotective (Boven et 
al., 2005; Verschraagen et al., 2003a). The efficacy of dimesna with cisplatin and 
docetaxel was further elucidated in a randomized phase II study in 151 patients with 
advanced non-small-cell lung cancer. Patients received 75 mg/m2 cisplatin and 75 g/m2 
docetaxel supported with darbepoetin and pegfilgrastim preceded with or without a fixed 
dose of 40 g dimesna every other week for up to six cycles. The dimesna dose was 
chosen was determined by the average body surface area of patients plus one standard 
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deviation multiplied by the 18.4 g/m2 used by Schilsky et al. (Miller et al., 2008; 
Schilsky et al., 2003). No difference between groups was observed in incidence of 
treatment delays or completion, or objective response rates, however median progression-
free/overall survival times were increased with the addition of dimesna (Miller et al., 
2008). Similar to mesna, it has been hypothesized that dimesna may potentiate the 
efficacy of anticancer agents by depletion of plasma GSH, without altering leukocyte 
GSH (Pendyala et al., 2000; Pendyala et al., 2003). Despite positive in vitro data 
(Hausheer et al., 2000), dimesna was ineffective at reducing neuropathy (Miller et al., 
2008). A second phase I trial of dimesna in patients with non-small-cell lung cancer 
completed by BioNumerik in collaboration with Tokyo-based Grelan Pharmaceutical 
Co., Ltd. (a subsidiary of Osaka-based Takeda Pharmaceutical Co., Ltd.) has recently 
been published. Twenty-one patients received 75 mg/m2 cisplatin and 175 mg/m2 
paclitaxel every three weeks for up to 4 cycles preceded by escalation doses of dimesna 
(4.1 - 41 g/m2). Although dose-limiting toxicities of dimesna were not reached, doses 
exceeding 18.4 g/m2 produced much greater frequency of IV site discomfort, facial 
flushing and dysgeusia (Masuda et al., 2010). A dose of 18.4 g/m2 provides a 
dimesna:cisplatin molar ratio of approximately 226:1, over 4-fold greater than the 
minimum molar ratio of 50:1 required for nephroprotection in rats (Hausheer et al., 
1998). Thus, this lead the authors to suggest dose of 18.4 g/m2 be used for future efficacy 
studies (Masuda et al., 2010). 
1.3.3.2  Phase III 
 BioNumerik in alliance with German-based Baxter Oncology GmbH (a division 
of Baxter International) has recently completed a large randomized, controlled, phase III 
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trial of paclitaxel and herceptin in combination with dimesna to reduce the incidence of 
neuropathy in 764 patients with metastatic breast cancer, however the results have not yet 
been released (ClinicalTrials.gov ID# NCT00039780). Perhaps because of the success of 
this first efficacy trial, recruitment for a second phase III trial of dimesna is currently 
underway to determine its efficacy in combination with cisplatin and taxane drugs 
docetaxel and paclitaxel in patients with advanced primary adenocarcinoma of the lung 
(ClinicalTrials.gov ID# NCT00966914). As the populations of patients administered 
dimesna grows, understanding the underlying biology and potential causes of variations 
within populations will aid in the effective application of this new chemoprotectant. 
 
1.4 Pharmacokinetics of Mesna and Dimesna  
Although mesna and dimesna are unique molecular entities and regulated as two 
separate drugs, each could be considered a metabolite of the other, and thus their 
dispositions are inextricably linked. By convention, due to the technical difficulties of 
stabilizing and distinguishing low-molecular weight disulfides of mesna, its metabolites 
are often quantified collectively, which can make interpretation of results difficult.  The 
metabolites mesna-mesna (i.e. dimesna), mesna-Cys, mesna-homocysteine, mesna-
cysteinylglutamate, mesna-cysteinylglycine, and mesna-GSH have been collectively 
termed “dimesna” in some studies (Ormstad & Uehara, 1982; James et al., 1987; Shaw & 
Weeks, 1987) while others refer to the mixed disulfides containing a single mesna moiety 
as “mesna”, quantifying dimesna (i.e. mesna-mesna) separately (Goren et al., 1998b; 
Verschraagen et al., 2003c). Because of this disparity in the literature, and reversible 
redox of sulfhydryls and disulfides, analysis of “total” mesna as the sum of all mesna 
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moieties (reduced, low-molecular weight, and protein bound) has been recommended as 
an acceptable measurement of its pharmacokinetics (Goren et al., 1998b). However, these 
conventions will likely be obviated by growing accessibility of mass spectrometry 
equipment to academic laboratories. 
1.4.1 Absorption 
Early studies of orally administered IV preparations of mesna demonstrated that 
mesna moieties could be adequately absorbed to allow significant excretion of mesna into 
the urine (Brock et al., 1984). The appearance of both mesna and dimesna in the medium 
of inverted isolated small intestine injected with [14C]dimesna (Ormstad et al., 1983) 
suggests the intestine possesses a reductive capacity and supports the clinical observation 
of the absorption of dimesna following oral administration (James et al., 1987; Shaw & 
Weeks, 1987). Although the small intestine is able to reduce dimesna to mesna, 
theoretically enhancing its efficacy, this newly reduced mesna rapidly oxidizes upon 
entering the circulation (Brock et al., 1981a; Ormstad et al., 1983). A lack of biliary 
excretion by isolated perfused rat liver suggests total mesna does not undergo 
enterohepatic circulation, allowing the fraction absorbed to be equated to bioavailability 
(Ormstad et al., 1983; Goren et al., 1998c). Mesna and dimesna are exclusively renally 
excreted (Brock et al., 1984; Kurowski & Wagner, 1997; Ormstad et al., 1983), allowing 
for estimation of bioavailability by analysis of cumulative urinary excretion following a 
single oral dose, in addition to the standard comparison of the area under the 
concentration-time curves (AUCs) following IV and oral doses (Rowland & Tozer, 
1995). Analysis of urine data of healthy volunteers and patients undergoing ifosfamide 
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therapy yielded mean total mesna bioavailabilities of 0.47 and 0.33, respectively, but 
were not statistically different (Burkert et al., 1984). 
A comparison of AUCs of total mesna following IV and oral 800 mg doses of 
mesna in an early pharmacokinetic study yields a bioavailability of 0.47, a close 
approximation of the bioavailability of 0.49 derived from 24 h urinary excretion data 
(James et al., 1987). Bioavailability of total mesna has now been established as 0.5, 
allowing oral doses of mesna for outpatient therapy to be simply administered at twice 
the IV dose (Baxter Healthcare Corporation, 2002). Although the uptake transporters 
responsible for the intestinal absorption of mesna and dimesna remain to be determined, 
mesna’s moderate bioavailability makes it an unlikely candidate for adverse intestinal 
drug-transporter interactions.  
1.4.2 Non-Enzymatic Metabolism 
Early studies of mesna’s in vivo fate reported complete spontaneous metal-
catalyzed oxidation of mesna within the circulation to its dimer, dimesna (Brock et al., 
1981c; Brock et al., 1981a; Ormstad et al., 1983). Similarly, mesna can also disulfide 
bond to low-molecular weight endogenous thiols Cys, GSH, homocysteine (Hcy), or 
cysteinyl-glycine. Mesna is moderately protein-bound, the majority of which binds 
covalently via a disulfide with the single non-intramolecular disulfide forming Cys 
residue of albumin, Cys34, displacing endogenous thiols (Stofer-Vogel et al., 1993; 
Urquhart et al., 2006). The disulfide bonding of mesna moieties within the oxidative 
environment of the plasma is believed to be responsible for mesna’s inability to inactivate 
circulating chemotherapeutics (Brock et al., 1982). 
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However, plasma thiols exist as an equilibrium of sulfhydryl, protein disulfides, 
and low-molecular weight disulfides (Sengupta et al., 2001), thus, a proportion of mesna 
is expected to remain as an active sulfhydryl. This proportion likely went undetected in 
earlier studies using less sensitive methods of detection available today. More recent 
studies of IV dimesna pharmacokinetics show a dose-dependent increase in mesna 
exposure of 6% to 8% of dimesna AUC (Verschraagen et al., 2003a; Masuda et al., 
2010). Whether the production of mesna within the circulation is due to mesna moieties 
reaching equilibrium with other circulating thiols as well as secretion of mesna by tissues 
remains to be determined. 
 In contrast to the circulation, intracellular dimesna concentrations have been 
hypothesized to be less than 1% of the mesna concentration (Hausheer et al., 2003). 
Similar to the reduction of glutathionylated molecules and inter- and intramolecular 
protein disulfide bonds, mesna disulfides may freely undergo thiol-disulfide exchange 
with endogenous thiols GSH and Cys to yield sulfhydryl mesna (Iversen et al., 2010; 
Urquhart et al., 2006; Verschraagen et al., 2004b). Although the kinetics of these 
reactions remain to be determined, they are hypothesized to proceed via a bimolecular 
nucleophilic substitution (SN2) reaction (Hausheer et al., 2003). 
1.4.3 Enzymatic Metabolism 
In addition to non-enzymatic (i.e. chemical) thiol exchange, thioredoxin and 
glutaredoxin systems of the thioredoxin family of thiol-disulfide oxidoreductases may 
also be involved in the reduction of dimesna (Verschraagen et al., 2004b). The 
thioredoxin and glutaredoxin systems are highly conserved, ubiquitous NADPH-
dependent protein complexes of eukaryotic cells responsible for maintaining the balance 
25 
between oxidizing and reducing conditions (Berndt et al., 2007; Holmgren, 1985). These 
redox enzymes attenuate the signaling of reactive oxygen species (ROS) second 
messengers (e.g. hydrogen peroxide) by reducing ROS-induced oxidative modifications 
such as inter- and intramolecular disulfides (R-S-S-R), glutathionylation (R-S-SG), 
sulfenation (R-SOH), sulfination (R-SO2H), sulfonation (R-SO3H), and S-nitrosylation 
(R-S-NO) (Meyer et al., 2009; Berndt et al., 2007). 
Reduction of dimesna by purified thioredoxin system consisting of the 12 kDa E. 
coli protein thioredoxin (trxA; Trx1, UniProtKB ID# P0AA25) and 55 kDa bovine 
thioredoxin reductase (TXNRD1; TR1, UniProtKB ID# O62768, EC 1.8.1.9) has been 
reported (Verschraagen et al., 2004b). Thioredoxin functions as an electron donor to 
disulfide-forming enzymes ribonucleotide reductase (Engstrom et al., 1974), methionine 
sulfoxide reductases (Brot & Weissbach, 1983), and peroxiredoxins (Rhee et al., 2005). 
Thioredoxin and glutaredoxin share a dicysteine active site Cys-X-X-Cys motif called the 
‘thioredoxin-fold’ (Holmgren et al., 1975; Martin, 1995). The N-terminal active site Cys 
residue of the thioredoxin-fold in thioredoxin(SH)2 reduces protein disulfides by forming 
a transient mixed disulfide followed by fast thiol-disulfide exchange oxidizing a pair of 
reactive Cys at the active site producing thioredoxin(S)2 (Holmgren, 1995). Alternatively, 
reduced thioredoxin(SH)2 may directly reduce dimesna to form two mesna moieties and 
thioredoxin(S)2. Reduction of thioredoxin(S)2 is facilitated by electron transfer from 
NADPH via thioredoxin reductase. Thioredoxin reductase is a flavin adenine 
dinucleotide (FAD)-containing homodimeric enzyme containing a selenocysteine 
(SeCys) as the penultimate residue at its C-terminal end, forming a Gly-Cys-SeCys-Gly 
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active site responsible for the recycling of oxidized thioredoxin(S)2 to reduced 
thioredoxin(SH)2 (Zhong et al., 2000). 
The cytosolic glutaredoxin system consists of 12 kDa glutaredoxin (GLRX1; 
thioltransferase-1, GRX1, UniProtKB ID#P35754, EC 1.8.4.2) and 56 kDa glutathione 
reductase (GSR; GR, UniProtKB ID#P00390, EC 1.8.1.7). Glutaredoxin is primarily 
recognized to facilitate the GSH-dependent transfer of electrons to ribonucleotide 
reductase for the synthesis of deoxyribonucleotides (Holmgren, 1976). It has since been 
discovered that glutaredoxin also regulates dehydroascorbate reduction (Wells et al., 
1990), apoptosis (Chrestensen et al., 2000; Daily et al., 2001), cellular differentiation 
(Takashima et al., 1999), and transcription factor signaling (Bandyopadhyay et al., 1998; 
Hirota et al., 2000; Nakamura et al., 1999). Similar to thioredoxin, the thioredoxin-fold 
of glutaredoxin(SH)2 reduces protein disulfides by forming a transient mixed disulfide 
followed by thiol-disulfide exchange producing oxidized glutaredoxin(S)2 (Bushweller et 
al., 1992). However, unlike thioredoxin, glutaredoxin(SH)2 specifically reduces 
glutathionylated proteins and mixed disulfides, yielding a glutaredoxin-GSH conjugate 
(Holmgren, 1989). Thus, it has been proposed that dimesna undergoes thiol-disulfide 
exchange with GSH forming a mesna-GSH mixed disulfide which can then be acted upon 
by glutaredoxin(SH)2, forming glutaredoxin-GSH and sulfhydryl mesna (Verschraagen et 
al., 2004b). Glutaredoxin-GSH conjugate can then be reduced to glutaredoxin(SH)2 by an 
additional molecule of GSH, forming oxidized glutathione (GSSG). The homodimeric 
flavoprotein glutathione reductase then recycles GSSG to two molecules of GSH via 
electron transfer from NADPH (Fernandes & Holmgren, 2004; Meister & Anderson, 
1983). Thus far, glutaredoxin has been shown to only bind GSH moieties of disulfides 
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(Berndt et al., 2007; Holmgren, 1989), therefore it is unlikely that dimesna is a substrate 
for glutaredoxin. 
Reduction of dimesna has been proposed to occur by enzymatic and non-
enzymatic mechanisms of thiol exchange;(Ormstad et al., 1983; Verschraagen et al., 
2004b) however, the reaction orders and rates of reduction relative to endogenous 
substrates remains unknown. The rapid reduction of dimesna and its mixed disulfides by 
tissue homogenates likely proceeds by multiple parallel pathways of thiol disulfide 
exchange, however the relative contribution of these pathways have yet to be determined. 
1.4.4 Distribution 
In vitro, both liver and kidney lysates can reduce dimesna to sulfhydryl mesna by 
GSH dependent mechanisms (Verschraagen et al., 2004b; Ormstad et al., 1983). 
However, in vivo, dimesna undergoes no hepatic reduction and known kidney selectivity 
(Ormstad et al., 1983; Verschraagen et al., 2004a). In a series of isolated perfused organ 
experiments, significant accumulation of mesna was observed following perfusion of 
isolated rat kidney with [14C]dimesna, while no accumulation of either dimesna or mesna 
was seen in perfused liver tissue (Ormstad et al., 1983). This was corroborated by a later 
study of perfused rat liver by Goren et al. Neither mesna nor dimesna accumulated within 
the liver or were excreted in the bile. However, a significant increase in sulfhydryl mesna 
was observed in liver effluent perfusate. This observation is likely due to the increased 
sensitivity of electrochemical detection utilized by Goren et al. compared to analysis of 
total free thiol with Ellman’s reagent performed by Ormstad et al. (Goren et al., 1998c; 
Ormstad et al., 1983). 
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Differences in organ exposure also were seen following injection of WARD 
colorectal tumour-bearing rats with either mesna or dimesna. Liver, tumour, and red 
blood cells showed little or no exposure (as measured by the AUC of mesna and dimesna 
per gram tissue) while the kidney AUC exceeded that of plasma (Verschraagen et al., 
2004a).  
Ascites is an accumulation of fluid in the peritoneum that commonly occurs with 
malignant cancers due to reduced lymphatic drainage as a result of metastases to the 
peritoneal space (Tamsma et al., 2001). This fluid may represent an additional 
compartment of drug distribution, potentially altering a drugs pharmacokinetics. 
However, a case report of mesna and dimesna pharmacokinetics in a cancer patient 
receiving cisplatin therapy found only 4% of the dimesna dose was present in ascetic 
fluid and only 0.02% of this was present as mesna. The authors conclude that dose 
adjustments are not necessary in patients with ascites because its presence is unlikely to 
alter dimesna pharmacokinetics (Verschraagen et al., 2003b). 
 An early and comprehensive study of mesna pharmacokinetics, still cited in its 
current Compendium of Pharmaceuticals and Specialities monograph (Canadian 
Pharmacists Association, 2009), was conducted in six healthy subjects by James et al. 
The authors reported an apparent volume of distribution of the central compartment (Vc) 
and whole body clearance of mesna equal to 0.652 L/kg and 1.23 L/kg/h, respectively; 
approximately 45.6 L/h and 86.1 L/h for a 70 kg subject (James et al., 1987). However, 
this rapid clearance of mesna (half-life of approximately 22 minutes) was derived from 
only the initial (i.e. alpha) phase and thus likely represents the loss of sulfhydryl mesna 
due to oxidation in the plasma, not necessarily loss from the volume of distribution. This 
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observation is consistent with an earlier study that reported a half-life of 18 minutes by 
measurement of total sulfhydryl oxidation in plasma using Ellman’s reagent (Pohl et al., 
1981). In contrast, a time-averaged renal clearance of 0.413 L/h/kg (approximately 28.9 
L/h for a 70 kg subject) was calculated from four hour urine collection data; likely 
representing a closer estimation of whole body clearance of total mesna. Dimesna, which 
is both a metabolite and prodrug of mesna, had a half-life of 1.17 h (77 minutes) (James 
et al., 1987). 
A study of combined IV and oral dosing of mesna involving ten patients receiving 
mesna during ifosfamide chemotherapy reported pharmacokinetic parameters of mesna 
and dimesna from single IV doses (Goren et al., 1997). The observed steady-state volume 
of distribution (Vss) of mesna of 30 L is less than the Vc reported by James et al. (45.6 L) 
(James et al., 1987). This difference is contrary to the definitions of volumes of 
distribution and their methods of calculation, which necessitates that Vc ≤ Vss ≤ Vβ, 
assuming the distribution of drug into plasma is faster than its distribution into tissues 
(Berezhkovskiy, 2007). The volume of the central compartment (Vc) is calculated as the 
ratio of the IV dose (i.e. amount of mesna in the body) and extrapolated initial 
concentration (C0), prior to equilibration with sites of distribution outside of plasma 
water, and is thus an underestimation of drug’s volume at steady-state. At the other 
extreme, the volume of distribution estimated by terminal rate coefficient (Vβ) is 
calculated as the ratio of the whole body clearance (CL) and terminal elimination rate 
constant (i.e. kel, kβ, or λz). However, Vβ is an overestimation of a drug’s distribution 
because of the greater rate of change of the plasma concentration than the amount of drug 
in the body during the terminal phase. At steady-steady, however, the rates of change of 
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observed plasma concentration and amount of drug in the body are equal, hence Vss 
calculated as the product of the CL and mean residence time (MRT) is considered a more 
accurate measure of a drug’s distribution (Berezhkovskiy, 2007). Thus, the disparity 
between these two small studies is likely due to population variance or pathological 
causes.  
 Goren et al. also provided an estimation of the Vss of dimesna. By assuming the 
amount of dimesna administered was equal to half of the IV mesna dose the authors 
calculated the Vss of dimesna to be 36 L (Goren et al., 1997). The equality of the apparent 
volumes of mesna and dimesna is likely due to the reversible redox cycling of mesna 
moieties as disulfides within a single compartment. For this reason, measurement of total 
mesna has been suggested to provide more therapeutically relevant pharmacokinetic 
parameters. The subsequent total mesna Vss was 21 L (Goren et al., 1997). 
A study of mesna pharmacokinetics in nine patients receiving immunosuppressive 
cyclophosphamide therapy during bone marrow transplantation also reported parameters 
of mesna and dimesna. Mesna Vss and CL parameters were 1.09 L/kg (approximately 
76.3 L for a 70 kg subject) and 0.244 L/kg/h (approximately 17.1 L/h for a 70 kg 
subject), respectively. Dimesna, measured as the sum of low-molecular weight disulfides, 
had a CL of 0.157 L/kg/h (approximately 11 L/h for a 70 kg subject). However, these 
parameter values reported by el Yazigi et al. are not widely referenced due to the sparse 
sampling (i.e. 2-3 data points) during the terminal phase (el Yazigi et al., 1997).  
 Direct measurement of dimesna and mixed disulfide pharmacokinetics with and 
without cisplatin in 25 patients enrolled in a phase II trial was presented in detail by 
Verschraagen et al. (Verschraagen et al., 2003a). Clinical pharmacodynamic data of this 
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trial was later reported by Boven et al. (Boven et al., 2005). Dimesna AUCs showed 
excellent linearity across all six dose levels ranging from 4.1 to 41 g/m2. Vss and CL 
parameters of dimesna ranged from 0.23-0.26 L/kg (approximately 17.2 L for a 70 kg 
subject) and 8.1-9.2 L/h/1.73 m2, respectively, across all dose levels with and without 
cisplatin (Verschraagen et al., 2003a). The half-life of dimesna (measured as the sum of 
mixed disulfides) was 1.4 h (Verschraagen et al., 2003a), closely approximating the 
dimesna half-life estimated following mesna administration (1.17 – 1.29 hours) (el Yazigi 
et al., 1997; James et al., 1987). Sulfhydryl mesna reached a Cmax at 1.4 hours with an 
AUC of approximately 8% of dimesna, across all dose levels. Vss and CL of mesna could 
not be determined without deconvolution of the rate of mesna production. However the 
reported terminal half-life of 2.75 hours is significantly longer than previous half-lives 
calculated during the initial phase (18 – 22 minutes) of non-enzymatic oxidation 
(Verschraagen et al., 2003a; Pohl et al., 1981; James et al., 1987). 
In a phase I trial reported by Masuda et al. dimesna pharmacokinetics were 
measured by liquid chromatography-mass spectrometry in 22 patients (Masuda et al., 
2010). Doses levels were identical to Verschraagen et al.; ranging from 4.1 – 41 g/m2 
(Verschraagen et al., 2003a). Concurrent cisplatin and paclitaxel administration had no 
effect on mesna or dimesna parameters. Mean dimesna parameters Vss, CL, and half-life 
across all dose levels were 14.0 L, 10.9 L/h, and 1.0 hour, respectively. AUC of 
sulfhydryl mesna was approximately 6.2% of dimesna (Masuda et al., 2010). 
Interestingly, these values are similar to those previously reported by Verschraagen et al. 
using electrochemical detection following sodium borohydride reduction to quantify 
dimesna as the sum of all mixed disulfides (Verschraagen et al., 2003a). Although not 
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presented in the reports, a comparison of dose normalized dimesna Cmax values obtained 
by the two analytical methods allows for estimation of the proportion of low-molecular 
weight disulfides to be 73.3% dimesna. The remaining 26.7% is likely made up of (in 
order of their endogenous concentrations): mesna-Cys, mesna-GSH, mesna-Hcy, mesna-
cysteinylglycine, and mesna-glutamylcysteine. 
1.4.5 Excretion 
As previously noted, mesna and dimesna are exclusively renally excreted at a 
clearance rate greater than glomerular filtration (Brock et al., 1984; Urquhart et al., 
2007a; James et al., 1987; Kurowski & Wagner, 1997; Ormstad et al., 1983). 
Theoretically, the magnitude of chemoprotection is proportional to the fraction of mesna 
moieties excreted as active sulfhydryls (Kurowski & Wagner, 1997; Manz et al., 1985). 
James et al. reported that the percentage of mesna excreted as a sulfhydryl from equal IV 
and oral doses are 31.8% and 17.6%, respectively (James et al., 1987). A similar result of 
35.9% urinary sulfhydryl mesna following IV dosing was reported in an earlier study 
which also utilized sulfhydryl mesna-specific analysis (Ikeuchi & Amano, 1985). Not 
surprisingly, roughly half as much mesna was excreted following oral dosing given 
mesna’s bioavailability of 0.5. In a comparison of IV and oral dosing, Goren et al. 
reported the percentage of sulfhydryl mesna excreted following IV dosing was equivalent 
to oral administration of twice the IV dose (41% IV versus 37% oral) consistent with the 
observations of James et al. (Goren et al., 1997; James et al., 1987). Despite low 
(approximately 8%) circulating sulfhydryl mesna, the percent urinary sulfhydryl mesna is 
approximately 8-fold greater, thus secreted low-molecular weight mesna disulfide may 
undergo reduction within the renal epithelia. In addition the renal clearances of mesna 
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and dimesna in excess of glomerular filtration and excretion imply uptake and active 
renal secretion by renal parenchyma. 
 To date, only a single study has examined the saturable uptake of dimesna by 
renal tissue. Using freshly isolated rat renal epithelial cells, the uptake of 100 µM 
[14C]dimesna was temperature dependent and inhibitable by the adenosine triphosphate 
(ATP) inhibitor para-trifluoromethoxyphenylhydrazide (FCCP), suggesting dimesna 
accumulation occurs by either primary or secondary active protein-dependent transport. 
Kinetic analysis by Lineweaver-Burk plot revealed a KM and Vmax of 22 µM and 1.4 
nmol/106 cells, respectively. However, only four concentrations of dimesna were tested, 
and without the use of an impermeable tracer (e.g. mannitol or Lucifer yellow) to control 
for increased permeability of the artificial system, passive transport of dimesna across the 
perfused vasculature could not be accounted for. Thus, observed kinetic parameters can 
only be considered approximations. The rate of dimesna uptake was not inhibited by 1 
mM GSSG, cystine (CySSyC), Cys, NAC, or mesna, and only slightly decreased in the 
presence of 1 mM GSH, however the significance was not determined. Unlike the rate of 
reduction of dimesna, the rate of [14C]dimesna uptake was independent of cellular GSH 
concentration. Hence GSH could be considered a cofactor of dimesna metabolism, but 
not its uptake. Accumulation of [14C]dimesna was approximately 100-fold greater in 
isolated perfused rat kidneys with functioning glomeruli, compared to kidneys whose 
filtration capability had been diminished by perfusion with 10% albumin. This lead the 
authors to conclude that the accumulation of dimesna is dependent on filtration and 
occurs primarily as a reabsorptive process across the apical (luminal) membrane of the 
renal tubules (Ormstad & Uehara, 1982). 
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1.5  Drug Uptake Transporters in Cancer 
Although able to bind reactive metabolites, mesna and dimesna do not interfere 
with the cytotoxic effects of cisplatin or ifosfamide (Araujo & Tessler, 1983; Boven et 
al., 2002; Brock et al., 1982; Millar et al., 1983; Scheef et al., 1979; Scheulen et al., 
1983).  This has been attributed to the rapid oxidation of mesna to inactive dimesna and 
the perception that such a polar substance would be unable to readily cross cell 
membranes (Brock et al., 1981a).  However, Ormstad et al. clearly demonstrated the 
presence of transporter-mediated dimesna uptake by the kidney (Ormstad & Uehara, 
1982). With the identification and characterization of a multitude of drug transporting 
proteins able to transport anionic, cationic, and zwitterionic molecules, the disposition of 
many chemotherapeutic drugs is now understood to be predominantly protein dependent 
(Dobson & Kell, 2008; Brock et al., 1981a; Ho & Kim, 2005). 
The efficacy of cancer chemotherapy is dependent on the accumulation of the 
drug at the site of action and presence of the target. Many cancers circumvent 
susceptibility by innate and adaptive mechanisms such as increased drug detoxification, 
increased drug target expression, mutations of drug targets, alterations in apoptosis and 
cell cycle, decreased facilitative drug uptake, and increased drug efflux (Bush & Li, 
2002; Desoize & Jardillier, 2000; Donnenberg & Donnenberg, 2005; Moscow et al., 
1995). 
The most studied, and perhaps most common, mechanism of drug resistance is the 
expression of membrane proteins of the energy-dependent ATP-binding cassette (ABC) 
transporter family. Prototypical drug efflux transporters Pgp (MDR1; ABCB1), BCRP 
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(ABCG2), MRP1 (ABCC1) were first discovered in cancer cell lines, and thus their role to 
facilitate drug resistance in cancer was immediately apparent (Cole et al., 1992; Dano, 
1973; Doyle et al., 1998; Juliano & Ling, 1976; McGrath & Center, 1988). The ability of 
the family of ABC transport proteins to confer drug resistance has been extensively 
reviewed (Szakacs et al., 2006).   
Conversely, prototypical drug uptake transporters of the SLC22 and SLCO 
superfamilies, OCT1 (SLC22A1) (Gorboulev et al., 1997d), OAT1 (SLC22A6) (Lopez-
Nieto et al., 1997b), OATP1A2 (SLCO1A2) (Kullak-Ublick et al., 1995) were first 
cloned from kidney and liver; tissues responsible for the clearance of drugs, and thus 
their roles have largely been studied in the context of drug absorption, distribution, 
metabolism, and excretion (ADME) (Hagenbuch, 2010). Hence members of the SLC22 
and SLCO superfamilies represent ideal candidates of the putative drug transporter(s) 
proposed by Ormstad et al (Ormstad & Uehara, 1982). Localization of these drug uptake 
transporters in cancerous and healthy human tissues along with known substrates 
commonly administered during chemotherapy are listed in Table 1.1. 
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Table 1.1   Cancer chemotherapy substrates and expression patterns of drug uptake transporters of the SLC22A and SLCO family in 
healthy and cancerous human tissues. 
 
Transporter (Gene) Chemotherapy Substrates Healthy Tissue Localization Cancerous Tissue Localization (change in expression*) 
 
SLC22A family 
 
  
OCT1 (SLC22A1) 
 
bamet-R2 (Briz et al., 2002j) 
bamet-UD2 (Briz et al., 2002i) 
cDPCP (Lovejoy et al., 2008a) 
cisplatin (Yonezawa et al., 
2006e) 
oxaliplatin (Zhang et al., 2006i) 
imatinib (Hu et al., 2008e; 
Thomas et al., 2004a; Wang et 
al., 2008c) 
meta-iodobenzyl-guanidine 
(Bayer et al., 2009b) 
 
 
adrenal gland a (Nies et al., 2009h) 
breast mammary epithelium a (Alcorn et al., 2002h; 
Kwok et al., 2006d) 
kidney a (Verhaagh et al., 1999f; Motohashi et al., 
2002e; Jung et al., 2008i) 
liver; basolateral & cholangiocytes a,b (Nies et al., 
2009g; Zhang et al., 1997) 
lung a (Monks et al., 2007~; Nies et al., 2009f) 
ovary a (Jung et al., 2008h) 
prostate a (Jung et al., 2008g) 
 
colon polyp (no change) a (Ballestero et al., 2006m) 
colon cancer (no change) a (Ballestero et al., 2006l; Zhang 
et al., 2006h) 
leukemia a (Wang et al., 2008b; Thomas et al., 2004b) 
non-small cell lung cancer (no change) a (Monks et al., 
2007}) 
OCT2 (SLC22A2) 
 
bamet-R2 (Briz et al., 2002h) 
bamet-UD2 (Briz et al., 2002g) 
cDPCP (Lovejoy et al., 2008b) 
cisplatin (Yonezawa et al., 2006a; 
Burger et al., 2010f) 
ormaplatin (Burger et al., 2010e) 
oxaliplatin (Yonezawa et al., 
2006b; Zhang et al., 2006g; 
Burger et al., 2010d)  
transplatin (Burger et al., 2010c) 
tetraplatin (Burger et al., 2010b) 
 
 
brain a,b (Busch et al., 1998) 
colon a (Jung et al., 2008f) 
heart a (Jung et al., 2008e) 
kidney; basolateral a,b (Motohashi et al., 2002d; 
Jung et al., 2008d; Gorboulev et al., 1997c) 
lung a (Monks et al., 2007|) 
skeletal muscle a (Jung et al., 2008c) 
small intestine a (Jung et al., 2008b) 
testis a (Jung et al., 2008a) 
 
 
colon cancer (increased) a (Zhang et al., 2006f) 
non-small cell lung cancer (decreased) a (Monks et al., 
2007{) 
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OCT3 (SLC22A3) 
 
meta-iodobenzyl-guanidine 
(Bayer et al., 2009a) 
oxaliplatin (Yonezawa et al., 
2006c; Zhang et al., 2006e) 
adrenal gland a (Nies et al., 2009e; Verhaagh et al., 
1999e) 
brain a,b (Wu et al., 1998a) 
breast mammary epithelium a (Alcorn et al., 2002g; 
Kwok et al., 2006c) 
heart a (Verhaagh et al., 1999d) 
lung a (Monks et al., 2007z) 
prostate a (Nies et al., 2009d) 
uterus a (Nies et al., 2009c) 
liver; basolateral & cholangiocytes a,b (Nies et al., 
2009b; Verhaagh et al., 1999c) 
lung a (Nies et al., 2009a) 
ovary a (Verhaagh et al., 1999b) 
prostate a (Verhaagh et al., 1999a) 
skeletal muscle a (Verhaagh et al., 1999g) 
 
breast cancer (decreased) a (Yokoo et al., 2008j) 
colon cancer (increased) a (Yokoo et al., 2008i) 
renal cancer (no change) a (Yokoo et al., 2008h) 
non-small cell lung cancer (decreased) a (Monks et al., 
2007y; Yokoo et al., 2008g) 
ovarian cancer (decreased) a (Yokoo et al., 2008f) 
rectal cancer (increased) a (Yokoo et al., 2008e) 
stomach cancer (increased) a (Yokoo et al., 2008d) 
uterine cancer (decreased) a (Yokoo et al., 2008c) 
OCTN1 (SLC22A4) 
doxorubicin (Okabe et al., 2008e) 
mitoxantrone (Okabe et al., 
2008d) 
 
bone marrow a (Tamai et al., 1997e) 
breast lactating mammary epithelium a,b (Alcorn et 
al., 2002f; Kwok et al., 2006a) 
heart a,b (McBride et al., 2009) 
lung a (Monks et al., 2007x; Tamai et al., 1997d) 
kidney a,b (Tamai et al., 1997c; Kwok et al., 2006b) 
prostate a (Tamai et al., 1997b) 
skeletal muscle a (Tamai et al., 1997a) 
small intestine a (Glaeser et al., 2007b) 
trachea a (Tamai et al., 1997f) 
 
non-small cell lung cancer (decreased) a (Monks et al., 
2007w) 
OCTN2 (SLC22A5) imatinib (Hu et al., 2008d) 
breast mammary epithelium a,b (Alcorn et al., 2002e; 
Kwok et al., 2006e) 
heart a,b (Grube et al., 2006b; Tamai et al., 1998c) 
kidney a,b (Tamai et al., 1998b; Kwok et al., 2006f) 
lung a (Monks et al., 2007v) 
skeletal muscle a (Tamai et al., 1998a) 
small intestine a (Glaeser et al., 2007e) 
 
non-small cell lung cancer (no change) a (Monks et al., 
2007u) 
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OCT6 (SLC22A16) 
bleomycin (Aouida et al., 2010b) 
daunorubicin (Okabe et al., 
2005g) 
doxorubicin (Okabe et al., 2005f) 
 
testis; Sertoli cells a (Enomoto et al., 2002d; Okabe 
et al., 2005e; Gong et al., 2002f) 
epididymus epithelial cells; apical a (Okabe et al., 
2005d; Enomoto et al., 2002c; Gong et al., 2002e)  
endometrium (secretory phase) a,b (Sato et al., 
2007d) 
foetal brain a (Gong et al., 2002k), foetal liver a 
(Okabe et al., 2005c; Gong et al., 2002j)  
bone marrow a (Okabe et al., 2005b; Gong et al., 
2002i), peripheral blood leukocytes a (Gong et al., 
2002h) 
 
acute lymphoblastic leukemia a (Okabe et al., 2005a; 
Gong et al., 2002g)  
acute myelogenous leukemia a (Okabe et al., 2005h; 
Gong et al., 2002a) 
chronic myeloid leukemia a (Gong et al., 2002b) 
endometrial cancer a,b (Sato et al., 2007c) 
ovarian cancer a,b (Ota et al., 2007b) 
OAT1 (SLC22A6) 
 
methotrexate (Sekine et al., 
1997a; Takeda et al., 2002) 
 
 
brain; apical (choroid plexus) a,b (Cihlar et al., 
1999a; Alebouyeh et al., 2003b) 
kidney; basolateral a,b (Motohashi et al., 2002c; 
Hosoyamada et al., 1999; Cihlar et al., 1999c; Sun 
et al., 2001g) 
lung a (Monks et al., 2007t) 
skeletal muscle a (Cihlar et al., 1999b) 
 
non-small cell lung cancer (no change) a (Monks et al., 
2007s) 
OAT2 (SLC22A7) 
 
5-fluoruracil (Kobayashi et al., 
2005b) 
methotrexate (Sun et al., 2001f) 
paclitaxel (Kobayashi et al., 
2005a) 
 
kidney; basolateral b (Enomoto et al., 2002b; Sun et 
al., 2001e) 
liver a,b (Shin et al., 2010; Sun et al., 2001d) 
lung a (Monks et al., 2007r) 
 
non-small cell lung cancer (no change) a (Monks et al., 
2007q) 
OAT3 (SLC22A8) methotrexate (Cha et al., 2001c; 
Takeda et al., 2002) 
 
adrenal tissue a (Asif et al., 2005b) 
brain; apical (choroid plexus) b (Alebouyeh et al., 
2003a) 
kidney; basolateral a,b (Motohashi et al., 2002b; Cha 
et al., 2001b; Sun et al., 2001c) 
lung a (Monks et al., 2007p) 
adrenal cancer a (Asif et al., 2005a) 
non-small cell lung cancer (no change) a (Monks et al., 
2007o) 
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OAT4 (SLC22A11) 
methotrexate (Takeda et al., 
2002) 
 
adrenal tissue a (Asif et al., 2005c) 
kidney; apical a,b (Cha et al., 2000; Babu et al., 
2002)  
liver a (Sun et al., 2001b) 
lung a (Monks et al., 2007n) 
 
adrenal cancer a (Asif et al., 2005d) 
non-small cell lung cancer (no change) a (Monks et al., 
2007m) 
 
SLCO family 
 
  
OATP1A2 (SLCO1A2) 
bamet-R2 (Briz et al., 2002f) 
bamet-UD2 (Briz et al., 2002e) 
imatinib (Hu et al., 2008c) 
methotrexate (Badagnani et al., 
2006b) 
 
brain capillary endothelia; basolateral (abluminal) 
a,b (Lee et al., 2005c; Bronger et al., 2005a; Gao et 
al., 2000) 
liver; apical b (Lee et al., 2005b) 
kidney; apical b (Lee et al., 2005a)  
lung a (Monks et al., 2007l) 
small intestine; apical a,b (Glaeser et al., 2007f) 
eye pars plana ciliary body epithelium; basolateral 
b (Gao et al., 2005e)  
breast mammary epithelium a (Alcorn et al., 
2002d) 
 
colon polyp (decreased) a (Ballestero et al., 2006k) 
colon cancer (decreased) a (Ballestero et al., 2006j) 
brain glioma a (Bronger et al., 2005b) 
breast cancer (increased) a,b (Meyer zu Schwabedissen et 
al., 2008d; Miki et al., 2006a) 
non-small cell lung cancer (no change) a (Monks et al., 
2007k) 
OATP1B1 (SLCO1B1) 
 
 
BNP1350 (Oostendorp et al., 
2009a) 
gimatecan (Oostendorp et al., 
2009b) 
lapatinib (Polli et al., 2008) 
methotrexate (Abe et al., 2001f; 
Sasaki et al., 2004a) 
SN-38 (Nozawa et al., 2005a; 
Oostendorp et al., 2009c) 
bamet-R2 (Briz et al., 2002d) 
bamet-UD2 (Briz et al., 2002c) 
liver; basolateral b (Hsiang et al., 1999; Konig et 
al., 2000a) 
small intestine a (Glaeser et al., 2007d) 
colon polyp (increased) a (Ballestero et al., 2006i) 
colon cancer (increased) a (Ballestero et al., 2006h) 
hepatocellular carcinoma (no change) a,b (Vavricka et al., 
2004d) 
hepatocellular carcinoma b (Cui et al., 2003a) 
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OATP1B3 (SLCO1B3) 
methotrexate (Abe et al., 2001e) 
docetaxel (Smith et al., 2005c) 
paclitaxel (Smith et al., 2005b) 
SN-38 (Yamaguchi et al., 2008c) 
liver; basolateral a,b (Abe et al., 2001d; Lee et al., 
2008d; Konig et al., 2000b) 
small intestine a (Glaeser et al., 2007a) 
 
breast cancer b (Muto et al., 2007c) 
colon polyp (no change) a (Ballestero et al., 2006g) 
colon cancer (no change) a (Ballestero et al., 2006f) 
colon cancer (increased) a,b (Lee et al., 2008c) 
colon cancer a,b (Abe et al., 2001c) 
gastric cancer a,b (Abe et al., 2001b) 
hepatocellular carcinoma (decreased) a,b (Vavricka et al., 
2004c) 
hepatocellular carcinoma b (Narita et al., 2009; Cui et al., 
2003b) 
non-small cell lung cancer (increased) a (Monks et al., 
2007j) 
pancreatic cancer a,b (Abe et al., 2001a) 
 
OATP1C1 (SLCO1C1) 
 
 
brain a (Pizzagalli et al., 2002b) 
eye pars plana ciliary body epithelium; basolateral 
b (Gao et al., 2005d) 
lung a (Monks et al., 2007i) 
testis; Leydig cells a,b (Pizzagalli et al., 2002a) 
 
 
brain glioma a (Bronger et al., 2005c) 
non-small cell lung cancer (no change) a (Monks et al., 
2007h) 
OATP2A1 (SLCO2A1) 
 
 
brain a (Lu et al., 1996i) 
breast a (Wlcek et al., 2008p) 
colon a (Lu et al., 1996h) 
eye a (Schuster et al., 1997) 
heart a (Lu et al., 1996g) 
kidney a (Lu et al., 1996f) 
liver a (Lu et al., 1996e) 
lung a (Monks et al., 2007g; Lu et al., 1996d) 
skeletal muscle a (Lu et al., 1996c) 
small intestine a (Lu et al., 1996b) 
testis a (Lu et al., 1996a) 
 
 
breast cancer (no change) a (Wlcek et al., 2008o) 
non-small cell lung cancer (decreased) a (Monks et al., 
2007f) 
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OATP2B1 (SLCO2B1)  
 
 
brain capillary endothelia; basolateral (abluminal) 
b (Bronger et al., 2005d) 
breast mammary epithelia cells a,b (Pizzagalli et 
al., 2003; Alcorn et al., 2002c)  
colon a (Englund et al., 2006; Meier et al., 2007) 
eye pars plana ciliary body epithelium; basolateral 
b (Gao et al., 2005c) 
heart a (Kullak-Ublick et al., 2001f) 
kidney a (Kullak-Ublick et al., 2001e) 
liver; basolateral a,b (Kullak-Ublick et al., 2001d) 
lung a (Monks et al., 2007e; Kullak-Ublick et al., 
2001c) 
ovary a (Kullak-Ublick et al., 2001b) 
skin a,b (Schiffer et al., 2003) 
small intestine a,b (Kobayashi et al., 2003; Glaeser 
et al., 2007c) 
spleen a (Kullak-Ublick et al., 2001a) 
 
 
brain glioma a (Bronger et al., 2005e) 
breast cancer (no change) a (Al Sarakbi et al., 2006b) 
breast cancer (decreased) a (Wlcek et al., 2008n) 
non-small cell lung cancer (no change) a (Monks et al., 
2007d) 
OATP3A1 (SLCO3A1) 
 
 
 
brain a  
breast mammary epithelium a (Wlcek et al., 
2008m; Alcorn et al., 2002b) 
heart a  
eye pars plana ciliary body epithelium; basolateral 
b (Gao et al., 2005b) 
kidney a  
lung a (Monks et al., 2007c) 
skin a  
testis a  
 
 
 
breast cancer (decreased) a (Wlcek et al., 2008l) 
non-small cell lung cancer (no change) a (Monks et al., 
2007b) 
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OATP4A1 (SLCO4A1) 
 
 
brain a  
breast mammary epithelium a (Wlcek et al., 2008k; 
Alcorn et al., 2002a) 
choroid plexus a  
colon a  
eye pars plana ciliary body epithelium; basolateral 
b (Gao et al., 2005a) 
kidney a  
liver a  
lung a (Monks et al., 2007a) 
skeletal muscle a  
small intestine a  
 
breast cancer (decreased) a (Wlcek et al., 2008j) 
brain glioma a (Bronger et al., 2005f) 
colon cancer (increased) a (Ancona et al., 2006) 
non-small cell lung cancer (no change) a (Monks et al., 
2007) 
OATP4C1 (SLCO4C1) methotrexate (Mikkaichi et al., 
2004a) 
 
breast a (Wlcek et al., 2008i) 
kidney a (Mikkaichi et al., 2004b) 
 
breast cancer (no change) a (Wlcek et al., 2008h) 
OATP5A1 (SLCO5A1) 
 
 
breast a (Wlcek et al., 2008g) 
 
breast cancer (no change) a (Wlcek et al., 2008f) 
OATP6A1 (SLCO6A1)  testis 
a (Lee et al., 2004a; Suzuki et al., 2003) 
 
bladder cancer a (Lee et al., 2004b) 
oesophageal cancer a (Lee et al., 2004c) 
lung cancer a (Lee et al., 2004d) 
 
 
* Relative to paired healthy surrounding tissue if available 
a mRNA by qRT-PCR or Northern blot 
b protein by Western blot or  immunohistochemistry 
Excellent large-scale screens of relative-mRNA expression of uptake transporter can be found elsewhere.(Bleasby et al., 2006; Hilgendorf et al., 2007; Okabe et 
al., 2008c)
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1.5.1 Organic Cation Transporters 
The organic cation transporters (OCTs) and organic cation/carnitine transporters 
(OCTNs) are polyspecific transporters that facilitate diffusion of cationic molecules less 
than 400 Da into the cell, with the electrochemical gradient (Koepsell et al., 2007a). The 
first OCT cloned, Oct1 (Slc22a1), was isolated from rat kidney based on N-
methylnicotinamide-inhibitable uptake of the cationic compound tetraethylammonium 
(TEA) (Grundemann et al., 1994). The first human OCT1 orthologue was later identified 
and found to be predominately expressed in liver (Gorboulev et al., 1997b). Current 
human cation transporters of the SLC22A superfamily include OCT1-3 (SLC22A1-3), 
OCTN1-2 (SLC22A4-5), and OCT6 (SLC22A16) (Koepsell et al., 2007c). 
OCT2 is predominantly expressed at the basolateral membrane of proximal and 
distal tubules of the kidney to facilitate uptake of prostaglandin E2 and prostaglandin F2α 
(Kimura et al., 2002; Motohashi et al., 2002a; Gorboulev et al., 1997a). OCT1 and OCT3 
are expressed at the sinusoidal membrane of hepatocytes where they likely facilitate the 
uptake of corticosterone, β-estradiol, and testosterone from the blood (Koepsell et al., 
2007b; Wu et al., 1998b). Although OCT3 is also referred to as the extraneuronal 
monoamine transporter due to its ubiquitous mRNA expression and affinity for dopamine 
and norepinephrine, each of the OCTs likely contributes to the clearance of endogenous 
monoamines because of their shared affinity for biogenic amines such as dopamine, 
epinephrine, norepinephrine, histamine, and serotonin (Eisenhofer, 2001; Wu et al., 
1998c). 
Expression of OCT1 has been linked to accumulation of the tyrosine kinase 
inhibitor imatinib, but not nilotinib in mononuclear cells. Imatinib is indicated for first-
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line therapy of chronic myeloid leukemia (CML) and produces complete cytogenetic 
remission in approximately 80% of patients. Investigations into the potential causes of 
optimal response revealed the enabling role of OCT1 in imatinib therapy. Inhibition of 
OCT1, but not OCT2 and OCT3, prevented imatinib accumulation in a human T-
lymphoblastoid cell line derived from a patient with acute lymphoblastic leukemia 
(Thomas et al., 2004c). To observe if a clinically relevant trend exists between OCT1 
mRNA expression and imatinib response, 30 patients with CML were classified as either 
responders, if they achieved complete cytogenetic remission, or non-responders. Bone 
marrow mononuclear cell OCT1 mRNA levels of non-responders were significantly 
lower than those of responders (Crossman et al., 2005). A trend was observed between 
OCT1 mRNA levels and intracellular retention of imatinib; however given the small 
sample size of 19 subjects the relationship was not significant (White et al., 2006). A 
wider screen of uptake transporters revealed that imatinib is a substrate for OCTN2, 
OATP1A2, OATP1B3, and only a weak substrate for OCT1. OCT1 expression may only 
be a marker for mononuclear cell imatinib accumulation by other transporters (Hu et al., 
2008b). In a relatively large cohort of 70 patients, OCT1 mRNA levels correlated with 
complete cytogenetic remission, progression-free survival, and overall survival, 
demonstrating OCT1 to be an important predictor to patient response (Wang et al., 
2008a). Supporting prior work suggesting imatinib is a substrate of OCT1, functional 
activity of OCT1 in mononuclear cells of patients with CML prior to imatinib treatment 
strongly correlates with successful therapy. Patients with higher OCT1-mediated imatinib 
uptake had a greater rate of complete molecular remission at five years, while low OCT 
activity correlated with lower event-free and overall survival rates and higher kinase 
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domain mutation rate. These clinical findings led the authors to suggest that measurement 
of OCT1 activity in patient mononuclear cells may be used to personalize imatinib dosing 
(White et al., 2010). 
Uptake transporters may also mediate adverse drug-drug interactions by either 
preventing clearance leading to intolerable toxicity or restricting permeability to target 
tumors. Such interactions are likely to become a greater concern as new therapies are 
given in-addition-to current standards of care rather than monotherapy. For example, 
although not a substrate, gefitinib has been shown to inhibit OCT1 and OCT2 activities 
(Galetti et al., 2010). Screening the new Src family kinase inhibitor saracatinib with 
current first-line therapies demonstrated attenuation in oxaliplatin efficacy in colorectal 
cancer cells. Transport studies revealed saracatinib-dependent antagonism of OCT2-
mediated oxaliplatin uptake (Morrow et al., 2010). 
Arguably the most widely used anti-cancer substrates of OCTs are the platinum-
based drugs cisplatin and oxaliplatin. While consensus exists that OCT1, OCT2, and 
OCT3 are capable of transporting oxaliplatin, but not carboplatin, variable transport of 
cisplatin by OCT-expressing mammalian cell lines has been reported (Burger et al., 
2010a; Yokoo et al., 2008b; Yonezawa et al., 2006d; Zhang et al., 2006d). OCTs may not 
be the only uptake transporters contributing to the differential efficacy of oxaliplatin 
(Holzer et al., 2006). Intracellular accumulation of oxaliplatin is also less susceptible than 
either cisplatin or carboplatin to copper transporter 1 (CTR1) which works to sequester 
platinum moieties to an intracellular compartment, preventing the formation of DNA 
adducts. More convincingly, expression of OCT1 and OCT2 has been shown to sensitize 
Madin-Darby canine kidney (MDCK) cells to oxaliplatin, but not cisplatin or carboplatin 
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cytotoxicity (Zhang et al., 2006c). Cisplatin was the first of these therapies to be 
approved by the FDA and is effective against a variety of solid tumors including 
testicular and ovarian cancers, but suffers from nephrotoxicity and acquired drug 
resistance (Raymond et al., 2002a). The later analogue carboplatin incited less nephro- 
and gastrointestinal toxicity, but suffered from a similar drug resistance profile, and thus 
was of little use against cisplatin-refractory tumors (Raymond et al., 2002c). In 
comparison, oxaliplatin showed greater efficacy against tumors previously resistant to 
platinum-based drugs (Raymond et al., 1998; Rixe et al., 1996). Subsequently oxaliplatin 
has been indicated for first- or second-line therapy with 5-fluorouracil (5-FU) and 
leucovorin against advanced colorectal cancer (Raymond et al., 2002b). Other anti-cancer 
agents melphalan, irinotecan, and vincristine are also likely substrates of OCT3, given its 
overexpression sensitizes cells in culture while inhibiting uptake of the organic cation 4-
methyl-pyridinium iodide (MPP) (Shnitsar et al., 2009b). 
The maintenance of expression of OCT1 and increase in OCT2 and OCT3 
expression in colorectal cancer may contribute to the greater effectiveness of oxaliplatin 
against colorectal cancer than either cisplatin or carboplatin seen clinically (Ballestero et 
al., 2006e; Yokoo et al., 2008a; Zhang et al., 2006b). Structure-activity experiments have 
demonstrated the 1,2-diaminocyclohexane (DACH) moiety of oxaliplatin facilitates its 
interaction with OCT1 and OCT2 (Zhang et al., 2006a). A further increase in efficacy has 
been sought by synthesizing new platinum agents that are also substrates for OCTs (Briz 
et al., 2002b; Lovejoy et al., 2008c). Third-generation platinum agent picoplatin is a 
substrate for OCT1 and OCT2, but not OCT3. Interestingly, OCT1-expressing human 
embryonic kidney cell (HEK293) xenografts were more susceptible to picoplatin than 
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wild-type, however pharmacokinetic parameters of picoplatin in wild-type and OCT1 
knock-out mice were not different (More et al., 2010). This suggests OCT1 may only 
control the tumor disposition of picoplatin and not its clearance. 
Bile acid-cisplatin derivatives bamet-R2 [cis-diammine-chloro-cholylglycinate-
platinum(II)] and bamet-UD2 [cis-diammine-bisursodeoxycholate-platinum(II)] showed 
greater accumulation in HEK293 cells expressing OCT1 or OCT2 compared to the 
cisplatin moiety alone (Briz et al., 2002a). Furthermore, no difference in accumulation of 
bamet-UD2 between Xenopus laevis oocytes injected with RNA isolated from either 
healthy tissue or colorectal cancers and polyps, suggesting bile acid derivatives may not  
suffer from the same intrinsic resistance as cisplatin (Ballestero et al., 2006d). The 
cationic analogue cis-diammine(pyridine)-chloroplatinum(II) (cDPCP) exploits the 
propensity of OCT1 and OCT2 to uptake monovalent cations, showing great 
accumulation in transfected cells. Moreover, cDPCP was less toxic to non-OCT 
expressing cells while maintaining potent transcription blockade and reduced 
susceptibility to mammalian excinuclease, the common mechanism of platinum-adduct 
repair (Lovejoy et al., 2008d). 
OCTN1 and OCTN2 are expressed at kidney proximal tubules, lactating breast 
epithelium, and cardiac tissues to facilitate excretion of cations and the uptake of 
carnitine, an essential molecule for mitochondrial fatty acid metabolism and energy 
production (Grube et al., 2006a). Little is known regarding the expression of OCTN1 and 
OCTN2 in cancers, only the maintenance of mRNA expression in non-small cell lung 
cancer has been found (Monks et al., 2007€). Given that overexpression of OCTN1 
sensitizes cells to mitoxantrone and doxorubicin by facilitating their cellular 
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accumulation, the expression of OCTN1 in common targets such as breast, ovarian, and 
prostate cancers should be investigated (Okabe et al., 2008b). OCTN2 has demonstrated 
modest uptake of imatinib, sorafenib, and sunitinib (Hu et al., 2008a; Hu et al., 2009). 
Given its expression in cardiac endothelia, organic cation transporters may also 
contribute to tyrosine kinase inhibitor-associated cardiac toxicity (Lenihan, 2008; Mann, 
2006). 
 OCT6, unlike other organic cation transporters of the SLC22A family, is 
preferentially expressed in the testis and hematopoietic cell types, but absent in the 
kidneys and liver (Enomoto et al., 2002e; Gong et al., 2002c; Okabe et al., 2005i). Early 
work to characterize OCT6 identified it as a doxorubicin transporter expressed in a 
variety of leukemias (Gong et al., 2002d; Okabe et al., 2005j). OCT6 expression has 
since been identified in malignant breast, endometrial, and ovarian tissues (Sato et al., 
2007b; Ota et al., 2007a). Expression of OCT6 varies throughout the menstrual cycle, 
peaking during the secretory phase. In vitro, mRNA expression of OCT6 by endometrial 
cancer cells is increased in response to progesterone (Sato et al., 2007a). Improved 
response rates to cyclophosphamide/doxorubicin/5-fluorouracil chemotherapy with the 
addition of medroxyprogesterone may be due to increased expression of doxorubicin 
transporter OCT6 by endometrial cancers (Ayoub et al., 1988). 
A pharmacogenomic study of patients receiving doxorubicin therapy has 
suggested a clinical role of OCT6 polymorphisms in breast cancer therapy. The T1226C 
variant of OCT6 was associated with a greater incidence of dose delay (a surrogate 
marker of toxicity), while the A146G, T312C, and T755C SNPs decreased the incidence 
of dose delay; however no OCT6 allele had any effect on patient survival (Bray et al., 
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2010). Due to the complexity of doxorubicin disposition, patient outcome is likely to be 
best described by a composite of ABCB1, CYP2B6, and SLC22A16 haplotypes. 
 The localization of OCT6 in the testis, and ability to sensitize testicular cancer 
cells to first-line chemotherapeutic agent bleomycin, suggests the presence of OCT6 may 
drive germ cell cancer cure rates (Aouida et al., 2010a). Furthermore, the propensity of 
other organic cation transporters to transport platinum agents makes OCT6 an ideal 
candidate to explain the remarkable therapeutic efficacy of cisplatin and oxaliplatin in the 
treatment of the majority of testicular cancers. Conversely, screening for OCT6 
expression prior to initiation of chemotherapy may help identify those patients requiring 
alternate chemotherapy regimens due to low uptake transporter expression. 
1.5.2 Organic Anion Transporters 
 First cloned from rat kidney, renal organic anion transporter 1 (Slc22a6; Oat1, 
originally NKT) was identified as a probenecid-inhibitable para-aminohippurate 
(PAH)/dicarboxylate exchanger (Sekine et al., 1997b; Lopez-Nieto et al., 1997a; Sweet 
et al., 1997). Human homologues include functionally characterized OAT1-4 (SLC22A6-
9) and URAT1 (SLC22A12; urate transporter 1) (Ahn & Nigam, 2009c). Six of the eight 
known OATs exist as linked gene pairs within the genome; OAT1-OAT3, OAT4-
URAT1, and OAT5-UST3 (unknown solute transporter 3) (Eraly et al., 2004). 
Coordinated transcription of these gene pairs is reflected in their pattern of tissue 
expression. OAT1 and OAT3 are expressed at the basolateral membranes of the proximal 
tubule and blood-brain barrier where they facilitate the first step in the clearance of 
uremic toxins such as indoxyl sulfate and neurotransmitter metabolites such as 
homovanillic acid (Sweet, 2005).  
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Renal OATs also play an important role in plasma urate homeostasis through its 
secretion by basolateral OAT1 and OAT3 and reabsorption by apical OAT4 and URAT1 
(Bakhiya et al., 2003; Enomoto et al., 2002a; Hagos et al., 2007; Ichida et al., 2003; 
Islam et al., 2008b). In the proximal tubule cell the basolateral sodium/dicarboxylate 
cotransporter 3 (SLC13A3; NaDC3) with the aid of mitochondrial production, establish 
an intracellular-to-extracellular concentration gradient of α-ketoglutarate (Pritchard, 
1995). Organic anion transporters 1 & 3 concentrate organic anions within the cell by 
exchanging an organic anion for the dicarboxylate anion α-ketoglutarate. Thus, OAT1 
and OAT3 are believed to facilitate the first step in the secretion of anionic uremic toxins 
such as indoxyl sulfate and indole acetate (Ahn & Nigam, 2009d; Deguchi et al., 2004). 
At the apical membrane, OAT4 concentrates organic anions in exchange for 
dicarboxylate anions succinate or α-ketoglutarate (Rizwan & Burckhardt, 2007). In 
contrast to other subfamily members, OAT2 is most highly expressed at the basolateral 
membrane of hepatocytes. OAT2 has been proposed to regulate hepatic metabolism by 
uptake of short-chain fatty acids, but its role and mechanism of function remain 
controversial (Islam et al., 2008a; Ahn & Nigam, 2009b). Each of the OATs have also 
shown specificity for endogenous steroids 5-dehydroepiandrosterone (DHEAS), estrone-
2-sulfate, and estradiol-17β-glucuronide, prostaglandins E2 and F2α, as well as cyclic 
nucleotides cAMP and cGMP, and thus likely play a role in hemodynamics and 
metabolism (Ahn & Nigam, 2009a; Islam et al., 2008c). 
 Like other members of the SLC family, our current knowledge of OAT 
expression in cancer is largely limited to cultured cell lines (Okabe et al., 2008a). A 
survey of solute carrier mRNA expression in 19 non-small cell lung carcinoma tumors 
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revealed a small decrease in OAT1 and little change in OAT2, OAT3, and OAT4 
compared to paired healthy tissue (Monks et al., 2007). In comparison to normal renal 
cortical slices, uptake of the prototypical OAT substrate PAH was absent in renal cell 
carcinoma tissue and declined with severity of the tumor stage (Fleck et al., 2000b; Fleck 
et al., 1997). However, drug uptake activity could be stimulated by dexamethasone 
(Fleck et al., 2000a), and thus may provide a mechanism for improved efficacy during 
combination therapy for advanced renal cell carcinoma in addition to NF-κB inhibition 
(Arai et al., 2008; Schoffski et al., 2009). 
The human OATs are known to interact with a wide variety of drugs, notably β-
lactam antibiotics, non-steroidal anti-inflammatories (NSAIDs), anti-virals, diuretics, and 
angiotensin-converting enzyme (ACE) inhibitors, however reports of anti-cancer agents 
as substrates for OATs are limited (Sekine et al., 2006). With the exception of paclitaxel 
transport by OAT2 (Kobayashi et al., 2005c), anti-cancer agent specificity of OATs 
appears to be restricted to anti-metabolites. Although only human OAT2 has been shown 
to transport 5-fluoruracil (5-FU) (Kobayashi et al., 2005d), rodent Oat1 and Oat3 have 
exhibited uptake of the anti-purines 6-mercaptopurine and 5-FU (Kobayashi et al., 2004; 
Mori et al., 2004). Transport by in human orthologues remains to be confirmed. 
A common substrate of the OATs is the anti-folate methotrexate (Cha et al., 
2001a; Sekine et al., 1997c; Sun et al., 2001a; Takeda et al., 2002). Methotrexate is 
eliminated by a combination of glomerular filtration and OAT1- and OAT3-mediated 
tubular secretion (Shen & Azarnoff, 1978). During chemotherapy, inhibition of OAT-
mediated clearance of methotrexate by NSAIDs or the uricosuric agent probenecid can 
lead to life-threatening myelosuppression and acute renal failure (Basin et al., 1991; 
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Ellison & Servi, 1985; Frenia & Long, 1992; Thyss et al., 1986). Patient response to this 
renally cleared folate analogue is likely determined by distribution by folate carriers 
RFC1 (reduced folate carrier 1; SLC19A1) and PCFT (proton coupled folate transporter; 
SLC46A1) and elimination by OATs (Zhao et al., 2008). The influence of renal OATs has 
been largely focused on the pharmacokinetics of anti-cancer agents, while expression of 
OATs in many cancers and the role of this subfamily on the potency of anti-cancer agents 
remain to be studied. 
1.5.3 Organic Anion Transporting Polypeptides 
 Transporters of the organic anion-transporting polypeptide (OATP) superfamily 
facilitate polyspecific sodium-independent uptake of amphipathic anions, zwitterions, and 
some cations. The first member of the SLCO (originally SLC21) superfamily was cloned 
from rat liver as a sodium-independent sulfobromophthalein and bile salt uptake 
transporter and denoted Oatp1. Transport of substrates may be driven by exchange with 
taurocholate, bicarbonate, or GSH. Eleven human OATPs of six families (OATP1-6) and 
four subfamilies (A-D) have since been cloned. The tissue localization and substrate 
specificity of the OATPs have implicated them as important determinants of drug 
disposition, toxicity, and efficacy (Hagenbuch & Gui, 2008a). 
 Currently, well-characterized members include the widely expressed OATP1A2 
(SLCO1A2) and OATP2B1 (SLCO2B1) and liver-specific OATP1B1 (SLCO1B1) and 
OATP1B3 (SLCO1B3). Prototypical substrates of OATPs are typically sterols such as the 
hormone estrone-3-sulfate (E1S) and bile acid taurocholate, but many members are 
capable of transporting common drugs such as ACE inhibitors, angiotensin receptor 
antagonists, antibiotics, and statins, hence interest in the effect of OATPs on 
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pharmacotherapy has continued to grow. OATPs fulfil a variety of physiological roles 
facilitating the metabolism and signalling of eicosanoids, estrogens, peptides, thyroid 
hormones, and their metabolites, in addition to mediating the first step in hepatic 
clearance of circulating bilirubin, bile acids and conjugates (Hagenbuch & Gui, 2008b). 
 Irinotecan (CPT-11) is approved as first-line therapy for the treatment of 
metastatic colorectal cancer; hence the role of intestinal OATPs in the accumulation of 
SN-38 by colorectal cancer is of great interest. Although the hepatic disposition of 
irinotecan is likely dependent on OCT3 (Shnitsar et al., 2009a), the potent metabolite SN-
38 may be a substrate of intestinal OATP1B1 and OATP1B3 (Nozawa et al., 2005b; 
Oostendorp et al., 2009d; Yamaguchi et al., 2008b). Expression of OATP1B1 and 
OATP1B3 protein in addition to OATP1A2 and OATP4A1 mRNA has been detected in 
colorectal cancers (Abe et al., 2001g; Ancona et al., 2006; Ballestero et al., 2006c; Lee et 
al., 2008b). Both SN-38 and its glucuronide are excreted into the gut via the bile. 
Following cleavage from the glucuronide by gut microflora, SN-38 may be reabsorbed by 
the intestine (Takasuna et al., 1996). Uptake of SN-38 by OATP1B1 has been observed 
by different laboratories; however, evidence for SN-38 transport by OATP1B3 is 
inconsistent and likely due to differences in transporter expression systems (Nozawa et 
al., 2005c; Yamaguchi et al., 2008a). The increased expression of SN-38 uptake 
transporters by neoplastic tissue may contribute to irinotecan’s efficacy (Ballestero et al., 
2006b; Lee et al., 2008a). Alternatively, overexpression of functional OATP1B3 confers 
apoptotic resistance in colon cancer cells by reduced transcriptional activity of p53 (Lee 
et al., 2008e). 
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 Similar to their tissue of origin, OATP1B1 and OATP1B3 are expressed in 
hepatocellular carcinomas (Cui et al., 2003c; Narita et al., 2009; Vavricka et al., 2004b). 
Due to the heterogeneity of cancers, even from the same tissue of origin, transporter 
expression varies between classifications. A detailed histological study of benign liver 
tumours revealed decreased staining of OATP1B1/1B3 in hepatocellular adenomas, while 
strong expression patterns were observed in focal nodular hyperplasias (Vander et al., 
2005). OATP1B1 and OATP1B3 were also detected in a large majority of hepatocellular 
carcinomas, while staining of cholangiocarcinomas and liver metastases of colorectal and 
pancreatic adenocarcinomas were negative (Cui et al., 2003d). Interestingly, in a study of 
13 paired hepatocellular carcinoma and healthy tissue samples, a decrease in OATP8 
protein expression was observed which correlated to an increase in the liver-enriched 
transcription factor hepatocyte nuclear factor 3β (HNF3β). In contrast, no significant 
change in OATPC expression was detected, suggesting a mechanism of differential 
regulation of expression in cancerous tissue (Vavricka et al., 2004a). Larger 
investigations into expression of these transporters are needed if the use of bile acid 
conjugates of anti-cancer drugs such as cisplatin is to be considered.  
A multitude of OATP mRNAs are expressed in non-small cell lung cancer, 
notably an up-regulation of OATP1B3 (Monks et al., 2007‚). OATP1B3 has also been 
shown to uptake current lung cancer drugs paclitaxel and docetaxel (Smith et al., 2005a). 
Common single nucleotide polymorphisms of OATP1B3 may only play a limited role in 
paclitaxel pharmacokinetics (Smith et al., 2007). However the relative contribution of 
tumor volume to paclitaxel apparent distribution is small, and whether tumor specific 
expression correlates to patient outcome remains to be determined. To this end, the use of 
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uptake transporter-specific radiotracers may help identify susceptible tumors and aid in 
optimizing anti-cancer therapy to prevent early drug resistance (Narita et al., 2009; 
Tsuboyama et al., 2010). 
Expression of uptake transporters may render tumors sensitive to hormonal 
growth stimuli. Uptake of E1S by many OATPs had lead to investigation into their role in 
hormone-dependent breast cancers. Many of the OATPs are expressed in breast cancers, 
including OATP1A2 (Meyer zu Schwabedissen et al., 2008c; Miki et al., 2006b), 
OATP1B3 (Muto et al., 2007b), OATP2A1 (Wlcek et al., 2008e), OATP2B1 (Al Sarakbi 
et al., 2006a), OATP3A1 (Wlcek et al., 2008d), OATP4A1 (Wlcek et al., 2008c), 
OATP4C1 (Wlcek et al., 2008b), and OATP5A1(Wlcek et al., 2008a). The proliferation 
of hormone-dependent breast cancer MCF-7 cells can be controlled by OATP1B3-
mediated uptake of E1S (Maeda et al., 2010; Nozawa et al., 2005d). Clinically, 
OATP1B3 may be expressed in up-to half of all breast carcinomas. OATP1B3 expression 
may also be a strong prognostic marker; correlating to low risk of recurrence in estrogen 
receptor-positive cases (Muto et al., 2007a). 
OATP1A2 is significantly up-regulated at the protein level in breast cancer and 
may also play a pivotal role in pathogenesis (Meyer zu Schwabedissen et al., 2008b; Miki 
et al., 2006c). Expression of OATP1A2 can be induced through binding of the nuclear 
pregnane X receptor (PXR) to a promoter region of SLCO1A2 (Meyer zu Schwabedissen 
et al., 2008a). Increased OATP1A2, in turn, induces breast cancer proliferation through 
accumulation of estrogen precursors. Given that estrone and 17β-estradiol are activators 
of PXR (Jacobs et al., 2005; Mnif et al., 2007), the subsequent increase in hormone 
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accumulation results in feed-forward regulation of OATP1A2 expression and breast 
cancer hyperplasia (Meyer zu Schwabedissen et al., 2008e). 
 Gliomas are characterized by strong chemoresistance due to the low permeability 
of the blood-brain barrier. Unlike at epithelial layers of other tissues, uptake transporter 
expression may confer resistance at the blood-brain barrier by abluminal expression; 
facilitating the clearance of anti-cancer agents from the brain parenchyma (Deeken & 
Loscher, 2007). A screen of a diverse panel of 61 glioma specimens revealed mRNA 
expression of OATP1A2, OATP1C1, OATP2B1, and OATP4A1. However, only 
OATP1A2 and OATP2B1 protein were present at the blood-brain and blood-tumor 
barriers, and absent in endothelial and glioma cells of tumors (Bronger et al., 2005g). 
Despite an apparent dearth of drug uptake transporter expression by gliomas, expression 
of known neuronal OAT and OCT transporters remains to be determined. 
Although relatively few studies have evaluated uptake of anti-cancer agents by 
OATPs, similar to the OATs, methotrexate may emerge as a common substrate (Abe et 
al., 2001h; Badagnani et al., 2006a; Mikkaichi et al., 2004c; Sasaki et al., 2004b). In 
vitro expression of OATP1B3 is capable of sensitizing cells to methotrexate (Abe et al., 
2001i). Given the expression of OATP1B3 protein in many colorectal cancers (Abe et al., 
2001j; Ballestero et al., 2006a; Lee et al., 2008f), its expression may contribute to the 
sensitization of tumors to anti-folate therapy. In conjunction with the growing list of anti-
cancer substrates, future investigations will elucidate the role of OATPs in cancer biology 
and its treatment. 
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1.6 Focus of Thesis 
The pharmacokinetics of drugs plays a crucial role in their clinical effectiveness. 
This is especially true of chemotherapeutics, where their distribution between cancerous 
and healthy tissue often determines a drug’s therapeutic index. Control of side effects 
associated with cancer chemotherapy is essential to provide adequate dosing of 
anticancer drugs. Mesna is a sulfhydryl drug that has been in use for the past thirty years 
to mitigate ifosfamide-induced hemorrhagic cystitis. Dimesna, the disulfide dimer and 
primary metabolite of mesna, is currently being evaluated as a prodrug in phase III trials 
for the treatment of cisplatin induced nephrotoxicity. Remarkably, mesna and dimesna 
specifically target the kidney without attenuation of the efficacies of ifosfamide or 
cisplatin.  
Circulating dimesna must gain entry to the kidneys and urine as chemically 
reduced mesna in order to exert its protective effects. In chapter two we elucidate the 
renal drug transporters responsible for reabsorption of dimesna into the proximal tubule 
cells and subsequent efflux of active mesna into the urine. In addition, we identify novel 
transcellular pathways of transporter-mediated active secretion of mesna by the proximal 
tubule cells. The clinical importance of our findings is highlighted by a controlled drug 
interaction study demonstrating that transporter-mediated secretion represents a 
significant fraction of total mesna clearance. 
In chapter three we examine in detail the kinetics of dimesna metabolism by non-
enzymatic thiol-disulfide thiol exchange with abundant endogenous thiols Cys and GSH, 
and further elucidate the roles of members of the thioredoxin family of oxidoreductases 
in the metabolism of dimesna. 
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 Glutathione is an endogenous antioxidant thiol that facilitates drug resistance by 
the detoxification of many anti-cancer agents (Gatti & Zunino, 2005). The depletion of 
GSH and its precursors, Cys and Hcy, in patients receiving mesna was originally 
investigated to provide a rationale for the potentiation of chemotherapy. The disulfide 
bonding of sulfhydryl (i.e. “free”) mesna to Cys34-albumin displaces endogenous thiols, 
increasing their free fraction and subsequent renal clearance (Urquhart et al., 2006; 
Urquhart et al., 2007a). Although mesna did indeed lower circulating GSH, Cys, and Hcy 
(Lauterburg et al., 1994; Pendyala et al., 2000; Stofer-Vogel et al., 1993), whether this 
contributes to the efficacy of co-administered ifosfamide remains to be determined. 
Interestingly, the application of mesna to lower plasma tHcy may itself be 
therapeutically useful. The non-protein forming thiol amino acid Hcy is a graded, 
independent risk factor for atherosclerosis and thrombosis (Chao et al., 1999; Graham et 
al., 1997; Nygard et al., 1997; Vasan et al., 2003; Wald et al., 2002). In chapter four we 
further develop the recent novel clinical application of mesna to lower plasma tHcy in 
ESRD (Urquhart et al., 2007b; Urquhart et al., 2008). Plasma tHcy levels are elevated in 
over 90% of patients with ESRD despite B-vitamin supplementation (House & Donnelly, 
1999; Spence et al., 1999; Wrone et al., 2004). Approximately 75% of Hcy is protein-
bound, and thus unavailable for clearance by routine hemodialysis (House et al., 2000; 
Mansoor et al., 1993). The use of mesna may provide an additional strategy to lower 
Hcy, and in turn, the atherothrombotic burden of ESRD. 
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The global hypothesis of this thesis is that the pharmacological characteristics of 
mesna and dimesna are determined by drug transporters and thiol metabolism. The 
specific objectives are: 
1) To identify the transporters responsible for the renal-specific disposition of mesna 
and dimesna. 
2) To determine the in vivo contribution of renal drug transporters to the 
pharmacokinetics of total mesna. 
3) To determine the enzymatic and non-enzymatic mechanisms of dimesna 
metabolism. 
4) To measure the effect of mesna to lower plasma total homocysteine (tHcy) in end-
stage renal disease (ESRD). 
 
 Mesna and dimesna have undergone continuous development for new indications 
throughout their history. Here we elucidate the biological characteristics of these 
compounds underlying their unique pharmacological properties and continue to expand 
the therapeutic application of mesna. 
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CHAPTER 2: IN VITRO AND IN VIVO ASSESSMENT OF THE ROLE OF 
ORGANIC ANION TRANSPORTERS IN THE DISPOSITION OF MESNA AND 
DIMESNA 
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2.1 Introduction 
 In the early 1980s, significant advancement in the safety of ifosfamide therapy 
was achieved by coadministration of mesna (sodium 2-mercaptoethane sulfonate) to 
reduce previously observed dose-limiting hemorrhagic cystitis (Andriole et al., 1987). 
Mesna exerts its protective effect within the urine, where its free sulfhydryl group is able 
to bind to, and thereby inactivate, reactive metabolites (Kurowski & Wagner, 1997). 
Within the circulation mesna exists primarily as its inactive dimer, dimesna (disodium 
2,2-dithio-bis-ethane sulfonate), which is currently undergoing clinical development as a 
prodrug (BNP7787; Tavocept™) to treat cisplatin-induced nephrotoxicity (Boven et al., 
2005; Verschraagen et al., 2003a). 
 Dimesna undergoes selective kidney reduction and elimination in excess of 
glomerular filtration (Ormstad et al., 1983; Urquhart et al., 2007; Brock et al., 1981; 
Verschraagen et al., 2004a). Remarkably, neither mesna nor dimesna interfere with the 
efficacy of coadministered antineoplastic agents (Millar et al., 1983; Verschraagen et al., 
2003a). This has been attributed to the rapid oxidation of mesna to dimesna and its 
apparent inability to readily cross cell membranes (Brock et al., 1981). However, with the 
identification and characterization of drug transporting proteins, the organ-specific 
disposition of drugs is now understood to be much more complex (Ho & Kim, 2005). 
Similar to drug metabolizing enzymes, the ability of drug transporters to influence 
the disposition of drugs raises the potential for transporter-mediated drug-drug 
interactions (DDIs) and polymorphisms of drug transporters to alter drug response 
(Giacomini et al., 2010; Maeda & Sugiyama, 2008). Loss of transport function, whether 
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due to genetic variation or coadministration of an inhibitor, may adversely alter the safety 
and efficacy of the drug by preventing its excretion or restricting access to its site of 
action. Amongst the renal drug transport proteins, uptake transporters OAT1 (SLC22A6) 
and OAT3 (SLC22A8) have been implicated as clinically relevant drug transporters that 
could potentially mediate DDIs of substrate drugs cleared by the kidney through active 
secretion. Indeed, labeling by the Food and Drug Administration of the antiviral cidofovir 
(Vistide®; Gilead) and the antihyperglycemic sitagliptin (Januvia™; Merck) has included 
information of interactions with OATs (Giacomini et al., 2010). 
Given the tissue-specific disposition of mesna and dimesna, and previously 
hypothesized obligatory reduction of dimesna by the kidney parenchyma (Ormstad & 
Uehara, 1982), our initial objective was to measure the dimesna transport capacity of 
renal and hepatic drug transporters. We extended our in vitro results with a clinical 
pharmacokinetic study using the transport inhibitor probenecid to determine the in vivo 
contribution of transporter-mediated secretion of combined mesna and dimesna.  
In light of our identification of uptake and efflux transporters of dimesna, we 
believe the organ specificity of dimesna, and therefore activation of dimesna to mesna 
within the proximal tubule cells, is the result of differential transport across epithelia. 
Polymorphisms of renal transport proteins or transporter-mediated drug-drug interactions 
may lower the efficacy of the chemoprotectants mesna and dimesna, potentially causing 
withdrawal from chemotherapy due to toxicity (i.e. dose delay). 
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2.2 Methods 
2.2.1 In vitro Screen of Drug Transporters Capable of Dimesna Transport 
Transport studies were performed in HeLa cells using a transient heterologous 
expression system as previously described (Cvetkovic et al., 1999; Kim et al., 1999). 
Human cervical carcinoma cell lines (HeLa cells) were seeded on 12-well plates and 
infected with recombinant vaccinia virus (vTF7-3, ATCC # VR-2153) in low serum Opti-
MEM (Invitrogen, Carlsbad, CA) prior to transfection of either cDNA (packaged in either 
pEF6/V5-His-TOPO or pcDNA3.1/V5-His-TOPO) or empty plasmid (1 µg total) with 
Lipofectin reagent (Invitrogen). cDNA in a 1:4 ratio of uptake to efflux was used in the 
experiments requiring transfection of both uptake and efflux transporters. Cells were 
incubated at 37°C for 16 hours prior to transport experiments. Uptake of [3H]dimesna (1 
mCi/mmol, > 98%purity, Moravek Biochemicals, Brea, CA) was determined in the 
presence and absence of probenecid (Sigma-Aldrich, St. Louis, MO) diluted in low serum 
Opti-MEM (Invitrogen) for transporter screens and Krebs-Henseleit bicarbonate (KHB) 
buffer for kinetic assays following 10 minute incubation at 37°C in a humidified 5% CO2 
atmosphere. A [3H]dimesna accumulation-time course determined 10 min to be within 
the initial linear uptake phase for each of the OATs tested. Cells were washed three times 
with ice cold phosphate-buffered saline and lysed with 1% sodium dodecyl sulfate prior 
to liquid scintilation counting. During initial screening of uptake transports, taurocholate 
uptake into cells transfected with sodium-taurocholate cotransporting polypeptide 
(NTCP; SLC10A) cDNA was used as a positive control for transfection and expression 
efficiency, as previously described (Glaeser et al., 2007; Tirona et al., 2003). Dimesna 
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uptake by organic anion transporter 4 (OAT4; SLC22A11) was used as a positive control 
during kinetic experiments. Cold dimesna used to assess dimesna uptake kinetics was a 
kind gift from Dr. G. Koren (University of Toronto, Toronto, Canada). 
2.2.2 In vitro Data Fitting and Statistical Analysis 
Parameters representing the affinity of dimesna for OATs (KM) and inhibition of 
transport by probenecid (Ki) were determined by nonlinear regression using Prism 
(GraphPad Software, Inc., San Diego, CA) assuming rapid equilibrium saturation kinetics 
and competitive inhibition. Calculated Kis of probenecid with OAT1 and OAT3 is within 
2-3-fold of stably-transfected cell lines (Takeda et al., 2001). Statistical analysis of 
dimesna uptake by screened uptake and efflux transporters was performed using one-way 
ANOVA followed by Tukey’s multiple comparison tests. P-values less than 0.05 were 
considered statistically significant. In vitro data fitting and statistical analysis was 
completed using Prism (GraphPad Software, Inc., San Diego, CA). 
2.2.3 In vitro Determination of Efflux Transporters Capable of Mesna Export 
HeLa cells transfected as outline above were incubated with [3H]dimesna (1 µM 
in KHB buffer) at 37°C for 60 minutes, [3H]mesna present in the supernatant was 
derivatized with monobromobimane (EMD Biosciences, Gibbstown, NJ), and separated 
by liquid chromatography and fractions detected by liquid scintilation counting.  Reduced 
[3H]mesna exported from transfected cells was derivatized by adding 100 µL of 
supernatant to 50 µL of 12.5 mM monobromobimane  followed by 50 µL of 50 mM Tris 
buffer (pH = 9.0). The reaction mixture was then incubated at 37°C for 15 minutes and 
50 µL of 4% acetonitrile: 96% 25 mM ammonium formate buffer (pH = 3.75) was added 
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to stabilize labeled thiols. Derivatized samples were injected onto a Zorbax SB-C18 
column (150 x 3.2 mm, 5 µm particle; Agilent Technologies, Santa Clara, CA) and eluted 
isocratically with 10% acetonitrile: 90% 25 mM ammonium formate: 0.1 % formic acid 
buffer containing 0.75 mM dibutylamine (pH = 3.75) at a flow rate of 0.6 mL/min by a 
Waters 510 LC pump (Waters, Milford, MA). Eluent was collected as one minute 
fractions directly into scintillation vials. Authentic labeled [3H]mesna was produced by 
chemical reduction of [3H]dimesna with NaBH4 in 0.05 M NaOH (Sigma-Aldrich) prior 
to derivatization and chromatographic and liquid scintillation analysis.  HeLa cells 
transfected with empty vector (pEF) or uptake transporter only (OAT4) were included as 
negative controls. 
2.2.4 Study Design and Volunteer Subjects 
Twelve healthy subjects (nine male; three female, mean age 31 years; range 22-
54, mean weight 78.5 kg; range 54-108, mean body surface area 1.95 m2; range 1.60-
2.36) were enrolled in a three session study. The study protocol was approved by The 
University of Western Ontario Health Sciences Research Ethics Board and all subjects 
provided written informed consent. Dimesna is currently an investigational new drug 
undergoing clinical development in the United States and has not been approved for use 
in Canada. However, the oral administration of intravenous mesna solution results in 
rapid oxidation of mesna to dimesna during absorption into the systemic circulation 
(Ormstad et al., 1983).  Thus, we chose to evaluate the pharmacokinetics of total mesna 
following administration of the OAT inhibitor probenecid. 
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Glomerular filtration rate was estimated by the 4 variable Modification of Diet in 
Renal Disease Study equation using serum creatinine values obtained prior to initiation of 
the study (Levey et al., 2007). Creatinine analysis was conducted in the core laboratory 
of University Hospital using the Jaffé reaction method (Spencer, 1986).  All subjects had 
eGFRs ≥ 102 mL/min/1.73 m2. 
During the first of three study sessions (Session 1), subjects received 0.4 g/m2 
mesna (Uromitexan®; Baxter Corporation, Mississauga, Canada) in 300 mL water. 
Following at least one week of washout, subjects received a single 1 g oral dose of 
probenecid during Session 2 and maintained a dosing regimen of 1 g oral probenecid 
(Benuryl®; Valeant Ltd., Montreal, Canada) twice daily, for six days.  During Session 3, 
subjects returned to the clinical research unit on the seventh day to receive 1 g oral 
probenecid one hour prior to receiving 0.4 g/m2 mesna in 300 mL of water. Peripheral 
venous blood samples (5 mL) were drawn just prior (0 h) and 1, 2, 3, 4, 5, 6, 7, 8, and 24 
hours after dosing and immediately centrifuged at 2,000 g to obtain plasma which was 
stored at -20°C until analysis. Total urine output was collected during each of the 24 hour 
study sessions, from which 4, 8, and 24 hour aliquots were stored at -20°C until analysis. 
2.2.5 Total Mesna Analysis 
Total mesna analysis was conducted with slight modification to methodology 
previously described (Urquhart et al., 2006). Disulfide bonds were completely reduced by 
addition of 53 mM NaBH4 in 0.05 M NaOH and incubation at 37°C for 5 minutes. 
Residual reducing agent was quenched by 1.2 M HCl (Sigma-Aldrich) and thiols were 
derivatized with 12.5 mM monobromobimane (25% acetonitrile, 3 mM EDTA) at 37°C 
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for 15 minutes.  Protein was precipitated by addition of 15% perchloric acid (Sigma-
Aldrich) and centrifugation. Supernatant pH was raised to 4.0 with 0.5 M citrate: 2.5 M 
NaOH solution (Sigma-Aldrich). Mesna derivatized with monobromobimane was 
injected onto a Zorbax SB-C18 column (150 x 3.2 mm, 5 µm particle) maintained at 
40°C in a Hewlett Packard 1090 LC (Agilent Technologies). Analytes were eluted with a 
gradient of 4% acetonitrile: 96% ammonium formate: 0.1 % formic acid containing 0.75 
mM dibutylamine (pH 3.75) to 17% acetonitrile: 83% ammonium formate: 0.1 % formic 
acid containing 0.75 mM dibutylamine (pH 3.75) over 20 minutes at a flow rate of 0.5 
mL/min. All solvents and reagents were of HPLC-grade or higher. Derivatized mesna 
was detected at 12.5 minutes by a Waters 474 scanning fluorescence detector (λexcitation = 
390 nm, λemission = 480 nm; Waters). The accuracy and precision of the assay were 1.3% 
and 2.0%, respectively. 
2.2.6 Probenecid Analysis 
Probenecid analysis was conducted by solid phase extraction followed by liquid 
chromatography and ultraviolet detection.  Briefly, 100 µL of plasma was mixed with 
internal standard (n-propyl p-hydroxybenzoate; Sigma-Aldrich) and loaded onto 1 mL 
C18 solid phase extraction tubes (100 mg end-capped ODS packing, Agilent 
Technologies) conditioned to manufacture’s specifications. Packing was washed with 1 
mL of Milli-Q water and analytes eluted with methanol containing 0.1% formic acid, 
0.1% triethylamine. Eluent was dried at 40°C under medical air and reconstituted with 
mobile phase prior to being injected onto a Novopak C18 column (50 x 3.9 mm, 5 µm 
particle; Waters) maintained at 40°C in a Hewlett Packard 1090 LC. Analytes were eluted 
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with a gradient of 25% methanol: 15% acetonitrile: 60% 10 mM potassium phosphate 
buffer: 0.08% triethylamine (pH = 3.0) to of 35% methanol: 35% acetonitrile: 30% 10 
mM potassium phosphate buffer: 0.08% triethylamine (pH = 3.0) over six minutes at a 
flow rate of 0.5 mL/min. Probenecid and internal standard were detected with a Hewlett 
Packard 1050 variable wavelength ultraviolet detector set to 244 nm (Agilent 
Technologies). The accuracy and precision of the assay were 3.5% and 9.0%, 
respectively. 
2.2.7 Pharmacokinetic Analysis 
Prior studies have shown probenecid elimination to be saturable at the dose used 
in this study (1 g twice-daily) (Cunningham et al., 1981; Selen et al., 1982). 
Simultaneous fitting of mean probenecid plasma concentrations from first (Session 2) to 
last (Session 3) doses determined that probenecid plasma concentration-time profiles 
were best described by a two-compartment model with nonlinear elimination from the 
central compartment. Data were transformed by relative weighting (weighted 1/y2) and 
least squares fitting of the model was performed using Scientist (Micromath Research, 
Salt Lake City, UT). 
Non-compartmental analysis of total mesna data was completed using WinNonlin 
(version 5.2, Pharsight, Mountain View, CA). Cmax and tmax were obtained directly. 
Observed AUCs for plasma and urine data were calculated by the linear trapezoidal 
method. Vss was calculated as Dose*AUMC0-∞/AUC0-∞2, CLu,renal was calculated as Ae 0-
24/(AUC0-24*fu). Net fraction of renal clearance due to secretion (CLsec) was calculated as 
(CLu,renal - fuGFR)/CLu,renal. 
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2.2.8 Estimation of Renal Clearance in the Presence of Probenecid 
The estimated decrease in renal clearance by inhibition of multiple elimination 
pathways was calculated as: 
CLu,renal,i = CLu,renal*((0.5/(1 + Iu,max/ Ki,OAT1)) +     
       (0.5/(1 + Iu,max/ Ki,OAT3))) (Eq. 2.1) 
where Iu,max is the maximum unbound concentration of probenecid obtained from fitting 
mean plasma data. Ki,OAT1 and Ki,OAT3 are  inhibition constants for OAT1, and OAT3, 
respectively, obtained from in vitro data (Ito et al., 2005). In the absence of absolute 
quantitative expression data, both transporters were assumed to contribute equally to total 
mesna clearance. 
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2.3 Results 
2.3.1 OATs are Responsible for Kidney-Specific Uptake of Dimesna 
Saturable, kidney-specific, uptake of dimesna has previously been observed in 
experiments using perfused organs and isolated epithelial cells (Ormstad & Uehara, 1982; 
Ormstad et al., 1983), yet the identity of the responsible transporter(s) remained to be 
elucidated. To identify potential transporters we screened 12 human uptake transporters 
using a heterologous transporter expression system in HeLa cells (Figure 2.1). Following 
a 10 minute incubation with 552 nM [3H]dimesna, only the predominantly renally-
expressed OAT1 (SLC22A6), OAT3 (SLC22A8), and OAT4 (SLC22A11) significantly 
increased dimesna accumulation in transfected cells. Interestingly, transporters of the 
hepatic OATP family did not increase dimesna accumulation over vector control, 
supporting the previously established lack of hepatic uptake of dimesna and mesna. 
Using a heterologous over-expression system in HeLa cells the uptake of dimesna 
by OAT1, OAT3, and OAT4 was determined to be saturable with KMs of 635.9 ± 279.6, 
390.3 ± 292.5, and 589.8 ± 232.9 µM, respectively (Figure 2.2). Uptake of dimesna by 
specific OATs was further characterized using probenecid, the prototypical inhibitor of 
the OAT family.  Using the previously measured KMs, the Ki of probenecid for OAT1, 
OAT3, and OAT4 was calculated directly to be 26.0 ± 8.9, 32.3 ± 14.5, and 55.9 ± 20.8 
µM, respectively (Figure 2.3). 
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2.3.2 Differential Efflux of Dimesna and Mesna by ATP-Binding Cassette (ABC) 
Transporters and MATE1 
Following identification of members of the OAT family as dimesna uptake 
transporters, we aimed to identify which efflux transporters are capable of exporting 
dimesna and mesna, thereby facilitating urinary secretion. We compared [3H]dimesna 
accumulation in HeLa cells co-transfected with OAT4 and empty vector (conferring 
uptake only) to cells co-transfected with OAT4 and efflux transporter (conferring both 
uptake and potential efflux). An efflux transporter capable of exporting either 
[3H]dimesna or its metabolite [3H]mesna would cause a significant decrease in cellular 
accumulation of radioactivity compared to cells co-transfected with OAT4 and empty 
vector. HeLa cells transfected with vector control and efflux transporter were included as 
negative controls. Each of the efflux transporters screened, BCRP (ABCG2), MATE1 
(SLC47A1), MRP1 (ABCC1), MRP2 (ABCC2), MRP4 (ABCC4), MRP5 (ABCC5), and 
Pgp (ABCB1) significantly reduced [3H]dimesna accumulation compared to cells only 
transfected with the uptake transporter OAT4 (Figure 2.4).  Although indicative of active 
efflux transport activity, a simple decrease in radioactivity could not differentiate 
between efflux of dimesna or mesna. Therefore, to determine whether efflux transporters 
were capable of exporting mesna (following intracellular reduction) we utilized the thiol-
specific reagent monobromobimane to derivatize free thiol present in the buffer following 
incubation of transfected cells with [3H]dimesna. Derivatization of [3H]mesna facilitated 
the separation from parent [3H]dimesna by liquid chromatography prior to detection by 
liquid scintillation counting.  Screening each OAT4-efflux transporter pair and 
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corresponding negative controls revealed that only HeLa cells co-transfected with OAT4 
and either MATE1, MRP2, or Pgp are capable of exporting [3H]mesna following 
incubation with [3H]dimesna (Figure 2.5). 
2.3.3 Secretion of Mesna by Proximal Tubule Cells 
The kidney has been implicated as the site of dimesna reabsorption, reduction to 
mesna, and subsequent secretion to the lumen. Here we propose that the luminal proximal 
tubule transporter OAT4 facilitates the reabsorption of dimesna, and therefore its 
reduction to mesna, whereas MATE1, MRP2, and Pgp facilitate mesna and/or dimesna 
efflux back into the lumen. Similarly, dimesna may be excreted unchanged by MRP4. 
Given the known localization of OAT1 and OAT3 at the basolateral side of proximal 
tubule cells and multiple efflux transporters at the luminal membrane, potential 
transcellular pathways may exist to permit the active secretion of both dimesna and 
mesna into the urine, following uptake of dimesna from the blood, thereby facilitating the 
conjugation of toxic metabolites of cisplatin and ifosfamide within the proximal tubule 
cells and urine (Figure 2.6). 
2.3.4 In vivo Effect of Probenecid on the Disposition of Mesna 
The urinary clearance of total mesna (the sum of all mesna moieties) exceeds 
glomerular filtration rate (Urquhart et al., 2007; James et al., 1987), furthermore the 
transfer of free (reduced) mesna to both the kidney parenchyma and urine is essential for 
its protective effect. In light of the identification of renal OAT transporters as responsible 
for the uptake of dimesna by proximal tubule cells, we aimed to determine the 
contribution of drug transporters to total mesna disposition in vivo. Probenecid has 
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proven to be a useful in vivo tool for the elucidation of the roles of OAT1 and OAT3 in 
the clearance of renally excreted drugs (Kim et al., 2005), although it also inhibits 
MATE1 and members of the MRP family, albeit at lower affinity (Deeley et al., 2006; 
Meyer zu Schwabedissen et al., 2010). 
To determine the in vivo contribution of transporter-mediated processes of the 
kidney to the disposition of total mesna, 12 healthy subjects with normal renal function 
(mean GFR = 7.3 L/h/1.73 m2; Table 2.1) and free of concomitant drugs were enrolled in 
a three session clinical study. Baseline characteristics of healthy volunteers are listed in 
Table 2.1. Oral mesna (0.4 g/m2) was given alone during Session 1. One week following 
Session 1, baseline probenecid profiles were established (Session 2) and subjects 
maintained on probenecid until receiving a second dose of mesna (Session 3), during 
which time both mesna and probenecid plasma concentrations were measured. 
Simultaneous fitting of mean probenecid plasma concentrations from first 
(Session 2) to last (Session 3) doses to a two-compartment model with non-linear 
elimination estimated a peak plasma probenecid concentration of 356.9 µM, which 
correlated to a maximum unbound concentration of 28.6 µM (Figure 2.7). Modeling of 
the concentration-dependent elimination of probenecid estimated a Vmax,i and KM,i of  
63.1 mg/h and 445 mg/L, respectively. 
As anticipated based on prior results (Urquhart et al., 2007), time-averaged renal 
clearance of total mesna during Session 1 (mesna only) was significantly higher than 
GFR for each subject (7.29 ± 0.71 versus 10.6 ± 2.2 L/h/1.73 m2; P < 0.001; Table 2.2 
and Table 2.1). Probenecid significantly increased plasma total mesna Cmax 1.4-fold 
109 
 
 
 
(102.5 ± 30.2 versus 147.4 ± 45.6 µmol/L; P = 0.005; Table 2.2) and total mesna area 
under the concentration-time curve (AUC) 91 ± 34% (894 ± 200 versus 1689 ± 409 
µmol·h/L; P < 0.001; Table 2.2) while decreasing average urinary excretion rate over 24 
hours by 17 ± 23% (960.0 ± 187.2 versus 771.9 ± 184.2 mg/h; P = 0.021; Table 2.2; 
Figure 2.8). Following probenecid administration, total mesna renal clearance (CLu,renal) 
decreased 55.1 ± 12.3% (10.6 ± 2.2 versus 4.7 ± 1.1 L/h/1.73 m2; P < 0.001; Table 2.2). 
In addition, the fraction of renal clearance due to secretion (CLsec) decreased 67.0 ± 
12.7% (0.80 ± 0.05 versus 0.26 ± 0.10; P < 0.001; Figure 2.9). Interestingly, the apparent 
steady-state volume of distribution (Vss/F) decreased 45.2 ± 13.4% (59.0 ± 17.8 versus 
31.3 ± 8.0 L; P < 0.001; Table 2.2), leaving the elimination half-life unaltered (7.3 ± 1.7 
versus 7.7 ± 1.4; P = 0.53; Table 2.2). Estimation of renal clearance due to OAT1 and 
OAT3 in the presence of probenecid by inhibition of multiple elimination pathways 
(Equation 2.1), using the maximum unbound plasma probenecid concentration of 28.6 
µM and in vitro Kis, predicted an unbound renal clearance of 5.33 L/h/1.73 m2. 
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Table 2.1 Baseline characteristics of healthy volunteers of clinical mesna-probenecid 
interaction study. 
Subject Sex Age Weight (kg) BSA (m2) Dose (mg) 
GFR  
(L/h/1.73 m2) 
1 M 23 102.0 2.29 916 8.16 
2 M 31 74.5 1.96 784 6.12 
3 F 30 63.5 1.68 672 7.68 
4 M 30 108.0 2.32 928 7.68 
5 F 26 54.0 1.60 640 6.30 
6 M 22 64.3 1.79 716 7.56 
7 F 22 60.0 1.66 664 7.50 
8 M 54 90.8 2.11 844 7.32 
9 M 51 75.0 1.89 756 6.78 
10 M 26 70.0 1.89 756 6.84 
11 M 25 108.8 2.36 944 7.02 
12 M 28 71.5 1.85 740 8.52 
Mean  31 78.5 1.95 780 7.29 
SD  11 19.1 0.26 106 0.71 
 
BSA, body surface area; GFR, glomerular filtration rate. 
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Table 2.2  Non-compartmental pharmacokinetic parameters of plasma total mesna 
concentration-time curves of clinical mesna-probenecid interaction study. 
Parameter Mesna Mesna + Probenecid P-value 
Cmax (µmol/L) 102.5 ± 30.2 147.4 ± 45.6 0.005 
tmax (h) 2.8 ± 1.6 3.4 ± 0.8 0.239 
AUC0-24 (µmol·h/L) 806.8 ± 163.5 1,479.0 ± 337.6 < 0.001 
AUC0-∞ (µmol·h/L) 894.0 ± 199.7 1,688.7 ± 409.0 < 0.001 
AUMC0-∞ 
(µmol·h2/L) 
8,692.5 ± 3,352.4 18,856.9 ± 6,915.0 < 0.001 
MRT0-∞ (h) 9.5 ± 1.8 11.0 ± 2.4 0.123 
Vss/F (L) 59.0 ± 17.8 31.3± 8.0 < 0.001 
Elimination half-life 
(h) 
7.3 ± 1.7 7.7 ± 1.4 0.532 
Ae 0-24 (mg/1.73 m2) 379.8 ± 45.2 312.5 ± 62.2 0.004 
Ae 0-24 (mg/h) 960.0 ± 187.2 771.9 ± 184.2 0.021 
CLu,renal (L/h/1.73 m2) 10.6 ± 2.2 4.7 ± 1.1 < 0.001 
 
Data are shown as mean ± SD, P-values calculated by paired t-test.  Cmax, peak 
concentration; tmax, time to peak concentration; AUC, area under plasma concentration-
time curve; AUMC0-∞, area under the first moment curve from 0 to infinity; MRT0-∞, 
mean residence time from 0 to infinity; Vss, volume of distribution at steady-state; F, 
bioavailability; Ae 0-24, amount excreted in urine from 0 to 24 hours; CLu,renal, unbound 
renal clearance; GFR, glomerular filtration rate. 
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Figure 2.1  Dimesna transport activity of human uptake transporters following 
heterologous expression in HeLa cells.  [3H]Dimesna (552 nM) was used for all 
experiments.  Cellular accumulation was measured after incubation at 37°C for 10 
minutes.  The data are expressed as percent of vector control (mean ± SE, n = 3). 
Differences between transfectants determined by ANOVA, *,** P < 0.05.  
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Figure 2.2  Kinetics of dimesna uptake by OAT1 (a), OAT3 (b), OAT4 (c) following 
heterologous transporter expression in HeLa cells. Transporter-mediated uptake was 
calculated as the difference between OAT-expressing cells and vector controls treated 
with dimesna of the same specific activity. Accumulated dimesna was assessed after 
incubation at 37°C for 10 min. Data represent mean ± SE (n = 3). 
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Figure 2.3  Kinetics of dimesna uptake by OAT1 (a), OAT3 (b), OAT4 (c) following 
heterologous transporter expression in HeLa cells. Transporter-mediated uptake was 
calculated as the difference between OAT-expressing cells and vector controls treated 
with dimesna of the same specific activity. Inhibitory effect of probenecid is expressed as 
% vector control. Accumulated dimesna was assessed after incubation at 37°C for 10 
min. Inhibition constant (Ki) was calculated assuming reversible one-site competitive 
binding, [3H]dimesna concentration of 467.5 nM, and the previously determined KM. 
Data represent mean ± SE (n = 4). 
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Figure 2.4  Dimesna transport activity of human efflux transporters following 
recombinant vaccinia-mediated expression in HeLa cells.  [3H]Dimesna (552 nM) was 
used for all experiments.  Cellular accumulation was measured after incubation at 37°C 
for 10 minutes.  The data are expressed as percent of vector control (mean ± SE, n = 5). 
Differences between transfectants determined by ANOVA, *,** P < 0.05). 
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Figure 2.5  Export of mesna by efflux transporters following incubation with dimesna. 
HeLa cells transfected with either efflux transporter alone (open circles) or uptake 
transporter OAT4 and efflux transporter (open triangles) by recombinant vaccinia. 
Following incubation with [3H]dimesna (1 µM) at 37°C for 60 minutes, [3H]mesna 
present in the supernatant was derivatized with monobromobimane and separated by 
liquid chromatography and fractions detected by liquid scintillation counting. (a) 
[3H]dimesna standards with and without chemical reduction to [3H]mesna prior to 
derivatization ([3H]mesna retention time ~12 min). (b) pEF (empty vector, open circles) 
and OAT4 (uptake transporter, open triangles), only. (c) - (i) efflux transporter and 
uptake-efflux transporter pairs. BCRP, breast cancer resistance protein; dpm, 
disintegrations per minute; MATE1, multidrug and toxin extrusion protein 1; MRP1, 2, 4, 
5, multidrug resistance protein 1, 2, 4, 5; Pgp, P-glycoprotein.  
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Figure 2.6   Localization of identified dimesna and mesna transporters in the proximal 
tubule cell. At the basolateral membrane dimesna may be taken up from the blood via 
OAT1 and OAT3. Following filtration at the glomerulus (a), dimesna may also be taken 
up into proximal tubule cells at the luminal (apical) membrane via OAT4 (b). 
Intracellularly, dimesna undergoes reduction to active mesna capable of conjugating toxic 
metabolites of cisplatin and ifosfamide. Intracellular dimesna may be actively exported to 
the urine across the apical membrane via MRP4, or may be reduced and subsequently 
actively exported as mesna by Pgp, MRP2, or in exchange for protons via MATE1. ATP, 
adenosine triphosphate; MATE1, multidrug and toxin extrusion protein 1, MRP2, 4, 
multidrug resistance protein 2, 4; OAT1, 3, 4, organic anion transporter 1, 3, 4; Pgp, P-
glycoprotein.  
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Figure 2.7  Mean plasma probenecid concentration Sessions 2-3. Healthy volunteers 
were given 0.4 g/m2  oral mesna (Session 1), 1 g oral probenecid  (Session 2) followed by 
1 g probenecid twice-daily for 6 days, and finally 0.4 g/m2  oral mesna (Session 3). Data 
fitted simultaneously to a two-compartment model with non-linear elimination (mean ± 
SD, n = 12). 
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Figure 2.8  Inhibition of total mesna clearance by probenecid. Healthy volunteers were 
given 0.4 g/m2  oral mesna (Session 1), 1 g oral probenecid  (Session 2) followed by 1 g 
probenecid twice-daily for 6 days, and finally 0.4 g/m2  oral mesna (Session 3). Mean 
plasma total mesna (a, b) and total mesna excreted (c) during Session 1 (mesna only, ◊) 
and Session 3 (mesna + probenecid, □). Data represent mean ± SD, n = 12. 
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Figure 2.9  Inhibition of total mesna clearance by probenecid. Healthy volunteers were 
given 0.4 g/m2  oral mesna (Session 1), 1 g oral probenecid  (Session 2) followed by 1 g 
probenecid twice-daily for 6 days, and finally 0.4 g/m2  oral mesna (Session 3). Fraction 
of renal clearance due to secretion with and without probenecid (* P < 0.001). Data 
represent mean ± SD, n = 12. 
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2.4 Discussion 
It has previously been hypothesized that the kidney specific disposition of the 
highly polar chemoprotectants mesna and dimesna is due to differential transport across 
the epithelia of various organs and tumors (Ormstad & Uehara, 1982; Ormstad et al., 
1983; Verschraagen et al., 2004a). We screened a diverse panel of uptake and efflux 
transporters. We note that OAT4, in addition to OAT1 and OAT3 are capable of 
significantly increasing cellular dimesna accumulation. Our observation that members of 
the OAT family of uptake transporters are capable of dimesna transport is perhaps not 
surprising when the structural similarities between the sulfamoyl group of probenecid and 
sulfonyl groups of dimesna are considered. However, there remains a substantial 
knowledge gap between the structure-function of transporters and their substrate 
specificities (Hagenbuch, 2010). 
In context of the known patterns of expression in the kidney, dimesna may be 
taken up by proximal tubule cells from either the apical (lumen) side via OAT4, or 
basolateral (blood) side via OAT1 and OAT3 (Ekaratanawong et al., 2004; Motohashi et 
al., 2002). The inability of the organic anion transporting polypeptides (OATPs) to 
uptake dimesna explains previous observations of dimesna’s poor hepatic permeability 
(Verschraagen et al., 2004a; Goren et al., 1998b; Ormstad et al., 1983). However, there 
exists conflicting data regarding the role of the liver in dimesna reduction (Goren et al., 
1998b; Ormstad et al., 1983). In vitro, both liver and kidney lysates can reduce dimesna 
to its active form by glutathione dependent mechanisms (Verschraagen et al., 2004b). 
However, in vivo, dimesna undergoes selective reduction by the kidney and subsequent 
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elimination (Ormstad et al., 1983; Brock et al., 1981; Verschraagen et al., 2004a). 
Previous experiments have shown significant accumulation of mesna following perfusion 
of isolated rat kidney with [14C]dimesna, while no accumulation of either dimesna or 
mesna was seen in perfused livers (Ormstad et al., 1983). Differences in organ exposure 
were also seen following injection of colorectal tumour-bearing rats with either mesna or 
dimesna.   Liver, tumour, and red blood cells experienced little or no exposure, while the 
kidney AUC exceeded that of plasma (Verschraagen et al., 2004a). Clinically, the dearth 
of OAT expression by many cancers treated by cisplatin-dimesna and mesna-ifosfamide 
therapies may explain these discrepancies.  It is important to note that although mesna is 
able to chelate reactive metabolites, dimesna and mesna are not tumor protective (Millar 
et al., 1983; Okabe et al., 2008; Verschraagen et al., 2003a). 
Uptake of dimesna by OAT1, OAT3, and OAT4 was moderately inhibited by 
probenecid (Kis = 26.0 - 55.9 µM) and saturable with apparently low affinities (KMs = 
390.3 - 635.9 µM) compared to reference substrates para-aminohippurate (PAH) and 
estrone-3-sulfate. However, both mesna and dimesna are typically given in gram 
quantities during chemotherapy, resulting in high circulating dimesna concentrations. For 
example, a single 0.8 g intravenous dose of mesna results in plasma and urine dimesna 
Cmax of approximately 183 µM and 4,300 µM, respectively (James et al., 1987). Patients 
undergoing ifosfamide chemotherapy typically receive 0.6 – 1.5 g/m2 of mesna 
intravenously over eight hours (Hensley et al., 2008). Due to the inherent stability of 
dimesna, it has been administered at doses up to 41 g/m2, resulting in plasma dimesna 
concentrations of upwards of 4,584 µM and urine concentrations of 84,900 µM 
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(Verschraagen et al., 2003a; Verschraagen et al., 2001). Since the KMs measured here are 
near or below clinically relevant concentrations of dimesna, our data support a significant 
role of OATs in the clearance of dimesna and this pathway may represent the rate 
limiting step in reuptake and transcellular secretion (Hensley et al., 2008; James et al., 
1987; Verschraagen et al., 2001; Verschraagen et al., 2003a). 
The ability of various efflux transporters to lower dimesna accumulation was 
tested using HeLa cells double-transfected with both OAT4, to facilitate dimesna uptake, 
and the efflux transporter of interest. Consistent with the polyspecific nature of many 
efflux transporters, each of the transporters screened (BCRP, MATE1, MRP1, MRP2, 
MRP4, MRP5, and Pgp) significantly lowered residual intracellular radioactivity 
following [3H]dimesna incubation, compared to transfection with OAT4 alone. To further 
characterize whether reduction in radioactivity was due to export of either [3H]dimesna or 
additionally its metabolite, [3H]mesna, we sought to label [3H]mesna exported from 
transfected HeLa cell cultures prior to isolation by liquid chromatography and scintilation 
counting. Although each of the efflux transporters screened could lower accumulated 
radioactivity, only MATE1, MRP2, and Pgp could export mesna in its reduced form. It 
should be noted that our methodology cannot rule out the export of both dimesna and 
mesna by MATE1, MRP2, and Pgp. MATE1 has previously been described as an 
electroneutral H+/organic cation exchanger (Otsuka et al., 2005). Our finding that this 
renal efflux transporter is capable of exporting the anionic drug mesna further expands its 
functional role within the kidney. 
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Despite the moderate protein binding of plasma total mesna (28%), its rate of 
renal excretion exceeds its filtration rate (Urquhart et al., 2007; James et al., 1987). In 
light of our identification of uptake and efflux transporters of dimesna, and given their 
known localization, the dimesna and mesna transporters outlined herein may represent 
both reabsorption-resecretion and transcellular secretion mechanisms of dimesna 
disposition (Figure 2.6). The apical uptake transporter OAT4 in concert with MATE1, 
MRP2, and Pgp may be responsible for the yet unidentified mechanism of dimesna 
reabsorption and subsequent secretion of mesna following intracellular reduction. 
Similarly, upon reabsorption of dimesna, it may be secreted back into the lumen via 
MRP4, or possibly MATE1, MRP2, and Pgp.  
Similar to the coordination of renal organic cation transporter 2 (OCT2/SLC22A2) 
and MATE1 in the transport of metformin (Meyer zu Schwabedissen et al., 2010), 
basolateral uptake transporters OAT1 and OAT3 in combination with apical efflux 
transporters MATE1, MRP2, MRP4, and Pgp represent a transcellular mechanism of 
mesna and/or dimesna excretion. Our results suggest that total urinary mesna not only 
originates from glomerular filtration, but also secretion facilitated by OAT1 and OAT3 of 
renal proximal tubule cells. Given that dimesna must gain access to the kidney 
parenchyma to exert its protective effect against cisplatin, and mesna must accumulate in 
the bladder to mitigate ifosfamide toxicity, inhibition of a combination of OAT1 and 
OAT3 has the potential to lower the tolerated dose or efficacy of such chemotherapeutic 
drugs. 
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The recognition that drug transporters can control the absorption, distribution, and 
excretion of drugs has led to a growing concern of the liability of genetic variability and 
transporter-mediated DDIs. Functional single nucleotide polymorphisms (SNPs) of many 
of the renal dimesna transporters have been previously identified. MATE1 SNPs c. 
404T>C (p. 159T>M) and c. 1012G>A (p. 338V>A) result in loss of function of 
metformin and tetraethylammonium transport activity in vitro (Meyer zu Schwabedissen 
et al., 2010). SNPs of the 5’ untranslated region of MRP2, -24C>T and -1019A>G, result 
in decreased transcription and have been linked to clinical irinotecan- and methotrexate-
induced toxicities (de Jong et al., 2007; Haenisch et al., 2007; Rau et al., 2006). 
Recently, functional SNPs of the relatively highly conserved OAT family have also been 
identified (Erdman et al., 2006; Bleasby et al., 2005; Fujita et al., 2005; Shima et al., 
2010). Although OAT1 SNPs do not appear to affect transport of prototypical substrate 
PAH (Fujita et al., 2005; Bleasby et al., 2005), SNP c. 728G>A (p. 50R>H) showed 
decrease affinity for nucleoside phosphonate analogs adefovir, cidofovir, and tenofovir 
(Bleasby et al., 2005). OAT3 SNP c. 913A>T (p. 305I>F) confers substrate specific 
decrease in transport activity (Erdman et al., 2006), and OAT4 SNPs c. 735C>T (p. 
121R>C) and c. 837G>A (p. 155V>G) result in lower plasma member expression and 
thus reduced transport activity (Shima et al., 2010). Possession of these SNPs alone or in 
combination may contribute to incidence of nephro- and urotoxicities resulting in dose 
delay, however the functional significance of polymorphisms of renal transporters in 
dimesna and mesna transport remains to be determined. 
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With respect drug-induced loss of function, the International Transporter 
Consortium has provided decision trees to aid in determining when a compound may be 
at risk of a transporter-mediated DDI, and suggested the use of probenecid as a known in 
vivo inhibitor of OAT1 and OAT3 for validation of in vitro findings (Giacomini et al., 
2010; Yasui-Furukori et al., 2005). Given our in vitro evidence, we sought to determine 
the in vivo contributions of renal drug transporters to the excretion of “total mesna” by 
coadministration of probenecid. 
Upon entering the circulation mesna undergoes spontaneous oxidation to its 
dimer, dimesna (Brock et al., 1981; Ormstad et al., 1983).  Similarly, mesna can also 
form a disulfide bond with Cys34-albumin or low-molecular weight endogenous thiols 
cysteine, homocysteine, or glutathione (GSH) (Urquhart et al., 2006).  By convention, 
due to the technical difficulties of stabilizing and distinguishing low-molecular weight 
disulfides of mesna, no standardized methodology for quantification of its metabolites 
exist, which can make interpretation of results difficult.  The mixed disulfides  mesna-
mesna (i.e. dimesna), mesna-cysteine, mesna-homocysteine, and mesna-GSH have been 
collectively termed “dimesna” in some studies (Ormstad & Uehara, 1982; Shaw & 
Weeks, 1987), while others refer to the mesna-cysteine, mesna-homocysteine, and 
mesna-GSH as “mesna”, quantifying dimesna (i.e. mesna-mesna) separately (Goren et 
al., 1998a; Verschraagen et al., 2003b). Due to the redox cycling between both forms of 
mesna and dimesna, either can lead to chemoprotection, thus the pharmacokinetic 
parameters of the sum of all mesna moieties termed “total mesna” were estimated to gain 
a more accurate estimation of drug disposition. 
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Non-compartmental pharmacokinetic analysis of the modulation of total mesna 
kinetics by probenecid revealed a significant decrease in CLu,renal (55.1%), without 
alteration of elimination half-life. To reconcile this, a corresponding decrease in Vss of 
45.2% was also observed. This decrease in apparent volume may represent restriction of 
total mesna distribution to kidney parenchyma due to inhibition of renal uptake 
transporters, and suggests plasma dimesna concentrations do not rapidly equilibrate with 
the kidney, despite being highly perfused. Unlike the liver, renal transporter-mediated 
interactions rarely alter a drug’s volume of distribution (Grover & Benet, 2009). 
Previously, clinical observations of decreases in volumes of distribution had been limited 
to only famotidine and procainamide following inhibition by probenecid and cimetidine, 
respectively (Inotsume et al., 1990; Somogyi et al., 1983). Oat3-/- mice have also 
demonstrated a decrease in steady-state volume of distribution of penicillin G and 
corresponding decrease in renal clearance (Vanwert et al., 2007). Thus, the distribution of 
total mesna represents a relatively unique case where inhibition of renal transporters leads 
to a significant lowering of the volume of distribution, presumably by restricting entry to 
the kidneys. 
Estimation of the magnitude of mesna-probenecid interaction by calculation of 
CLu,renal,i from in vitro Ki data and maximum unbound probenecid plasma concentrations 
assuming parallel pathways of elimination by OAT1 and OAT3 approximated the 
observed decrease in CLu,renal in presence of inhibitor (CLu,renal = 4.7 ± 1.1 versus 
CLu,renal,i = 5.33 L/h/1.73 m2).  However the concentration-time profile of drug at its site 
of action cannot be captured by this ratio, nor can the time-course of urine exposure be 
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generated by non-compartmental methods for the purpose of estimating the 
pharmacodynamic effect. Future modeling of changes in transporter-mediated 
disposition, whether due to drug interactions or genetic variation, should not only account 
for alterations in transporter-mediated clearance, but also volume of distribution in order 
to accurately predict resultant drug concentration-time profiles. 
The observed changes in plasma exposure and average urinary excretion rate of 
91% and 17%, respectively, imply the interaction between probenecid and total mesna to 
be a modest DDI. However, in the context of transporter mediated-DDI, the observed 
55.1% decrease in time-averaged renal clearance of total mesna is in line with the 
observed decreases in the clearance of other OAT substrates acyclovir (32%), cidofovir 
(32%), and furosemide (66%) by probenecid interaction (Li et al., 2006). Despite current 
dosing regimes, the incidence of moderate (hematuria) to severe (renal failure) 
ifosfamide-induced urotoxicity remains 3.5 – 6.7% per chemotherapy cycle (Hensley et 
al., 2008). Considering the disposition of mesna is essential to chemotherapeutic efficacy, 
such a decline in secretion may raise the risk of hematuria, but could be easily 
compensated by an increased dose because of mesna’s wide margin of safety. Most 
importantly, coadministration of probenecid significantly decreased the fraction of total 
mesna cleared by renal transporter-mediated secretion (67.0%). Given that OAT1 and 
OAT3 function as uptake transporters enabling access to the kidney parenchyma which 
represents a significant proportion of total mesna’s volume of distribution, a decrease in 
tissue concentration of this magnitude would likely lower the clinical efficacy of dimesna 
to mitigate cisplatin induced nephrotoxicity. This observation also brings to light findings 
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that drugs reliant on secretion for their clinical efficacy, such as diuretics, may be 
particularly susceptible to transporter-mediated DDIs because of the inability of 
glomerular filtration to adequately compensate for the loss of urinary clearance (Eraly et 
al., 2006; Vallon et al., 2008). 
The results presented here suggest the apical uptake transporter OAT4 in concert 
with apical efflux transporters MATE1, MRP2, and Pgp represent the previously 
hypothesized mechanism of renal reabsorption and re-secretion required for intracellular 
reduction of dimesna and excretion of mesna by the proximal tubule cells.  In addition, 
basolateral uptake transporters OAT1 and OAT3 in concert with apical efflux 
transporters facilitate the transcellular flux of total mesna into the urine. The coordinated 
uptake of dimesna and efflux of mesna by renal drug transporters may play an important 
role in the activation of dimesna and subsequent inactivation of toxic metabolites of 
ifosfamide and cisplatin. Alteration of drug transporter activity due to SNPs or drug 
interactions may contribute to the incidence of dose delay due to toxicity in patients 
receiving such chemotherapies. 
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CHAPTER 3: ENZYMATIC AND NON-ENZYMATIC MECHANISMS OF 
DIMESNA METABOLISM 
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3.1  Introduction 
The metabolism of the chemoprotectant dimesna to its constituent mesna moieties 
is an essential step in the mitigation of ifosfamide-induced hemorrhagic cystitis and 
cisplatin-induced nephrotoxicity (Boven et al., 2002; Hensley et al., 2008; Kurowski & 
Wagner, 1997). Interestingly, mesna does not attenuate the anti-cancer efficacy of 
concurrently administered ifosfamide. This has been attributed to the rapid metal-
catalyzed oxidation of mesna to it disulfide dimer, dimesna (Brock et al., 1981b; Brock et 
al., 1981a; Brock et al., 1982). Similarly, co-administration of dimesna has no effect on 
the pharmacokinetics of cisplatin (Boven et al., 2002).  
In addition to homodimerization, mesna may form mixed disulfides with the low-
molecular weight thiols cysteine, reduced glutathione (GSH), homocysteine, γ-glutamyl-
cysteine, or cysteinyl-glycine, or become covalently protein bound to Cys34-albumin. 
Recent work by our laboratory and others has demonstrated that the formation of mesna-
Cys34-albumin following mesna and dimesna dosing can be exploited to increase the 
fraction of homocysteine available for clearance (Lauterburg et al., 1994; Pendyala et al., 
2000; Pendyala et al., 2003; Stofer-Vogel et al., 1993; Urquhart et al., 2006; Urquhart et 
al., 2007b; Urquhart et al., 2007a). 
Homocysteine is a non protein-forming amino acid intermediate of the methionine 
cycle and precursor of GSH biosynthesis (Finkelstein, 1998; Selhub, 1999). Elevated 
plasma total homocysteine (defined as the sum of all sulfhydryl, low molecular-weight 
disulfide, and protein bound homocysteine (Mudd et al., 2000)) is a graded, independent 
risk factor for the development of cardiovascular disease and vascular access thrombosis 
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amongst patients requiring chronic hemodialysis (Bostom et al., 1997; Mallamaci et al., 
2002; Moustapha et al., 1998; Robinson et al., 1996; Shemin et al., 1999). 
The ability of mesna to increase the dialyzable fraction of homocysteine by thiol-
disulfide exchange at Cys34-albumin in uremic plasma has motivated further expansion of 
the therapeutic applications of mesna to the treatment of hyperhomocysteinemia in end-
stage renal disease (ESRD) (Urquhart et al., 2006; Urquhart et al., 2007b).  
The redox equilibrium and metabolism of sulfhydryl mesna, and its disulfide 
dimesna, are key determinants of their therapeutic applications. The identification of 
renal uptake and efflux transporters of dimesna (chapter two) has raised the possibility of 
active secretion of mesna into the urine following intracellular reduction. Cellular redox 
homeostasis is maintained by members of the oxidoreductase family of enzymes, notably 
the thioredoxin and glutaredoxin systems, and the abundant redox buffers GSH and 
cyst(e)ine (Cys; CySSyC) (Holmgren, 1989; Meister & Anderson, 1983). These systems 
have previously been implicated in the metabolism of dimesna, yet the kinetics and 
contributions of enzymatic and non-enzymatic mechanisms remain to be elucidated 
(Shanmugarajah et al., 2009; Verschraagen et al., 2004).  
The objective of this study was to investigate potential enzymatic and non-
enzymatic mechanisms of dimesna metabolism. To determine the mechanisms underlying 
dimesna redox equilibrium in the presence of the two most abundant biological thiols, 
Cys and GSH, we sought to measure the kinetics of their respective reactions using a 
model of two sequential bimolecular nucleophilic substitution (SN2) reactions. An SN2 
reaction proceeds by a nucleophilic thiol (e.g. mesna or GSH) displacing disulfide 
bonded thiol moieties (e.g. mesna-mesna, mesna-GSH). Enzymatic activities of 
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recombinant enzymes of the thioredoxin and glutaredoxin systems, mouse kidney and 
liver homogenates, and HeLa cell lysate were also measured in the presence of dimesna 
and the known substrates oxidized glutathione (GSSG) and 5,5'-dithio-bis-2-nitrobenzoic 
acid (DTNB). Finally, the contribution of both enzymatic and non-enzymatic activites 
present in HeLa cell lysates was charaterized by a significant loss of mesna production 
that was evaluated following lysate protein denaturation. This approach permitted an 
accurate prediction of mesna production by denatured cell lysate due to non-enzymatic 
thiol-disulfide exchange alone. 
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3.2  Materials and Methods 
3.2.1 Materials 
5,5'-dithio-bis-2-nitrobenzoic acid (DTNB), bovine insulin, oxidized glutathione 
(GSSG), reduced glutathione (GSH), mesna, nicotinamide adenine dinucleotide 
phosphate (NADPH), recombinant human glutaredoxin (GLRX1; thioltransferase-1, 
GRX1, UniProtKB ID # P35754, EC 1.8.4.2), glutathione reductase (GSR; GR, 
UniProtKB ID # P00390, EC 1.8.1.7), thioredoxin (TXN1; TRX1, UniProtKB ID # 
P10599, EC 1.8.4.10), and purified rat thioredoxin reductase 1 (Txnrd1; Trxr1, 
UniProtKB ID # O89049, EC 1.8.1.9) were purchased from Sigma-Aldrich Canada Ltd. 
(Oakville, Ontario). Monobromobimane (Thiolyte, MBB) was obtained from EMD 
Biosciences (Gibbstown, NJ). Dimesna was a kind gift from Dr. Gideon Koren 
(University of Toronto, Canada). 
3.2.2 Enzymatic Activity of Purified Glutaredoxin and Thioredoxin Systems 
 Activity of the glutaredoxin system comprised of 0.01 U glutaredoxin 
(approximately 14.15 nM), 0.01 U glutathione reductase (approximately 80.59 nM), and 
1 mM NADPH was measured spectrophotometrically at 340 nm by the initial rate of 
oxidation of NADPH as previously described (Mavis & Stellwagen, 1968). Endogenous 
substrate GSSG (1 mM) was included in each assay as a positive control.  
 Activity of the thioredoxin system comprised of 0.35 U thioredoxin 
(approximately 0.5 µM), 0.05 U thioredoxin reductase (approximately 11.75 nM), and 
0.2 mM NADPH was measured spectrophotometrically at 340 nm by the initial rate of 
oxidation of NADPH as previously described (Arner et al., 1999). Insulin (0.016 mM) 
was included in each assay as a positive control.  
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Inhibition of the reduction of 1 mM DTNB by thioredoxin reductase in the 
presence of 1 mM dimesna and 1 mM NADPH was examined by monitoring the 
production of TNB at 412 nm as previously described (Arner et al., 1999). 
3.2.3 Enzymatic Activity of Tissue Homogenates and Cell Lysate 
 Five Female DBA/lacJ mice were anesthetised by isofluorane inhalation. Liver 
and kidneys were removed and homogenized on ice with a motorized Tissue Tearor in 
PBS with 1 mM EDTA. Human cervical adenocarcinoma (HeLa) cells (ATCC # CCL-2) 
were cultured in DMEM (Lonza, Walkersville, Maryland) containing 10% FBS 
(Invitrogen, Carlsbad, CA), penicillin (50 U/mL) (Invitrogen), and streptomycin (50 
µg/mL) (Invitrogen) at 37°C in a humidified 5% CO2 atmosphere.  Three passages of 
cells were grown to 80% confluence, harvested by scraping, and lysed by repetitive 
freeze-thaw in PBS containing 1 mM EDTA. Total protein was measured by Pierce BCA 
protein kit (Pierce, Rockford, IL) and samples diluted in PBS containing 1 mM EDTA, 
aliquotted, and stored at -70°C. 
 Enzymatic activities of 1 mg/mL tissue homogenates and cell lysate supplemented 
with 1 mM NADPH were measured spectrophotometrically at 340 nm by the initial rate 
of oxidation of NADPH with and without 1 mM dimesna and 1 mM GSSG, alone and in 
combination. 
3.2.4 Spectrophotometric Assay of Enzymatic Activity 
Assays of enzymatic activity were carried out using a Thermo Multiskan 
Spectrum spectrophotometer (Thermo Electron, Waltham, MA). Enzymatic activities of 
experiments utilizing NADPH as a cofactor were monitored by a decrease in absorbance 
at 340 nm at one minute intervals for 60 min. Enzymatic activities of experiments 
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utilizing DTNB as a substrate were monitored by an increase in absorbance at 412 nm 
due to the production of TNB at 10 s intervals for 5 min. All reaction mixtures were 
dissolved in PBS (pH = 7.0) containing 1 mM ethylenediaminetetraacetic acid (EDTA) 
and pipetted in triplicate into a clear 96-well plate warmed to 37°C on a Zipvac 96 
evaporator heating block (Glas-Col, Terre Haute, IN) to a final reaction volume of 200 
µL. NADPH was added immediately prior to spectrophotometric measurements at 37°C.  
Negative controls containing all reagents except dimesna or endogenous substrates were 
included in each assay to control for background absorbance. 
3.2.5 Reduction of Dimesna by Non-Enzymatic Thiol-Disulfide Exchange and Cell 
Lysates  
 To detect the presence of an enzymatic reduction of dimesna in cell lysates, 
untreated and denatured lysates were incubated with 1 mM dimesna and mesna 
production measured following fluorescence derivatization. Redox enzymes were 
inactivated and removed by heating lysate at 95°C for 5 min followed by centrifugation 
at 14,000 g for 10 min. Dimesna was added to a final concentration of 1 mM immediately 
prior to incubation of lysates in 1.7 mL microcentrifuge tubes at 37°C. Non-enzymatic 
thiol-dimesna exchange was examined using final concentrations of dimesna, cysteine, 
and GSH ranging from 10 to 3000 µM diluted in PBS containing 1 mM EDTA and 
incubated in 1.7 mL microcentrifuge tubes at 37°C. Aliquots of 50 µL were collected at 
0, 5, 10, 15, 30, 60, and 90 min and transferred to a second microcentrifuge tube 
containing 25 µL of 12.5 mM MBB (25% acetonitrile, 3 mM EDTA). Derivatization was 
initiated by addition of 25 µL of 50 mM Tris buffer (pH = 9.0) and incubation at 37°C for 
15 min. Cell lysates were additionally treated with 25 µL of 15% perchloric acid and 
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centrifuged at 9,000 g for 5 min to precipitate proteins. Supernatant pH was adjusted to 
approximately 4.0 by addition of 20 µL of 0.5 M citrate: 2.5 M sodium hydroxide 
solution. Samples were diluted with 4% acetonitrile: 96% 25 mM ammonium formate 
buffer (pH = 3.75) as necessary prior to analysis. 
3.2.6 Thiol Analysis 
Thiol analysis was conducted by high performance liquid chromatography with 
fluorescence detection (HPLC-FD) with slight modification to methods previously 
described.(Urquhart et al., 2006) Thiols derivatized with monobromobimane were 
injected onto a Zorbax SB-C18 column (150 x 3.2 mm, 5 µm particle) maintained at 
40°C in a Hewlett Packard 1090 LC (Agilent Technologies, Santa Clara, CA). Analytes 
were eluted with a gradient of 4% acetonitrile: 96% ammonium formate containing 0.75 
mM dibutylamine (pH = 3.75) to 17% acetonitrile: 83% ammonium formate containing 
0.75 mM dibutylamine (pH = 3.75) over 20 min at a flow rate of 0.5 mL/min. Retention 
times of derivatized cysteine, GSH, and mesna were approximately 5.3, 8.3, and 12.5 
min, respectively. Peaks were detected by a Waters 474 scanning fluorescence detector 
(λexcitation = 390 nm, λemission = 480 nm; Waters, Milford, MA). The accuracy and precision 
of the assay were 1.3% and 2.0%, respectively. 
3.2.7 Determination of Non-Enzymatic Thiol-Disulfide Exchange Micro-Rate 
Constants 
Reduction of dimesna by cysteine and glutathione can be summarized by the 
reaction scheme outlined in Figure 3.1. Given the mass balance equation: 
MM0 = M/2 + MM + RM/2      (Eq. 3.1) 
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Where MM0 is the starting dimesna concentration, and M, MM, and RM represent mesna, 
dimesna, and mixed mesna disulfide species, respectively. The reaction scheme can be 
quantified by a system of ordinary differential equations:  
R' = k2*RM*M - k1*R*MM - k3*R*RM + k4*RR*M  (Eq. 3.2) 
MM' = k2*RM*M - k1*R*MM     (Eq. 3.3) 
RR' = k3*R*RM - k4*RR*M      (Eq. 3.4) 
RM' = k1*R*MM - k1*RM*M - k3*R*RM + k4*RR*M  (Eq. 3.5) 
M' = 2*(k1*R*MM - k2*RM*M + k3*R*RM - k4*RR*M)   (Eq. 3.6) 
where RR represents the oxidized species of the starting thiol. Second-order micro-rate 
constants k1, k2, k3, and k4 were estimated by simultaneous regression to both mesna 
and either Cys or GSH data presented in Figures 3.2 and 3.3. Least-squares fitting was 
performed using Scientist software (Micromath Research, Salt Lake City, UT). 
3.2.8 Modeling of Non-Enzymatic Reduction of Dimesna in HeLa cell Incubations 
 Dimesna, mesna, mesna-Cys, Cys, CySSyC, mesna-GSH, GSH, and GSSG 
concentration-time courses of untreated and denatured cell lysates due to non-enzymatic 
reactions were predicted using basal Cys and GSH concentrations and supplemented 
dimesna concentration as initial values of differential Equations 3.2 – 3.6. Dimesna 
consumption and mesna production due to Cys and GSH exchange were summed. Mesna, 
Cys, and GSH concentration-time courses were regressed to observed values for 
calculation of coefficients of determination using Scientist software (Micromath 
Research). 
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3.2.9 Calculation of Dimesna/Mesna Equilibrium Constant 
At equilibrium, the magnitude of flux between species, as determined by the 
product of the second-order rate constants and concentrations of species, is equal, thus 
the equilibrium constant for the dependent reactions outlined in Figure 3.5 can be derived 
as: 
              k1*R*MM = k2*RM*M      (Eq. 3.7) 
             k3*R*RM = k4*RR*M      (Eq. 3.8) 
           RM = (k4*RR*M)/(k3*R) 
Substituting Equation 3.8 into Equation 3.7 yields: 
           k1*R*MM = (k2*k4*RR*M2)/(k3*R)      
    k1*k3*R2*MM = k2*k4*RR*M2 
  (k1*k3)/(k2*k4) = (RR*M2)/(R2*MM)      
  Keq = (RR*M2)/(R2*MM)     
        = (k1*k3)/(k2*k4)      (Eq. 9) 
where Keq represents the equilibrium constant. 
3.2.10 Calculation of Dimesna/Mesna Half-Cell Potential 
 Calculation of Keq for dimesna in the presence of the standard biological reducing 
agent GSH facilitates indirect calculation of the half-cell potential of the dimesna/mesna 
redox system (E°’MSSM/MSH) by the Nernst equation: 
E°’MSSM/MSH = E°’GSSG/GSH + (R*T/n*F)*ln(Keq)   (Eq. 3.10) 
Where E°’GSSG/GSH is the half-cell potential of glutathione at pH 7.0 (-0.262 V (Millis et 
al., 1993)), R is the gas constant (8.314 J K-1 mol-1), T is the absolute temperature of the 
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reaction (310 K), n is the number of electrons transferred (2), and F is the Faraday 
constant (96485 J V-1 mol-1). 
3.2.11 Data Analysis and Statistics 
 Observed pseudo-first-order rate constants (kobs = k [dimesna]) were determined 
by fitting the first-order exponential association and decay functions to mesna and 
Cys/GSH concentration-time data, respectively. Significant differences between 
enzymatic activity of kidney and liver homogenates and cell lysates were determined 
using one-way ANOVA followed by Tukey’s multiple comparison tests. Pairwise 
analysis of enzymatic data was performed using Student’s t test. Pairwise analysis of 
fitted micro-rate constants was performed non-parametrically by Mann-Whitney U test, 
due to non-normal distribution. A P < 0.05 was considered a statistically significant 
difference. Curve fitting and statistics were conducted using Prism (GraphPad Software, 
Inc., San Diego, CA). 
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Figure 3.1   Production of mesna by bimolecular nucleophilic substitution (SN2) 
reactions whereby a nucleophilic thiol (e.g. Cys or GSH) first displaces a mesna moiety 
of dimesna yielding mesna and a mixed disulfide, followed by substitution of the mesna 
moiety of the mixed disulfide, producing a second molecule of mesna and a 
homogeneous disulfide. Rate constants k1, k2, k3, k4 and species R, MM, RM, RR, and M 
denote parameters and variables (respectively) utilized to describe equilibrium kinetics in 
Equations 3.1 – 3.6. 
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3.3. Results 
3.3.1  Non-Enzymatic Reduction of Dimesna 
 Fluorescence derivatization followed by HPLC-FD allowed for the simultaneous 
measurement of mesna, Cys, and GSH thiols following incubation in PBS containing 1 
mM EDTA at 37°C, pH = 7.0. The addition of EDTA facilitated the stabilization of thiols 
prior to the start of the experiment, but had no effect on the rate of thiol exchange in the 
presence of disulfide (data not shown), consistent with previously published observations 
(Verschraagen et al., 2004). 
3.3.1.1 Estimation of Reaction Order and Macro-Rate Constants 
Concentration-time courses of mesna production and corresponding thiol 
consumption following incubation of 1000 µM dimesna with a range of Cys and GSH 
concentrations (10 – 3000 µM) (Figure 3.2) and 1000 µM Cys or GSH with a range of 
dimesna concentrations (10 – 3000 µM; Figure 3.3) obeyed pseudo-first-order kinetics. 
The observed molar ratio of mesna production was approximately 2:1 for each mole of 
Cys or GSH consumed across all concentrations (mesna/cysteine = 2.12 ± 0.27, 
mesna/GSH = 2.06 ± 0.14). 
Plots of estimated velocities (0 – 10 min or 0 – 15 min) were linear with slopes 
approximating unity at or below equimolar concentrations of reactants, indicating the rate 
of mesna production is first-order for each of the reactants (Figure 3.4). The slope of the 
secondary plot of observed pseudo-first-order rate constants of mesna production yielded 
apparent second-order rate constants of 1.394 x 10-4 µM-1 min-1 and 0.275 x 10-4 µM-1 
min-1 for reduction of dimesna by Cys and GSH, respectively (Figure 3.5). 
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3.3.1.2 Estimation of Micro-Rate Constants 
Measurement of both reactant (i.e. Cys and GSH) and product (i.e. mesna) 
sulfhydryls allowed for estimation of the micro-rate constants of Equations 3.2-3.6 
describing the proposed thiol-disulfide reaction scheme (Figure 3.1). Micro-rate constants 
simultaneously fitted to mesna and Cys or GSH concentration-time courses are 
summarized in Table 3.1. Coefficients of determination were consistently high for 
predicted time courses of the reduction of dimesna by Cys (mesna r2 = 0.995 ± 0.002, 
Cys r2 = 0.983 ± 0.011) and GSH (mesna r2 = 0.969 ± 0.022, Cys r2 = 0.965 ± 0.023). 
Rate constants k1, k2, and k3 were significantly different between reactants Cys and 
GSH (P < 0.05, Table 3.1). 
3.3.1.3 Calculation of Dimesna Redox Equilibrium Constants and Half-cell Potential 
of Disulfide Bond 
Using rate constants listed in Table 3.1, the equilibrium constants of dimesna in 
the presence of Cys and GSH were calculated by Equation 3.9 to be 0.200 and 1.697, 
respectively. Calculation of the half-cell potential of the dimesna disulfide bond in the 
presence of GSH (Equation 3.10) resulted in a dimesna/mesna redox potential of -0.255 
V. 
3.3.2  Enzymatic Reduction of Dimesna 
Enzymatic activities of purified enzymes and homogenates incubated at 37°C in 
PBS containing 1 mM EDTA resulting in the oxidation of NADPH were monitored 
spectrophotometrically in the presence and absence of dimesna and known disulfide-
containing substrates. 
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3.3.2.1 Direct Reduction of Dimesna by Thioredoxin System 
An equimolar concentration of dimesna was unable to inhibit reduction of DTNB 
to 2-nitro-5-thiobenzoic acid (TNB) by thioredoxin reductase (1.64 ± 0.10 versus 1.67 ± 
0.07 mAU TNB s-1, P = 0.733). However, the thioredoxin system demonstrated a 
significant dimesna concentration-dependent increase in enzyme velocity, in addition to 
prototypical substrate bovine insulin (Figure 3.6). A proposed mechanism of dimesna 
reduction by the thioredoxin system is summarized in Figure 3.7. 
3.3.2.2 Indirect Reduction of Dimesna by Glutaredoxin System 
Upon addition of dimesna to the glutaredoxin system, no significant change in 
NADPH concentration was detected. However, co-incubation of dimesna with GSH 
facilitated a significant increase in enzymatic activity by the glutaredoxin system (3.48 ± 
0.75 nmol NADPH min-1) compared to either dimesna or GSH alone (-0.183 ± 0.570 and 
0.297 ± 0.187 nmol NADPH min-1, respectively, P < 0.001, Figure 3.8).  
Incubation of glutathione reductase with its endogenous substrate, GSSG, resulted 
in rapid oxidation of NADPH that was not inhibitable by co-incubation with equimolar 
dimesna (17.97 ± 1.79 versus 18.49 ± 4.79 nmol NADPH min-1, P = 0.873) suggesting 
dimesna does not bind to the catalytic site of glutathione reductase. A proposed 
mechanism of dimesna reduction by the glutaredoxin system is summarized in Figure 3.9. 
3.3.2.3 Enzymatic Reduction of Dimesna by Tissue and Cell Homogenates 
Enzymatic activity of mouse kidney and liver homogenates and HeLa cell lysate 
for dimesna reduction are presented in Figure 3.10. No activity was observed with 
dimesna alone in any homogenate. The rate of GSSG reduction with and without dimesna 
was greater in kidney than liver and HeLa cell homogenates when normalized to protein 
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concentration (P < 0.001, Figure 3.10). Enzymatic reduction of GSSG in all homogenates 
was unaltered by the presence of dimesna (Figure 3.10). Co-incubation of dimesna with 
increasing concentrations of GSH showed a saturable, concentration-dependent increase 
in enzymatic activity that was equivalent between kidney and liver homogenates (kidney 
kobs = 0.782 ± 0.04 versus liver kobs = 8.527 ± 0.465 mM-1, P = 0.231; kidney plateau = 
8.527 ± 0.465 versus liver plateau 6.896 ± 0.647 nmol NADPH min-1 mg protein-1, P = 
0.074, Figure 3.11). 
3.3.3  Contribution of Enzymatic and Non-Enzymatic Mechanisms of Reduction of 
Dimesna in HeLa Cell Lysates 
 Fluorescence derivatization of mesna and reactant sulfhydryls of Cys and GSH 
enabled direct quantitation of rates of production and depletion (respectively) by HPLC-
FD.  
3.3.3.1 Reduction of Dimesna by HeLa Cell Lysate Before and After Denaturation 
Incubation of HeLa cell lysate with 1 mM dimesna yielded saturable mesna 
production (kobs = 0.057 ± 0.002 min-1, plateau = 87.7 ± 1.3 µM) and concurrent decrease 
of endogenous Cys and GSH at observed rates of 0.141 ± 0.006 min-1 and 0.033 ± 0.001 
min-1, respectively (Figure 3.12).  Following denaturation, the observed rate of mesna 
production significantly increased (0.095 ± 0.001 min-1, P < 0.001, Figure 3.12) while the 
concentration of mesna produced significantly  decreased (29.7 ± 1.2 µM, p < 0.001, 
Figure 3.12). Denaturation significantly decreased the basal GSH concentration (1.70 ± 
0.04 µM versus 13.0 ± 0.08 µM, P < 0.001, Figure 3.12). No change in GSH 
concentration of denatured lysate was detected in the presence of dimesna (P = 0.079, 
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Figure 3.12). Low molecular-weight thiols cysteinylglycine, cysteinylglutamate, and 
homocysteine were not detected in HeLa cell lysates. 
3.3.3.2 Modeling of Sulfhydryl and Disulfide Species in HeLa Cell Lysate 
 Application of Equations 3.1-3.6 describing a two-step thiol-disulfide exchange 
reaction (Figure 3.1) enabled predictive modeling of the absolute contribution of non-
enzymatic reduction of dimesna by cell lysate. Using fitted micro-rate constants listed in 
Table 3.1, basal concentrations of endogenous thiols (i.e. Cys and GSH) concentration-
time courses of mesna, Cys, and GSH following incubation of HeLa lysates were 
predicted (Figure 3.13). Cys and GSH concentrations during incubation of HeLa lysate 
were well predicted by r-squared values of 0.822 and 0.937, respectively. Resultant 
mesna production, due to non-enzymatic thiol-disulfide exchange alone, accounted for 
only 58% of total sulfhydryl mesna produced (50.98 versus 87.89 µM, r2 = 0.383, Figure 
3.13). Removal of cytosolic enzyme activity resulted in significantly lower total 
sulfhydryl mesna production (30.83 ± 1.74 versus 87.89 ± 2.07 µM, P < 0.001, Figure 
3.13) that was largely predicted by Cys-mediated non-enzymatic reduction of dimesna 
with coefficients of determination of mesna and Cys concentration-time courses of 0.993 
and 0.802, respectively. 
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Table 3.1   Estimated second-order micro-rate constants of SN2 reaction scheme in 
Figure 3.5, n = 12, P-value calculated non-parametrically by Mann-Whitney U test. 
 
Cys + dimesna 
10-4 (µM min-1) 
GSH + dimesna 
10-4 (µM min-1) 
P 
 
Mean SE Mean SE  
     
 
k1 0.681 0.033 0.408 0.168 0.001 
k2 1.648 0.275 3.218 2.568 0.004 
k3 1.160 0.130 16.509 5.662 0.023 
k4 2.399 0.605 1.233 0.227 0.301 
 
 
 
159 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.2   Non-enzymatic reduction of 1 mM dimesna by cysteine (a, b) and 
glutathione (c, d) mediated thiol exchange in PBS, 1 mM EDTA at 37°C, pH = 7.0. Free 
thiol was measured by MBB derivatization followed by liquid chromatography with 
fluorescence detection. Fitted curves (solid lines) correspond to one-phase exponential 
association and one-phase exponential degradation of mesna production and thiol (Cys or 
GSH) loss. Starting thiol concentrations are in micromolar. Data represented as mean ± 
SE, n = 3. 
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Figure 3.3   Non-enzymatic reduction of dimesna by 1 mM cysteine (a, b) and 1mM 
glutathione (c, d) mediated thiol exchange in PBS, 1 mM EDTA at 37°C, pH = 7.0. Free 
thiol was measured by MBB derivatization followed by liquid chromatography with 
fluorescence detection. Fitted curves (solid lines) correspond to one-phase exponential 
association and one-phase exponential degradation of mesna production and thiol (Cys or 
GSH) loss. Starting dimesna concentrations are in micromolar. Data represented as mean 
± SE, n = 3. 
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Figure 3.4   Initial velocities of mesna production by dimesna with excess Cys (a), Cys 
with excess dimesna (b), dimesna with excess GSH (c), and GSH with excess dimesna 
(d). Slope of the lines indicate thiol exchange of dimesna is first order for each of the 
reactants. Data represented as mean ± SE, n = 3. 
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Figure 3.4    
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Figure 3.5   Observed first-order rate constants (kobs) of mesna production in the presence 
of excess Cys (a) and GSH (b) versus starting dimesna concentrations. Slope of the line 
indicates second-order rate constant for the reduction of dimesna by cysteine (a) and 
GSH (b). Data represented as mean ± SE, n = 3. 
a              b 
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Figure 3.6   Reduction of dimesna by purified recombinant thioredoxin (500 nM) and 
thioredoxin reductase (11.75 nM) in PBS, 1 mM EDTA at 37°C, pH = 7.0. Enzyme 
velocities were measured by analysis of NAD formed spectrophotometrically at 340 nm. 
Data represented as mean ± SE, n = 3. Differences between incubations determined by 
ANOVA *, **, *** P < 0.01. 
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Figure 3.7   Scheme of dimesna (MSSM) reduction by the thioredoxin system. The N-
terminal active site Cys residue of thioredoxin(SH)2 reduces protein disulfides by 
forming a transient mixed disulfide followed by fast thiol-disulfide exchange oxidizing a 
pair of reactive Cys at the active site producing thioredoxin(S)2. Alternatively, reduced 
thioredoxin(SH)2 may directly reduce dimesna to form two mesna moieties and 
thioredoxin(S)2. Reduction of thioredoxin(S)2 is facilitated by the flavoprotein 
thioredoxin reductase via electron transfer from NADPH. 
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Figure 3.8   Reduction of dimesna by purified recombinant glutaredoxin (14.15 nM) and 
glutathione reductase (80.59 nM) in PBS, 1 mM EDTA at 37°C, pH = 7.0. Enzyme 
velocities were measured spectrophotometrically at 340 nm. Data represented as mean ± 
SE, n = 3. Differences between incubations determined by ANOVA, * P < 0.01. 
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Figure 3.9   Scheme of dimesna (MSSM) reduction by the glutaredoxin system. Similar 
to thioredoxin, the N-terminal active site Cys residue of glutaredoxin(SH)2 reduces 
protein disulfides by forming a transient mixed disulfide followed by fast thiol-disulfide 
exchange oxidizing a pair of reactive cysteines at the active site producing oxidized 
glutaredoxin(S)2. Additionally, glutaredoxin(SH)2 specifically reduces S-glutathionylated 
proteins and mixed disulfides, yielding a glutaredoxin-GSH conjugate. Dimesna 
(MSSM), although not a substrate of glutaredoxin, can first undergo non-enzymatic thiol 
exchange with GSH to produce the mixed mesna-glutathione disulfide (MSSG). MSSG 
can subsequently be reduced by glutaredoxin producing mesna and a glutaredoxin-GSH 
conjugate. The glutaredoxin-GSH conjugate can be reduced to glutaredoxin(SH)2 by an 
additional molecule of GSH, forming oxidized glutathione (GSSG). Glutathione 
reductase recycles GSSG to two molecules of GSH via electron transfer from NADPH. 
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Figure 3.9 
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Figure 3.10   Enzymatic activity of mouse kidney and liver homogenates, and HeLa cell 
lysates in the presence of 1 mM NADPH, 1 mM oxidized glutathione (GSSG) and/or 1 
mM dimesna (MSSM). Data represented as mean ± SE, kidney and liver; n = 5, HeLa; n 
= 3, *,** P < 0.01. 
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Figure 3.11   Enzymatic activity of mouse kidney (○) and liver (□) homogenates 
incubated with 1 mM NADPH, 1 mM dimesna, and increasing concentrations of reduced 
glutathione (GSH). Data represented as mean ± SE, n = 5. 
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Figure 3.12   Mesna (a), Cys (b), and GSH (c) concentrations following incubation of 
HeLa cell lysate (1 mg/mL in PBS, 1 mM EDTA) with 1 mM dimesna at 37°C before 
(○) or after (□) protein denaturation. Data represented as mesna ± SE, n = 3. 
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Figure 3.13   Predicted concentrations of thiol species due to non-enzymatic thiol 
exchange as described by Equations 3.1-3.6 using second-order rate constants listed in 
Table 3.1 and basal endogenous thiol concentrations of HeLa lysate before (a) or after (b) 
denaturation. Observed mesna (∆), Cys (○), and GSH (□) concentrations presented in 
Figure 3.12 are plotted as reference.  
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3.4  Discussion 
The reduction of the disulfide dimesna to its two mesna thiol moieties is essential 
for conjugation of reactive metabolites of cisplatin and ifosfamide during chemotherapy 
(Boven et al., 2002; Hensley et al., 2008; Kurowski & Wagner, 1997). Furthermore, in 
vitro experiments have shown that sulfhydryl mesna is capable of increasing the 
dialyzable fraction of homocysteine by thiol-disulfide exchange at albumin-Cys34 in 
uremic plasma (Urquhart et al., 2006). Thus, the redox equilibrium and metabolism of 
sulfhydryl mesna and its disulfide dimesna play an important role their pharmacology. 
In this chapter, we quantify the non-enzymatic reduction of dimesna by the two 
most abundant endogenous thiols, Cys and GSH, and determine their contribution to the 
overall capacity of the common HeLa cell line to metabolize dimesna. Enzymatic 
reduction of dimesna is also demonstrated by two purified members of the 
oxidoreductase family of redox enzymes. Measurements of enzymatic activity of mouse 
kidney and liver homogenates and modeling of non-enzymatic thiol-disulfide exchange 
reactions of cell lysates demonstrate that enzymatic and non-enzymatic mechanisms work 
in concert to reduce dimesna to mesna. 
Circulating mesna exists primarily as low molecular-weight and albumin-Cys34-
bound disulfides due to rapid metal-catalyzed oxidation facilitated by the rich availability 
of oxygen as an electron acceptor within the blood (Brock et al., 1981a; Brock et al., 
1981b; Ormstad et al., 1983). Intracellularly, the oxidoreductase enzymes thioredoxin 
and glutaredoxin and thiol-based redox buffers cyst(e)ine and glutathione are responsible 
for maintaining redox homeostasis, and have been implicated in potential pathways of 
dimesna metabolism (Shanmugarajah et al., 2009; Verschraagen et al., 2004). 
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Similar to endogenous intracellular low molecular-weight disulfides cystine, 
homocystine, and GSSG, we hypothesized that dimesna undergoes thiol-disulfide 
exchange with thiolate anion-forming sulfhydryl groups via an SN2 reaction.  This 
reaction is commonly presented as a two-step reaction. Each step describes the transfer of 
a single electron and subsequently the formation and consumption of the mixed disulfide 
intermediate (i.e. RSSM, Figure 3.1) (Jocelyn, 1972). 
To examine the validity of this mechanism of thiol-dimesna exchange we 
measured the concentration-time courses of mesna production and consumption of Cys 
and GSH using 12 different combinations. Semi-logarithmic plots of combinations of 
dimesna and thiols indicated more than one linear phase and thus an overall reaction 
order greater than one. Logarithmic plots of first-order exponential functions describing 
initial reaction velocities and reactant concentrations yielded linear slopes with respect to 
each reactant indicated the velocity is directly proportional to the concentration of each 
reactant (i.e. first-order). As previously reported for other thiols (Gilbert, 1995), the rate 
of thiol-disulfide exchange is dependent on the concentrations of both reactants (i.e. the 
‘thiol’ and ‘disulfide’) hence the overall rate of dimesna consumption was expected to 
proceed via a second-order reaction. This is confirmed by the positive linear slopes of the 
plots of the observed pseudo-first-order rate constants with respect to dimesna in the 
presence of excess thiol. As anticipated from the steeper concentration-time courses of 
Cys compared to those of GSH, the second-order rate constant of Cys was approximately 
5-fold greater than that of GSH. This difference in reactivity is likely due to the lower 
acid dissociation constant of cysteine (pKa = 8.2-8.5 (Benesch & Benesch R., 1955)) than 
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that of GSH (pKa = 8.7 (Srinivasan et al., 1997)) ensuring greater ionization of the Cys 
thiol to a thiolate anion under physiological conditions. 
Rates of thiol-disulfide exchange between Cys and GSH with dimesna in 
phosphate buffer were recently evaluated (Shanmugarajah et al., 2009; Verschraagen et 
al., 2004). Verschraagen et al. reported first-order rate constants for the net loss of 1000 
µM dimesna when co-incubated with single concentrations of Cys or GSH (500 µM 
each). Consistent with our results, the authors reported the rate of loss of dimesna to be 
significantly higher when mixed with Cys than GSH (Verschraagen et al., 2004). 
Shanmugarajah et al. later expanded on the kinetics of non-enzymatic dimesna reduction 
by determining the forward and reverse second-order rate constants describing the 
transfer of the first electron and formation of the mixed disulfide. The values of forward 
and reverse rate constants, although consistent with the single concentration of dimesna 
and thiol used (100 µM), are likely only apparent rate constants because of the omission 
of the transfer of the second electron and formation of the final oxidized thiol (i.e. 
CySSyC and GSSG) (Shanmugarajah et al., 2009). Whether or not only half of the 
reaction can accurately predict the quantity of mixed disulfide produced at equilibrium 
remains to be determined by fully characterizing the combined reactions of thiol-dimesna 
exchange. 
In the absence of data to support a more complicated reaction mechanism 
accounting for transient hydrogen bond and dipole formation of elemental reactions, the 
stoichiometry of the overall production of mesna was determined empirically to be 
approximately double for each mole of Cys or GSH consumed. Intuitively, this ratio 
arises because dimesna is a homodimer of two mesna moieties. This allowed for 
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formulation of differential Equations 3.1 – 3.6 to quantify the species following the 
reaction scheme outlined in Figure 3.1. 
To fully characterize the non-enzymatic mechanism of dimesna reduction by Cys 
and GSH, we sought to determine the four second-order micro-rate constants of the 
differential equations describing the two reversible redox reactions. It should be noted 
that these rate constants describe the flux of sulfhydryl species and not their reactive 
thiolate anion form. However, the fraction of thiol in the thiolate anion form is directly 
proportional to its pKa and thus conditional on the pH of the system, which remained 
constant at pH = 7.0. 
A number of observations regarding the tendency of thiol species to exchange 
with one another can be made from fitted rate-constants. First, the rate of reaction 
between Cys and dimesna is likely the rate limiting step and may explain why 
Shanmugarajah et al. were able to obtain an acceptable coefficient of determination using 
only this first reaction (Shanmugarajah et al., 2009). The simple equilibrium constant of 
this first reaction (k1/k2) is approximately 3-fold greater for Cys than GSH, and within 
the 2-5-fold range of apparent first- and second-order rate constants reported here and 
previously (Shanmugarajah et al., 2009; Verschraagen et al., 2004). Also, the rate 
constants of the second reaction suggest different affinities of cysteine and GSH species 
for mesna. Whereas formation of the mesna-Cys mixed disulfide is favoured, and thus 
more stable than CySSyC, the reverse is true of mesna-GSH, with GSSG existing as a 
more stable product. This pattern may be related to the relative differences in half-cell 
potentials. The redox potential of GSH (E°’RSSR/RSH = -0.262) is slightly lower than that 
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of cysteine (E°’RSSR/RSH = -0.245) at pH =7.0, thus GSSG possesses a more stable 
disulfide bond than cystine (Jocelyn, 1972; Millis et al., 1993).  
To provide insight into the thermodynamic stability of dimesna compared to 
CySSyC and GSSG, the Keq of the proposed reaction mechanism was derived. 
Calculation of Keq of dimesna when mixed with Cys or GSH revealed Keqs of 0.200 and 
1.697, respectively. A Keq < 1 implies the reverse reaction is more favoured, suggesting 
dimesna is a more stable species than CySSyC. A Keq > 1 of dimesna when mixed with 
GSH implies a tendency of the forward reaction to be favoured, because it yields the 
more stable disulfide product GSSG (Millis et al., 1993). These observations are 
consistent with the existence of mesna moieties predominately as dimesna in patient 
plasma, despite circulating total Cys concentrations of approximately 300 µM. In 
contrast, only approximately 3 µM of GSH is present in plasma to facilitate reduction of 
dimesna by a more favourable reaction (Masuda et al., 2010; Pendyala et al., 2000; 
Verschraagen et al., 2003). 
Direct measurement of oxidation potentials of thiols by potentiometric methods is 
complicated due to formation of metal-thiol complexes at electrode surfaces, hence the 
half-cell potential of thiols are inferred using their Keqs when mixed with a common 
redox buffer of known half-cell potential, such as GSH; representing the oxidation of 
mesna by GSSG (Jocelyn, 1972; Szajewski & Whitesides, 1980). For comparison to 
previously established half-cell potentials of other endogenous and common therapeutic 
thiols, the half-cell potential of the disulfide bond of dimesna was determined indirectly 
using the equilibrium constant of dimesna in the presence of GSH and its established 
half-cell potential. The half-cell potential of mesna (-0.255 V) is similar to the redox 
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potentials of therapeutic and endogenous thiols captopril (-0.287 V), cysteamine (-0.260 
V), Cys (-0.245 V), GSH (-0.262 V), homocysteine (-0.256 V), and penicillamine (-0.243 
V) and much like the redox potentials of these thiols, favours oxidation (E°’RSSR/RSH < 0) 
(Jocelyn, 1972; Millis et al., 1993). Thus, our findings provide a mechanistic explanation 
for the greater reduction of CySSyC and homocystine by mesna than for GSSG in vitro 
(Pendyala et al., 2000), and clinical observations of dramatic Cys and homocysteine 
depletion with only a modest decline in GSH during mesna therapy (Pendyala et al., 
2000; Lauterburg et al., 1994; Stofer-Vogel et al., 1993; Smith et al., 2003).  
Remarkably, the ability of mesna to deplete circulating homocysteine levels by 
thiol-disulfide exchange has recently lead to its use in patients with end-stage renal 
disease (ESRD). Elevated plasma total homocysteine is a graded, independent risk factor 
for the development of cardiovascular disease and vascular access thrombosis amongst 
patients requiring chronic hemodialysis (Bostom et al., 1997; Mallamaci et al., 2002; 
Moustapha et al., 1998; Robinson et al., 1996; Shemin et al., 1999). Earlier work by our 
laboratory demonstrated that mesna can act as an effective thiol exchange agent to 
increase the free fraction of plasma total homocysteine (Urquhart et al., 2006), and 
increased its dialytic clearance (Urquhart et al., 2007b). The calculated redox potential of 
dimesna/mesna further supports the development of mesna as a therapeutic thiol 
exchange agent for lowering total plasma homocysteine without depletion of the 
endogenous antioxidant GSH. 
Thiol-disulfide exchange of dimesna may be catalyzed by the ubiquitous 
thioredoxin and glutaredoxin systems of the oxidoreductase family of redox proteins 
(Holmgren, 1989). Both thioredoxins and glutaredoxins catalyze the reversible reduction 
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of disulfide bonds by means of a dithiol/disulfide motif, Cys-X-X-Cys, known as the 
‘thioredoxin fold’ (Holmgren et al., 1975; Martin, 1995). The reactive N-terminal Cys 
residue readily forms a thiolate anion which acts as a strong nucleophile attacking the 
substrate disulfide to form a transient mixed disulfide. This mixed redoxin-substrate 
disulfide is then reduced by the, now deprotonated, C-terminal Cys residue of the 
thioredoxin fold producing oxidized redoxin and reduced substrate (Berndt et al., 2007; 
Holmgren, 1995). Thioredoxins are then specifically reduced by the selenocysteine of the 
active site of the flavoprotein thioredoxin reductase (Gladyshev et al., 1996; Zhong et al., 
2000). Oxidized glutaredoxins, on the other hand, are chemically reduced by GSH, 
forming GSSG which is then reduced by the flavoprotein glutathione reductase (Meister 
& Anderson, 1983). Both systems actively maintain thiol redox homeostasis through use 
of NADPH as a final electron donor (Holmgren, 1989). 
Human thioredoxin systems cytosolic/nuclear thioredoxin 1/thioredoxin reductase 
1 and mitochondrial thioredoxin 2/thioredoxin reductase 2 are ubiquitously expressed and 
essential for ribonucleotide synthesis (Engstrom et al., 1974), ROS signalling,(Rhee et 
al., 2005) nuclear receptor signalling (Grippo et al., 1985; Matthews et al., 1992), 
apoptosis (Ueno et al., 1999), and embryonic development (Nonn et al., 2003). 
Enzymatic reduction of dimesna has been proposed to proceed via the thioredoxin 
system consisting of the 12 kDa E. coli protein thioredoxin (trxA; Trx1, UniProtKB ID # 
P0AA25) and 55 kDa bovine thioredoxin reductase (TXNRD1; TR1, UniProtKB ID # 
O62768, EC 1.8.1.9.) however the significance of the findings relative to  controls was 
not reported (Verschraagen et al., 2004). In the present study, we demonstrate a 
concentration-dependent increase in enzymatic activity of a thioredoxin system 
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consisting of recombinant human thioredoxin and purified rat thioredoxin reductase in 
the presence of clinically relevant dimesna concentrations. Given that dimesna was 
unable to lower the rate of reduction of DTNB by thioredoxin reductase, dimesna is most 
likely reduced directly by thioredoxin (Figure 3.7). 
The glutaredoxin system, in concert with GSH, has also been implicated as a 
mechanism of dimesna reduction (Ormstad et al., 1983; Verschraagen et al., 2004). 
Isoforms of the human glutaredoxins include cytosolic glutaredoxin 1, and mitochondrial 
glutaredoxins 2 and 5 (Berndt et al., 2007). The catalytic activities of these redoxins are 
dependent on the availability of GSH and so are inexorably linked to the activity of 
glutathione reductase to maintain a high cellular GSH/GSSG ratio (Meister & Anderson, 
1983). Together with cofactors GSH and NADPH, the glutaredoxin system facilitates 
ribonucleotide synthesis (Holmgren, 1979), dehydroascorbate reduction (Wells et al., 
1990), redox signalling (Shelton et al., 2005), nuclear receptor signalling 
(Bandyopadhyay et al., 1998; Hirota et al., 2000), apoptosis (Chrestensen et al., 2000; 
Daily et al., 2001), and cellular differentiation (Takashima et al., 1999). 
Incubation of dimesna with 12 kDa glutaredoxin from rat liver (Glrx; Grx1, 
UniProtKB ID # Q9ESH6, EC 1.8.4.2; formerly thiol transferase) and 53 kDa yeast 
glutathione reductase (GLR1; GR, UniProtKB ID # P41921, EC 1.8.1.7, formerly EC 
1.6.4.2) increased the sulfhydryl concentration of the mixture at a rate similar to dialyzed 
cytosolic fractions of kidney homogenate (Ormstad et al., 1983). Reduction of dimesna 
by purified enzymes of the glutaredoxin system consisting of the 10 kDa E. coli protein 
glutaredoxin (grxA; Grx1, UniProtKB ID # P68688, EC 1.8.4.2) and yeast glutathione 
reductase when supplemented with GSH has also been reported using spectrophotometric 
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measurement of NADPH oxidation (Verschraagen M, 2004). Consistent with the results 
of Verschraagen et al. using non-mammalian enzymes (Verschraagen et al., 2004), 
enzymatic activity of the human cytosolic glutaredoxin system was only observed 
following co-incubation of GSH with dimesna. This was corroborated by the inability of 
1 mM dimesna to inhibit reduction of equimolar GSSG by glutathione reductase. Taken 
together, dimesna is not a clinically relevant substrate of either of the enzymes of the 
glutaredoxin system. The catalytic site of glutathione reductase is believed to be highly 
specific to the γ-glutamylcysteine residues of GSH (Meister & Anderson, 1983), thus, the 
formation of glutathionylated mesna moieties (i.e. mixed disulfides) by chemical thiol-
disulfide exchange of GSH with dimesna facilitates enzymatic activity. 
Similar to findings from the purified glutaredoxin system, supplementing kidney 
and liver homogenates with GSH dramatically increased the enzymatic activity. The 
equivalency between kidney and liver homogenates, despite the greater reductive 
capacity of the kidney, suggests that formation of the glutathione-mesna mixed disulfide 
represents the rate limiting step in GSH-mediated enzymatic reduction of dimesna. Our 
results suggest that GSH-dependent reduction of dimesna by kidney and liver reported 
here and elsewhere (Goren et al., 1998; Ormstad & Uehara, 1982; Ormstad et al., 1983) 
derives from a combination of non-enzymatic GSH-dimesna exchange and glutaredoxin-
catalyzed reduction of mesna-GSH disulfides. 
Perfused organ experiments have implicated the kidneys and liver as sites of 
dimesna metabolism (Goren et al., 1998; Ormstad & Uehara, 1982; Ormstad et al., 
1983). In addition, work presented in chapter two demonstrated secretion of mesna by a 
HeLa cell heterologous expression system following dimesna incubation. To measure the 
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relative capacities of these tissue types to enzymatically reduce dimesna, the oxidation of 
NADPH by HeLa cell and mouse kidney and liver homogenates was evaluated. Kidney 
homogenate possessed the greatest capacity to enzymatically reduce GSSG, presumably 
due to the high expression of glutathione reductase by renal tissue. Similar to purified 
enzyme systems, the addition of dimesna to GSSG-supplemented homogenates had no 
effect on enzymatic activity. Interestingly, the addition of dimesna alone to homogenates 
had no significant effect on basal enzymatic activity. Using the more sensitive method of 
liquid chromatography-electrochemical detection to directly measure dimesna reduction, 
Verschraagen et al. were able to demonstrate an increase in dimesna reduction with the 
addition of NADPH to kidney homogenate, suggesting the existence of enzyme-
facilitated reduction (Verschraagen et al., 2004). The apparent lack of enzymatic activity 
in our system may be due to the low sensitivity of spectrophotometric methodology. 
Although one mole dimesna or GSSG is reduced for every mole of NADPH consumed, 
the limit of quantitation of the spectrophotometric measurement of NADPH oxidation is 
25 to 50 fold higher than detection of thiols by liquid chromatography-coupled 
electrochemical detection or fluorescence derivatization (Shanmugarajah et al., 2009; 
Urquhart et al., 2006). 
 As an alternative approach to test for the presence of enzyme-dependent reduction 
of dimesna in HeLa cells, the rates of mesna production and Cys or GSH consumption 
were simultaneously measured in HeLa cell lysates before and after inactivation of 
enzymes by denaturation and centrifugation. Incubation of dimesna with untreated cell 
lysate resulted in production of mesna and concurrent decline in basal Cys and GSH 
concentrations. Following denaturation of enzymes, mesna production was significantly 
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decreased. Although the concentration-time course of Cys remained unaffected, basal 
GSH was significantly lower, presumably due to the loss of glutathione reductase. 
Although dimesna reduction was clearly lowered by denaturation, whether the observed 
decrease in mesna production was due to a loss of redox enzymes or a consequence of a 
loss of non-enzymatic GSH-mediated thiol exchange alone, due to lowered basal GSH 
concentrations, was not immediately apparent. 
To determine the contributions of enzymatic and non-enzymatic mechanisms of 
dimesna reduction in HeLa cells, the concentration-time courses of thiols species were 
predicted in silico by our model of thiol-dimesna exchange using parameters fitted in 
previous in vitro experiments. Application of the model using basal Cys and GSH 
concentrations resulted in good fits (r2 > 0.82) to observed data for both untreated and 
denatured lysates. Interestingly, predicted mesna production due to non-enzymatic thiol 
exchange alone could only account for just over half of the mesna found in untreated 
lysate, suggesting the existence of an enzymatic mechanism of dimesna reduction. Upon 
removal of cellular enzymes by denaturation, the residual mesna production was almost 
entirely accounted for by non-enzymatic cysteine-dimesna exchange, further supporting 
the hypothesis that enzymatic reduction significantly contributes to the intracellular 
metabolism of dimesna. Deviation of predicted concentrations from observed values may 
be due to the contribution of additional intracellular low molecular weight thiols such as 
homocysteine, γ-glutamylcysteine, and cysteinylglycine. 
In addition to prediction of product and reactant thiols, the use of micro-rate 
constants allows for calculation of concentrations of mixed disulfide reaction 
intermediates.  The importance of the production of mesna mixed disulfides containing a 
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terminal γ-glutamate moiety in the mitigation of cisplatin-induced nephrotoxicity has 
recently been proposed (Hausheer et al., 2010a; Hausheer et al., 2010b). Toxication of 
cisplatin proceeds by S-glutathionylation and sequential cleavage of glutamate, glycine, 
and cysteine residues by γ-glutamyltranspeptidase (GGT), aminopeptidase N (APN), and 
finally cysteine-S-conjugate-β-lyase (CCBL) to form reactive thiolate-platinum species 
(Hanigan et al., 1994; Hanigan et al., 1996; Hanigan et al., 2001; Townsend et al., 2003). 
Mesna was previously believed to be the sole active metabolite of dimesna; able to 
directly conjugate to cisplatin, thereby preventing its metabolic activation. Hausheer et al. 
has since demonstrated that mesna mixed disulfides containing a terminal γ-glutamate 
moiety, such as mesna-glutathione and mesna-cysteinyl-glutamate, inhibit GGT and APN 
activity (Hausheer et al., 2010a; Hausheer et al., 2010b). Our finding that mesna-GSH 
mixed disulfide is formed by non-enzymatic GSH-dimesna exchange at concentrations 
approximately 30% of intracellular mesna, suggests that inhibition of the toxication 
pathway of cisplatin by dimesna represents an additional clinically relevant mechanism 
of chemoprotection. 
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CHAPTER 4: MESNA FOR THE TREATMENT OF 
HYPERHOMOCYSTEINEMIA IN HEMODIALYSIS PATIENTS 
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4.1 Introduction  
Homocysteine (Hcy) is a thiol containing amino acid ubiquitously formed by the 
demethylation of methionine. Homocysteine represents a key branch point in the 
methionine cycle and its concentration is tightly regulated intracellularly. Once formed, 
Hcy can be recycled back to methionine via the vitamin B12 and folic acid dependent or 
betaine dependent remethylation pathways, catabolized to cystathionine via the vitamin 
B6 dependent transsulfuration pathway, or exported from cells into the vascular space 
(Figure 4.1) (Finkelstein, 1998). Once in the bloodstream, Hcy rapidly undergoes thiol 
exchange with circulating low-molecular weight thiols, covalent protein binding with -
Cys34-albumin, and auto-oxidation. Thus, Hcy within the plasma is comprised of reduced 
(sulfhydryl) Hcy (~1%) low-molecular weight disulfides (20 - 30%) and protein bound 
Hcy (70 - 80%) collectively termed total homocysteine (tHcy) (Hortin et al., 2006; 
Mansoor et al., 1992). 
Homocysteine metabolism can be adversely affected by many genetic, disease, 
and dietary factors, resulting in a plasma tHcy concentration ≥ 15 µmol /L (termed 
hyperhomocysteinemia; ≥ 2.03 mg/L) (Brattstrom et al., 1998; Broxson, Jr. et al., 1989; 
Jacques et al., 1996; Mudd et al., 1969; Mudd et al., 1985). It is well established that 
decreased glomerular filtration rate, and therefore progression of chronic kidney disease 
(CKD), is inversely correlated with plasma tHcy (Anwar et al., 2001; Arnadottir et al., 
1996). Culmination of CKD to end-stage renal disease (ESRD) results in 
hyperhomocysteinemia in the majority of patients undergoing maintenance hemodialysis 
(Bostom & Lathrop, 1997; House & Donnelly, 1999; House et al., 2000; Tamura et al., 
1996). 
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Many studies have shown plasma tHcy to be a strong, independent, predictor of 
atherosclerosis and thrombosis in ESRD (Bostom & Culleton, 1999; Mallamaci et al., 
2002; Moustapha et al., 1998; Robinson et al., 1996; Welch & Loscalzo, 1998). The 
relative risk of cardiovascular events, including mortality, was shown to increase by 1% 
per micromolar increase in plasma tHcy in a prospective study by Moustapha et al. 
(Moustapha et al., 1998). Another prospective trial by Mallamaci et al. reported patients 
in the third plasma tHcy tertile were 8.2 times more likely to suffer an atherothrombotic 
event than patients in the first tertile (Mallamaci et al., 2002). 
In most patient populations plasma tHcy can be normalized by supplementation 
with combinations of folic acid, B12, and vitamin B6 (Ubbink et al., 1993; Ubbink et al., 
1994). Unfortunately folic acid, betaine, serine, vitamin B6, and vitamin B12 supplements 
fail to normalize plasma tHcy in patients with ESRD (Bostom et al., 1995; Bostom et al., 
1996a; Elian & Hoffer, 2002; House & Donnelly, 1999; Spence et al., 1999). Increasing 
Hcy removal by increasing dialysis membrane pore size have also proven 
ineffective(House et al., 2000; Vriese et al., 2003). The inability of high dose folic acid 
and B vitamins to normalize plasma tHcy or impact cardiovascular outcomes has been 
highlighted in the recently completed Homocysteinemia in Kidney and End-Stage Renal 
Disease (HOST) trial (Jamison et al., 2007). Taken together, these observations suggest 
investigation of alternate treatment modalities to lower tHcy in patient with ESRD is 
justified. 
A promising strategy for lowering tHcy in ESRD is to increase Hcy excretion by 
thiol exchange. Thiol exchange utilizes a sulfhydryl containing drug that is able to 
exchange with Cys34-albumin bound Hcy thereby enhancing the dialyzable, sulfhydryl 
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and low-molecular weight, fraction of plasma tHcy.  Scholze et al. have used this strategy 
successfully with the mucolytic thiol agent N-acetylcysteine (NAC) (Scholze et al., 2004). 
Use of the chelating agent dimercaptosuccinic acid (DMSA) by our group proved 
ineffective (House et al., 2004). In vitro analysis of mesna, a drug indicated for the 
chelation of reactive oxazaphosphorine metabolites, would be efficacious at increasing 
dialytic clearance of Hcy (Urquhart et al., 2006). Lauterburg et al. previously 
demonstrated a remarkable decline of plasma cysteine and tHcy in patients receiving 
intravenous mesna as an adjunct to ifosfamide chemotherapy (Lauterburg et al., 1994). 
Recently we demonstrated that a single, predialysis, 5 mg/kg intravenous bolus of 
mesna significantly increases the dialytic clearance of tHcy (Urquhart et al., 2007b). In 
addition, plasma tHcy remained significantly lower two days after mesna administration. 
Despite these initial positive findings, prolonged administration of 5 mg/kg mesna failed 
to normalize elevated plasma tHcy in a randomized, placebo-controlled trial (Urquhart et 
al., 2008). Therefore a larger dose of mesna would be required to correct plasma tHcy 
levels in ESRD. Since cancer patients undergoing ifosfamide chemotherapy routinely 
receive 10 – 12 mg/kg intravenous mesna thrice daily, we presumed 12 mg/kg 
intravenous mesna thrice weekly would be well tolerated in dialysis patients and have a 
greater impact in regard to lowering tHcy. 
We hypothesized that 12 mg/kg intravenous mesna, at the beginning of each 
dialysis session, over the course of one week would lower plasma tHcy levels compared 
to placebo. Following positive results, a second study was conducted to evaluate the 
decline of tHcy during thrice weekly 12 mg/kg mesna, for four weeks. A cumulative tHcy 
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lowering effect may indicate mesna as an effective agent to normalize plasma tHcy in 
patients on dialysis. 
The objective of this study was to determine if routine 12 mg/kg intravenous 
mesna will provide a cumulative decrease in plasma tHcy over a four week period in 
vitamin-replete hemodialysis patients.
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Figure 4.1    Methionine pathway.  Enzymes and vitamin cofactors indicated by open and 
shaded ellipses, respectively.  Abbreviations used: 5,10-MTHF, 5,10-
methylenetrahydrofolate; 5-MTHF, 5-methyltetrahydrofolate; AdoHcy, S-
adenosylhomocysteine; AdoMet, S-adenosylmethionine; BHMT, betaine-homocysteine 
methyltransferase; CBS, cystathionine ß-synthase; Cys, cysteine; Cysta, cystathionine; 
DHF, dihydrofolate; DHFR, dihydrofolate reductase; DMG, dimethylglycine; GGCS, γ-
glutamylcysteine synthase; γ-GluCys, γ-glutamylcysteine; GS, glutathione synthase; 
GSH, glutathione; Hcy, homocysteine; MAT, methionine adenosyl transferase; Met, 
methionine; MS, methionine synthase; MTHFR, methylenetetrahydrofolate reductase; 
SAHH, S-adenosylhomocysteine hydrolase; SHMT, serine hydroxymethyltransferase; 
THF, tetrahydrofolate; TS, thymidylate synthase. 
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4.2 Methods 
4.2.1 Subjects 
 Eight patients on maintenance hemodialysis (7 males, 1 female) were recruited 
from the London Health Sciences Centre – University Campus and South Street 
Hemodialysis Units for the initial pilot study to evaluate mesna treatment for one week. 
Following analysis of the pilot study, a second trial of four week duration was conducted. 
Ten patients on maintenance hemodialysis (8 males, 2 females) were recruited from the 
London Health Sciences Centre – South Street Hemodialysis Unit.  Inclusion criteria for 
both studies were: Replavite® daily multivitamin supplementation (containing 6 µg 
vitamin B12, 10 mg vitamin B6, and 1 mg folate; WN Pharmaceuticals, Mississauga, 
Canada), thrice weekly hemodialysis for at least 90 days with a high flux biocompatible 
membrane, and willingness to give written informed consent. Patients were excluded 
from the study if they had malnutrition (normalized protein catabolic rate < 1.0 g/kg/d), 
low serum albumin < 3.0 g/dL (< 30 g/L), were clinically unstable, or were women of 
child bearing potential who refused to practice adequate contraception. The Health 
Sciences Research Ethics Board at the University of Western Ontario approved the study 
protocol. The study protocol also received a No Objection Letter (NOL) from the 
Therapeutic Products Directorate of Health Canada, as required for clinical research with 
off-indication pharmaceuticals in Canada. Patients were dialyzed with Fresenius Optiflux 
hollow fiber dialyzers (Fresenius AG, Bad Homburg, Germany). 
4.2.2 Design of Studies 
 Both studies were placebo-controlled, double-blind, randomized, cross-over trials.  
Subjects were randomized by a computerized randomization program to receive either 
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mesna or placebo (equal volume of saline) prior to crossing over to the alternate 
treatment arm.  Twelve-milligram per kilogram mesna was diluted four-fold in normal 
saline and administered over five minutes at the beginning of dialysis by intravenous 
injection into the venous return of the dialysis blood circuit. This was repeated three 
times during each week of treatment, corresponding to the beginning of each patient’s 
dialysis session.   
During the initial pilot study mesna and placebo arms were one-week in length 
and were interceded by a single week of washout during which time subjects received 
only routine dialysis. Blood samples were drawn pre- and postdialysis at the beginning of 
each treatment arm. Predialysis blood samples were drawn 44 hours after completing the 
final cycle of each arm for comparison of plasma tHcy concentrations following one 
week of mesna and placebo treatments.   
Analysis of samples of the pilot study suggested a longer treatment would further 
lower plasma tHcy. The second study was of similar design to the first, but extended the 
treatment arms to four weeks. In addition, twelve-day washout periods followed each 
treatment arm to measure the duration of detectable levels of plasma mesna within 
subjects. Five millilitre blood samples were drawn predialysis once a week during the 
twelve-week study period and postdialysis at the beginning and end of each treatment 
arm. All blood samples were immediately placed on ice and centrifuged within 30 
minutes to obtain plasma that was frozen until completion of the study. 
4.2.3 Dialysate Collection 
The sum of all spent dialysate was collected from three subjects during their first 
dialytic sessions of placebo and mesna arms of the four-week study for calculation of the 
207 
 
 
total excretion of Hcy, Cys, and mesna. Dialysate was collected in 44 gallon (166.6 L) 
Rubbermaid® Brute® drums (Atlanta, GA) lined with disposable biohazard bags. Ten 
milliliter samples were drawn from the accumulated dialysate every 5 minutes until 30 
minutes and at 1, 2, 3 hours and immediately after the end of dialysis (either 3.5 or 4 
hours). Drums were continuously weighed using Longacre Racing Products, Inc. 
AccuSetTM Computerscales® (Monroe, WA). Net weight of dialysate (total weight minus 
drum weight) was recorded at each collection time to allow for calculation of volume and 
subsequent calculation of Hcy, Cys, and mesna excretion. 
4.2.4 Sample Analysis & Statistical Methods 
Plasma tHcy, tCys, and total mesna (sum of mesna sulfhydryl, low-molecular 
weight disulfides, and protein-bound mesna) were measured by modification of the 
chromatographic method described by Urquhart et al. (Urquhart et al., 2006). Citrate, 
sodium borohydride (NaBH4), ethylenediaminetetraacetic acid (EDTA), hydrochloric 
acid (HCl), sodium hydroxide (NaOH), and perchloric acid were purchased from Sigma-
Aldrich (Sigma-Aldrich, St. Louis, MO). Monobromobimane (MBB) was obtained from 
EMD Biosciences (Gibbstown, NJ). All solvents and reagents were of HPLC-grade or 
higher. Disulfide bonds were completely reduced by addition of 53 mM NaBH4 in 0.05 
M NaOH and incubation at 37°C for 5 minutes. Residual reducing agent was quenched 
by 1.2 M HCl and thiols were derivatized with 12.5 mM monobromobimane (25% 
acetonitrile, 3 mM EDTA) at 37°C for 15 minutes. Protein was precipitated by addition 
of 15% perchloric acid and centrifugation. Supernatant pH was raised to 4.0 with 0.5 M 
citrate: 2.5 M NaOH solution prior to injection onto a Zorbax SB-C18 column (150 x 3.2 
mm, 5 µm particle) maintained at 40°C in a Hewlett Packard 1090 LC (Agilent 
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Technologies, Santa Clara, CA). Mesna was eluted at 12.5 minutes with a gradient of 4% 
acetonitrile: 96% ammonium formate: 0.1 % formic acid containing 0.75 mM 
dibutylamine (pH 3.75) to 17% acetonitrile: 83% ammonium formate: 0.1 % formic acid 
containing 0.75 mM dibutylamine (pH 3.75) over 20 minutes at a flow rate of 0.5 
mL/min. tHcy and tCys were eluted at 7 and 15 minutes, respectively, with 4% 
acetonitrile: 96% ammonium formate: 0.1 % formic (pH 3.75) at a flow rate of 0.5 
mL/min. Derivatized thiols were detected by a Waters 474 scanning fluorescence detector 
(λexcitation = 390 nm, λemission = 480 nm; Waters, Milford, MA). The accuracy and precision 
of the assay were 1.3% and 2.0%, respectively. Results are mean ± SD. Inter-dialytic 
changes in plasma tHcy were tested for significance by repeated measures analysis of 
variance (ANOVA) followed by Tukey’s multiple comparison tests. Predialysis plasma 
tHcy concentrations at the end of each treatment arm of the one-week study were 
analyzed by paired t-test.   
For determination of the sample size required for the four-week study, it was 
assumed that longer treatment would produce a difference in plasma tHcy equal to or 
larger than the previous pilot study. Sample size was calculated using the mean difference 
in plasma tHcy observed following one week of mesna (2.87 µmol/L), with a standard 
deviation of 1.97 µmol/L, and level of significance (α) of 0.05. A sample size of 5 
subjects would be sufficient to detect this difference with 90% power (Friedman LM et 
al., 1996). A total of 10 subjects were recruited to account for a dropout rate of 50%.   
Amounts of tCys, tHcy, and total mesna excreted, predialysis plasma tHcy, and 
areas under the concentration-time curves (AUCs) of plasma tHcy throughout the four-
week study during placebo and mesna arms were compared by paired t-test. Inter-dialytic 
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changes in plasma tHcy at the beginning and end of each treatment arm were tested for 
significance by repeated measures ANOVA followed by Tukey’s multiple comparison 
tests. Calculations of AUCs and statistical tests were completed using Prism (GraphPad 
Software, Inc., San Diego, CA). P-values less than 0.05 were considered statistically 
significant. 
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4.3 Results 
4.3.1 One Week study 
Seven of the eight subjects recruited for the one-week pilot study had 
hyperhomocysteinemia (plasma tHcy ≥ 15 µmol /L [≥ 2.0 mg/L]). Subjects’ baseline 
characteristics are listed in Table 4.1. Mesna significantly decreased the postdialysis 
plasma tHcy greater than placebo during the first dialysis cycle of each arm (% decline 
during dialysis, placebo = 45.2 ± 11.6%, mesna = 68.8 ± 13%, p < 0.001). Following one 
week of 12 mg/kg IV mesna, predialysis plasma tHcy was significantly lowered by 12.8 
± 7.8% compared to placebo (placebo: 23.4 ± 8.0 µmol/L vs. mesna: 20.5 ± 7.6 µmol/L, 
P = 0.0044). 
4.3.2 Four Week study 
The observation of a significant decline in plasma tHcy after only one week of 
mesna administration, motivated extension of the treatment period to four weeks. A 
second study was conducted with ten subjects with ESRD receiving thrice weekly 12 
mg/kg mesna for four weeks. Over the course of the 12 week study period one subject 
received a kidney transplant, one subject was withdrawn due to vascular access 
complications, and one subject died from acute myocardial infarction due to co-
morbidity. Each event was determined to be unrelated to mesna therapy. Five of the 
seven subjects to complete the second study had hyperhomocysteinemia. Subjects’ 
baseline characteristics are listed in Table 4.2. 
Predialysis plasma total mesna concentrations were at steady-state between weeks 
one and four (Figure 4.2), and declined to 9.9 ± 4.9 µmol/L twelve days after the last 
dose. No significant decline in predialysis plasma tHcy was detected after four weeks 
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(placebo: 18.3 ± 8.5 µmol/L versus mesna: 18.7 ± 6.3 µmol/L, P = 0.41). Areas under the 
plasma tHcy concentration-time curves of four-week placebo and mesna treatments were 
also not significantly different (placebo: 547.6 ± 206.5 µmol/L · day vs. mesna: 515.2 ± 
158.0 µmol/L · day, P = 0.2042, Figure 4.3).  
 The effect of dialysis on decreasing plasma tHcy was significantly greater after 
the first dose of mesna (day 0), compared to the inter-dialytic changes during placebo. 
However, the last dose of mesna (day 28) caused a drop in plasma tHcy that was not 
significantly different than placebo (% drop placebo, day 0 = 40.1 ± 10.1%; placebo, day 
28 = 40.1 ± 10.1%; mesna, day 0 = 65.8 ± 8.3%; mesna, day 28 = 42.0 ± 7.7%, Figure 
4.4). 
Also measured during the study, was the total mesna, tHcy, and tCys excreted by 
three patients throughout their dialysis sessions, following their first doses of saline and 
mesna. Interestingly, mesna significantly increased the area under the dialysate tHcy 
amount-time curve (placebo: 24.0 ± 12.4 mg · h vs. mesna: 30.4 ± 14.3 mg · h, P = 
0.0206, Figure 4.5). More importantly the total tHcy excreted during dialysis was 
significantly improved following mesna administration (placebo: 12.2 ± 6.4 mg versus 
mesna: 14.7 ± 6.6 mg, P = 0.0068) while creatinine excretion was unaffected (placebo:  
1357 ± 189 mg vs. mesna: 1571 ± 528 mg, P = 0.28). The amounts of tCys excreted 
during dialysis after mesna and placebo was not different (placebo: 354.4 ± 133.8 mg 
versus mesna: 303.4 ± 99.6 mg, P = 0.0823). 
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Table 4.1   Baseline Patient Characteristics; one-week study 
Subject Sex Age 
Weight  
(kg) 
Vitamin 
B12 
(pmol/L) 
Serum 
Folate 
(nmol/L) 
Albumin 
(g/dL) 
tHcy 
(µmol/L) 
1 M 28 68.2 564 26.8 36 19.4 
2 M 67 104.4 297 >54.5 31 21.2 
3 M 61 69.3 305 41.5 34 12.6 
4 M 62 94.5 144 >54.5 36 27.1 
5 M 67 120.3 255 40.4 39 31.6 
6 F 28 42.9 610 >54.5 31 16.1 
7 M 55 76.4 296 43.3 34 30.9 
8 M 75 89.7 648 >54.5 36 25.1 
Mean  55.4 83.2 390 46.3 35 23.0 
SD  17.8 24.2 188 10.1 3 6.8 
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Table 4.2   Baseline Patient Characteristics; four-week study 
Subject Sex Age 
Weight 
(kg) 
Vitamin 
B12 
(pmol/L) 
Serum 
Folate 
(nmol/L) 
Albumin 
(g/dL) 
tHcy 
(µmol/L) 
1 M 56 84.3 389 >54.5 36 32.3 
2 M 59 95.9 >1476 >54.5 36 12.7 
3 M 49 66.7 429 >54.5 30 16.8 
4 M 76 88.4 1246 >54.5 36 22.7 
5 M 32 74.9 326 23.4 35 21.8 
6 F 78 82.1 460 >54.5 31 10.9 
7 F 78 65.0 488 >54.5 38 12.0 
Mean  61 79.6 556 50.1 34 18.5 
SD  17 11.4 343 11.8 4 7.7 
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Figure 4.2   Predialysis plasma total mesna concentrations of seven subjects administered 
12 mg/kg of mesna thrice weekly for four weeks and twelve days after the last dose. 
Results are expressed as mean ± SD, n = 7. 
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Figure 4.3   Predialysis plasma tHcy concentrations of seven subjects administered 12 
mg/kg of mesna (∆) and an equal volume of saline (□) thrice weekly for four weeks and 
twelve days after the last dose. Results are expressed as mean ± SD, n = 7. 
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Figure 4.4   Pre- and postdialysis plasma tHcy concentrations following the first (day 0) 
and last (day 28) doses of placebo and mesna. Results are expressed as mean ± SD, n = 7, 
*, ** P < 0.05.  
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Figure 4.5   tHcy excreted by three subjects administered 12 mg/kg of mesna (∆) and an 
equal volume of saline (□) during the first dialytic session of each treatment arm. Results 
are expressed as mean ± SD, n = 1-3. 
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4.4 Discussion 
The incidence of kidney failure is growing as the population ages. The only cure 
for ESRD is kidney transplantation; however adult patients in Canada must wait an 
average of ten years before transplantation (Zaltzman, 2006). Meanwhile, patients are 
confined to dialysis treatment. The incidence of cardiovascular mortality amongst ESRD 
patients 55 to 64 years of age is 15-fold higher than the general population (Collins et al., 
2001). Effective treatment of cardiovascular disease in ESRD is crucial to aid in the 
survival of patients until transplantation. 
Plasma tHcy concentrations observed in ESRD commonly exceed 20 µmol/L and 
may explain the discrepancy between the incidence of cardiovascular disease amongst 
dialysis patients and the general population (Becker et al., 1997). Elevated plasma tHcy is 
a predictor of death and atherothrombotic events within dialysis patients free of 
malnutrition (Bostom et al., 1997; Mallamaci et al., 2002; Moustapha et al., 1998). 
Recent meta-analysis followed by subgroup analysis of randomized controlled trials 
(Righetti et al., 2006; Wrone et al., 2004; Zoungas et al., 2006) using folic acid to lower 
plasma tHcy within the dialysis patient population reported null results (Bazzano et al., 
2006). Furthermore, the addition of vitamin B6 and B12 to folic acid supplementation also 
failed to affect cardiovascular event rates (Mann et al., 2008). The inability of vitamin 
supplementation to normalize plasma tHcy in ESRD has previously been demonstrated, 
thus the Hcy lowering effect achievable by vitamins may not yield significant 
atherothrombotic benefit, especially in the advanced atherosclerosis seen in ESRD 
(Lindner et al., 1974). 
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An alternative strategy for lowing tHcy in ESRD is thiol exchange. Currently 
potential thiol exchange agents NAC, DMSA, and mesna have been tested in vivo with 
mixed results (Bostom et al., 1996b; Friedman et al., 2003; House et al., 2004; Scholze et 
al., 2004; Thaha et al., 2006; Urquhart et al., 2007b; Ventura et al., 1999; Ventura et al., 
2003). N-acetylcysteine given orally (1.2 g twice daily for four weeks) produced a 19% 
decrease in tHcy levels, although this decline failed to reach significance (Friedman et al., 
2003). When a single 5 g dose was given intravenously, a decline in predialysis plasma 
tHcy concentration was detected two days after dosing (Scholze et al., 2004). Using a 
sustained-release formulation of NAC given twice daily, Nolin et al. has recently shown 
both 0.6 g and 1.2 g doses significantly lower plasma tHcy in ESRD 21.5% and 24.8%, 
respectively, following two weeks of treatment (Nolin et al., 2010). Although the 
author’s rationale for using NAC was to reduce oxidative stress by providing a precursor 
for glutathione synthesis, no change in circulating tCys or glutathione was detected in 
healthy controls or ESRD (Nolin et al., 2010), suggesting that γ-glutamyl cysteine 
synthase, the rate limiting step in glutathione synthesis (Meister, 1988), is adequately 
saturated by baseline cysteine concentrations. Furthermore, no change in oxidative stress-
markers asymmetric dimethylarginine and protein carbonyl concentrations were detected 
(Nolin et al., 2010).  The observed decline in plasma tHcy was likely due to continuous 
NAC-mediated thiol exchange provided by the sustained-release formulation. 
Our group has recently tested both DMSA and mesna as potential thiol exchange 
agents in vivo. In a well-powered study, oral DMSA (2.5 mg/kg/d, 4 weeks) failed to 
lower plasma tHcy levels (House et al., 2004). Conversely, we have shown that mesna 
can effectively increase the efficacy of Hcy removal by dialysis. Subjects who received a 
220 
 
 
single 5 mg/kg IV dose of mesna showed a significant decline in plasma tHcy of 2.3 ± 
1.8 µmol/L (0.3 ± 0.2 mg/L) two days after administration.(Urquhart et al., 2007b) 
However, when dosing was extended to thrice weekly predialysis for eight weeks, no 
significant lowering effect was observed (Urquhart et al., 2008). 
To further decrease plasma tHcy concentrations between dialysis sessions, both 
dose and duration of mesna were increased in the initial pilot study presented here. Eight 
subjects received 12 mg/kg at the beginning of each dialysis session for one week. The 
result of this study was a decrease in predialysis tHcy of 2.9 ± 2.0 µmol/L, significantly 
lower compared to a week of placebo, but a meager change compared to the single 5 
mg/kg dose which yielded a decline of 2.3 ± 1.8 µmol/L. Unfortunately, due to sparse 
sampling it is unknown whether this further decline is the result of increased dose, 
duration, or both. 
To test the ability of 12 mg/kg mesna to further lower plasma tHcy a second study 
of adequate statistical power and longer duration was conducted. Ten subjects were 
recruited and given mesna and saline thrice weekly for four weeks according to a cross-
over trial design. Predialysis blood samples were drawn weekly for measurement of 
plasma total mesna, tHcy, and tCys throughout treatment. Plasma total mesna 
concentrations appeared to be at steady-state between days 7 and 28. Despite giving a 
dose of mesna over two-fold higher than our previous study, which utilized 5 mg/kg, the 
mean steady-state concentration of plasma total mesna was no higher during the four-
week study presented here (12 mg/kg: 110.8 ± 43.6 µmol/L [18.16 ± 7.15 mg/L); 5 
mg/kg at 4 weeks: 104.8 ± 51.8 µmol/L [17.18 ± 8.49 mg/L], at 8 weeks: 106.2 ± 38.4 
µmol/L [17.41 ± 6.30 mg/L] ). The apparent loss of linear pharmacokinetics typically 
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observed in cancer patients, may be the result of first-order dialytic removal of mesna 
prior to distribution to plasma albumin. 
It has previously been shown in ESRD that thiol exchange lowers tHcy by 
increasing clearance (Urquhart et al., 2007b). This mechanism was reinforced by data 
gathered from urine tHcy measurements following 10 mg/kg oral mesna administration in 
healthy subjects (Urquhart et al., 2007a). Based on previous studies of mesna in healthy 
controls and ESRD patients, it’s reasonable to conclude that the dialytic and/or urinary 
excretion of tHcy is enhanced by mesna. Collection of the total volume of dialysate spent 
during the dialytic session has confirmed this unequivocally. The total tHcy excreted 
during dialysis was significantly improved following mesna administration (placebo: 12.2 
± 6.4 mg versus mesna: 14.7 ± 6.6 mg, P = 0.0068). Dialysate was collected during the 
first day of each treatment arm, thus during initial sampling each subject was naïve to 
treatment.   
The failure to normalize plasma tHcy, in the present study following four weeks 
of mesna, and our previous study (Urquhart et al., 2008), may be explained by the 
apparent loss of mesna efficacy. Postdialysis plasma tHcy on day 28 was significantly 
higher than day 0 of mesna therapy, and no difference was observed between placebo and 
mesna on day 28. Unfortunately dialysate collection was not repeated at the end of each 
arm, thus the decline in mesna’s efficacy was not confirmed by comparison of Hcy 
excretion on day 0 to day 28. 
 This apparent loss of efficacy may be explained by a change in the protein 
binding equilibrium of plasma thiols in the presence of mesna at steady-state. Increasing 
the mesna concentration within the plasma releases Hcy sulfhydryl by occupying protein 
222 
 
 
previously bound to Hcy. With successive doses of mesna, fewer Hcy-Cys34-albumin 
sites are available for thiol exchange. Free, sulfhydryl Hcy may then be sequestered to 
plasma protein non-specifically, preventing its dialytic clearance. 
Additionally, patients may develop resistance to thiol exchange therapy over the 
course of treatment by a compensatory increase in Hcy production. Previous work by our 
laboratory has shown decreased Hcy production rates of erythrocytes and peripheral 
blood mononuclear cells (PBMCs) isolated from ESRD patients with 
hyperhomocysteinemia due to a significantly lower ratio of substrate S-adenosyl-
methionine to inhibitor S-adenosyl-homocysteine (Cutler et al., 2006; Urquhart et al., 
2002). Acutely increasing plasma tHcy excretion may serve to increase this ratio, and 
thus increase Hcy production, returning patients to a state of chronic 
hyperhomocysteinemia. 
A number of groups have reported the ability of pharmacological parenteral 
vitamin B12 doses to significantly lower plasma tHcy concentrations in most dialysis 
patients (Elian & Hoffer, 2002; Hoffer et al., 2000; Kaplan et al., 2001; Obeid et al., 
2005b; Sombolos et al., 2002). Thiol exchange could be an important adjunctive therapy 
to parenteral B12 to lower plasma tHcy of those patients who remain at risk. 
Elevated levels of tHcy in patients with renal disease were first observed by 
Wilcken et al. in 1979 (Wilcken & Gupta, 1979). They were also the first to note that 
supplementation with the cofactors of the methionine cycle can lower plasma tHcy 
(Wilcken et al., 1981). Using oral doses of folic acid (5 mg/d) and pyridoxine (100 mg/d) 
combined with intramuscular vitamin B12 (1 mg/d) they were able to reduced plasma 
tHcy concentrations by about one-third.  This led to the investigation of single doses of 
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individual vitamins. Wilcken et al. observed the greatest Hcy-lowering effect from folic 
acid, with a minor effect from B12, and no change after pyridoxine treatment (Wilcken et 
al., 1981). Following the conclusion that folic acid deficiency was the greatest 
determinant of elevated plasma tHcy, many studies have been carried out with a 
multitude of doses of folic acid (Arnadottir et al., 1993; Arnadottir et al., 2000; Bostom 
et al., 2000; Dierkes et al., 1999; Manns et al., 2001; Sunder-Plassmann et al., 2000; 
Tremblay et al., 2000). From these studies it can be concluded that 1 mg/d folic acid is 
equipotent in Hcy-lowering ability to 2.5, 5, and 15 mg/d; each producing a reduction in 
plasma tHcy of about one-third within vitamin naïve patients.  
The clinical trial completed by Wrone et al. highlights the ineffectiveness of 
increasing folate doses above 1 mg/d on both plasma tHcy concentrations and incidence 
of cardiovascular morbidity and mortality in patients with ESRD. Patients received 
standard vitamin supplementation (12.5 mg pyridoxine, 6 µg B12) plus 1, 5, or 15 mg 
folic acid daily. After a median follow-up of 24 months no significant differences in 
survival or cardiovascular events were observed between groups. In addition, the 
proportion of patients reaching normal tHcy levels (tHcy < 15 µmol/L) did not differ 
between folic acid dosages (Wrone et al., 2004). Prior to mandatory folic acid 
fortification of grains, Bostom et al. compared the effect low-dose versus high-dose oral 
vitamin supplements in 27 dialysis patients. Patients were randomized to receive either 1 
mg/d folic acid, 10 mg/d pyridoxine, and 12 µg/d B12 or 15 mg/d folic acid, 100 mg/d 
pyridoxine, and 1 mg/d B12 for eight weeks.  Following treatment, mean plasma tHcy was 
30% lower in patients receiving high-dose vitamins, yet the authors concluded that folic 
acid alone accounted for the observed decline (Bostom et al., 1996a). It is likely that folic 
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acid was responsible for the decline in tHcy observe in both groups compared to baseline 
concentrations. However, in light of later studies outlining the equipotency of 1 mg and 
15 mg doses, folic acid alone could not account for the observed decline in tHcy between 
groups. 
 Nowadays, oral multivitamin supplementation and intake of fortified grains is 
commonplace amongst patients with ESRD. For this reason most dialysis patients are not 
folate deficient, and despite this the prevalence of hyperhomocysteinemia remains high.  
Vitamin B12 may be the next limiting factor in Hcy metabolism catabolism. 
 Although standard oral vitamins, containing 6 – 12 µg of vitamin B12, are 
sufficient to maintain normal serum cobalamin levels within dialysis patients (reference 
range: 200 – 672 pmol/L) recent evidence suggests that these levels do not necessarily 
lead to the required intracellular levels. Mononuclear cells of dialysis patients have a 
diminished vitamin B12 uptake capacity compared to healthy controls (Obeid et al., 
2005a). This is likely due to down-regulation of holotranscobalamin (holoTC) receptors 
as a result of serum holoTC accumulation (Herrmann & Obeid, 2005).  Combined with 
the low bioavailability of vitamin B12 (approximately 10-fold lower than folic acid) it 
should follow that parenteral dosing is necessary to achieve the supra-physiological 
serum concentrations required to restore the re-methylation pathway of Hcy in ESRD. 
 A handful of trials have evaluated the effect of intravenous vitamin B12 on plasma 
tHcy of dialysis patients (Elian & Hoffer, 2002; Hoffer & Elian, 2004; Hoffer et al., 
2005b; Kaplan et al., 2001; Koyama et al., 2002).  Forms of vitamin B12 used include 
those found in serum (hydroxocobalamin and its precursor cyanocobalamin) and 
intracellularly (methylcobalamin). In a prospective, randomized, controlled trial Hoffer et 
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al. observed a 32% decrease in patients receiving standard oral vitamin therapy (1 mg/d 
folic acid, 6 mg/d pyridoxine, and 10 µg/d vitamin B12) plus 1 mg/wk subcutaneous 
hydroxocobalamin compared to those patients receiving standard vitamins following 16 
weeks of treatment (Elian & Hoffer, 2002). When dosing was repeated at two week 
intervals in a separate trial their group only observed an 11.5% decline in plasma tHcy 
(Hoffer et al., 2005b). Methylcobalamin given as 500 mg intravenous doses after each 
dialysis session for three weeks by Koyama et al. produced a 50% decline in plasma tHcy; 
normalizing all patients within the treatment arm (Koyama et al., 2002).  Although the 
results of Koyama et al. and Hoffer et al. are positive, costs of methylcobalamin and 
hydroxocobalamin are high due to their instability. Comparison of 1 mg/wk intravenous 
doses of hydroxocobalamin and cyanocobalamin (an inexpensive preparation commonly 
used to treat pernicious anemia) by Hoffer et al. demonstrated that both preparations are 
equally effective at lowing plasma tHcy in ESRD. Plasma tHcy was lowered 
approximately one-third by both treatments, despite cyanocobalamin producing 
cobalamin levels 3- to 5-fold lower than hydroxocobalamin treatment. It should be noted 
that even during cyanocobalamin treatment serum cobalamin levels were 10- to 20-fold 
higher than baseline levels (4,900 – 13,200 pmol/L compared to 531-625 pmol/L) (Hoffer 
et al., 2005a).   
 Parenteral vitamin B12 supplementation (1 mg/wk) in addition to standard vitamin 
therapy (1 mg/d folic acid, 6 mg/d pyridoxine, and 10 µg/d vitamin B12) can lower 
plasma tHcy concentrations of most dialysis patients below 15 µmol/L. However 
additional Hcy lowering therapies such as thiol exchange may be necessary to further 
treat patients who remain hyperhomocysteinemic. The target plasma tHcy concentration 
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is accepted as less than 15 µmol/L (Kang et al., 1992), however epidemiological 
evidence suggests that even levels above 9 µmol/L warrant treatment (Hackam et al., 
2000). It has been recently shown that the odds ratios for venous thrombosis fail to reach 
significance only when plasma tHcy drops below 12 µmol/L. Subsequently, the authors 
proposed that the cut-off for hyperhomocysteinemia be lowered to 12 µmol/L (Castanon 
et al., 2007). To date, no treatment has been able to achieve this level in the majority of 
dialysis patients studied. 
With the recently completed large vitamin trials (Norwegian Vitamin Trial 
(Bonaa et al., 2006), Heart Outcomes Prevention Evaluation 2 (Lonn et al., 2006), and 
Vitamin Intervention for Stroke Prevention (Toole et al., 2004)) showing no effect on 
cardiovascular disease, it has been suggested that alternate methods of Hcy lowering 
should developed (Loscalzo, 2006). In addition to parenteral vitamins, the appropriate 
dosing regimen of mesna may be the necessary tool to lower plasma tHcy and test the 
Hcy theory of cardiovascular disease in ESRD.  
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5.1 Summary and Future Areas of Research 
5.1.1 In vitro and in vivo Assessment of the Role of Organic Anion Transporters in 
the Disposition of Mesna and Dimesna 
The successful therapeutic use of mesna for the mitigation of ifosfamide-induced 
hemorrhagic cystitis and, more recently, dimesna as a chemoprotectant against cisplatin-
induced nephrotoxicity is in large part due to kidney-specific reduction of their 
circulating inert disulfides (Brock et al., 1981a; Verschraagen et al., 2003). Upon 
entering the circulation mesna is rapidly oxidized to its inactive dimer, dimesna (Brock et 
al., 1981a; Brock et al., 1981b). Circulating dimesna must pass into the kidney 
parenchyma, be reduced to mesna, and subsequently be excreted into the urine to exert its 
protective effects. 
Dimesna was originally hypothesized to be confined to the vascular space due to 
its highly polar sulfonate groups (Brock et al., 1981a). Experiments using isolated 
perfused rat organs later demonstrated mesna accumulation in the kidneys, but not liver, 
following dimesna perfusion (Goren et al., 1998; Ormstad & Uehara, 1982). More recent 
experiments have corroborated these findings and further demonstrated a lack of 
accumulation of mesna into colorectal tumours and red blood cells (Verschraagen et al., 
2004a). 
Thus far, only Ormstad et al. have examined the saturable uptake of [14C]dimesna 
by renal tissue. Temperature- and ATP-dependent uptake of dimesna was observed using 
isolated rat renal epithelial cells. Reduction of glomerular filtration of perfused rat 
kidneys resulted in a dramatic decline in [14C]dimesna accumulation, leading the authors 
to conclude that the appearance of mesna in the urine occurs by filtration of plasma 
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dimesna, re-absorption of dimesna at the apical (luminal) brush border membrane, and re-
secretion into the urine by an as yet unidentified mechanism (Ormstad & Uehara, 1982). 
This conclusion, however, cannot account for renal clearance exceeding glomerular 
filtration rate (GFR) (James et al., 1987; Urquhart et al., 2007a) and thus suggests a 
mechanism involving renal transport proteins. The identity of these transporters remained 
to be determined. 
In chapter two we elucidated the renal drug transporters responsible for 
reabsorption of dimesna into the proximal tubule cells and subsequent efflux of active 
mesna into the urine. In addition, we identified novel transcellular pathways of 
transporter-mediated active secretion of mesna by the proximal tubule cells. Interestingly, 
an initial screen of known drugs uptake transporters revealed only renally-expressed 
organic anion transports (OAT) 1, 3, and 4 were capable of dimesna uptake, supporting 
previous observations (Ormstad & Uehara, 1982; Ormstad et al., 1983; Verschraagen et 
al., 2004a). Kinetic analysis of these transporters suggested they are clinically relevant 
given the high doses of mesna and dimesna administered during chemotherapy. Efflux 
transporters breast cancer resistance protein (BCRP), multidrug and toxin extrusion 1 
(MATE1), multidrug resistance proteins MRP1, MRP2, MRP4, MRP5, and P-
glycoprotein (Pgp) significantly reduced dimesna accumulation. Apical renal transporters 
MATE1, MRP2, and Pgp were also capable of mesna efflux. Within the proximal tubule, 
therefore, dimesna may undergo reabsorption from the lumen by apically expressed 
OAT4 and, following intracellular reduction, re-secretion as mesna by MATE1, MRP2, 
and Pgp. This pathway accounts for the previously hypothesized activation of dimesna to 
mesna by renal epithelia (Ormstad & Uehara, 1982). Additionally, basolateral uptake 
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transporters OAT1 and OAT3 in concert with apically expressed efflux transporters 
MATE1, MRP2, MRP4, and Pgp represent novel pathways of dimesna and mesna 
transcellular secretion and potential mechanisms by which renal clearance of total mesna 
exceeds GFR. 
The clinical relevance of our findings was highlighted by a controlled drug 
interaction study with probenecid in which inhibition of renal drug transporters 
significantly reduced both renal clearance and volume of distribution of mesna moieties, 
leading to a significantly decreased rate of urine excretion and subsequent increase in 
plasma exposure. The identification of mesna and dimesna transporters provides 
mechanisms by which genetic variability or drug-drug interactions may decrease the 
efficacy of these chemoprotectants, increasing the risk of ifosfamide- and cisplatin-
induced toxicities and consequent reduction in cancer therapy. 
 As outlined in the discussion of chapter two, a number of functional 
polymorphisms exist for many of the renal transporters indentified. The significance of 
these polymorphisms, particularly in combinations of uptake and efflux transporters, can 
be tested by site-directed mutagenesis of wild-type clones previously screened using our 
heterologous expression system.  
Fruitful in vitro results may lead to clinical study of total mesna pharmacokinetics 
of subjects stratified by genotype. It should be noted, however, that the frequencies of 
functional polymorphisms of renal drug transporters of interest are often very low, even 
within specific ethic ancestries (Bleasby et al., 2005; Erdman et al., 2006; Fujita et al., 
2005; Shima et al., 2010). MRP2 SNPs -24C>T and -1019A>G are an exception; with 
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frequencies of 0.15 to 0.19 and 0.54, respectively, in Caucasians (de Jong et al., 2007; 
Rau et al., 2006). 
Diuretics are commonly administered with intravenous hydration to mitigate 
urinary tract irritation during ifosfamide and cisplatin chemotherapies (Hensley et al., 
2008; Hogle, 2007). However, like dimesna, many loop diuretics (e.g. furosemide, 
torsemide) are substrates of OATs and their renal clearance and subsequent 
pharmacodynamics are therefore mediated predominantly by transporter-facilitated 
secretion (Vallon et al., 2008; Vormfelde et al., 2006). Whether co-administration of loop 
diuretics decreases mesna secretion could be assessed by urine collection during 
chemotherapy in a non-invasive observational study. Ultimately, a balance between 
adequate cytotoxic metabolite conjugation by mesna and dilution by diuretics must be 
determined to optimize patient outcome. 
 Clinically, our results demonstrate OATs contribute significantly to the 
pharmacokinetics of total mesna. Given the highly conserved nature these genes, the 
contribution of OATs to the pharmacodynamics of mesna and dimesna can be tested 
using knock-out animal models. The clearance and pharmacodynamics of diuretics have 
similarly been tested using Oat1-/- and Oat3-/- mice (Vallon et al., 2008). Comparison of 
biochemical markers of nephrotoxicity (e.g. blood urea nitrogen, kidney injury molecule-
1 mRNA, micro-hematuria) and histology of wild-type and knock-out mice receiving 
mesna with ifosfamide or dimesna with cisplatin may demonstrate the importance of Oats 
in chemoprotection. 
One of the most interesting pharmacokinetic findings following probenecid 
dosing was the decrease in the volume of distribution of total mesna. This may be due to 
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prevention of distribution within the kidney, necessitating the existence of basolateral 
efflux transporter(s) to facilitate distribution between kidney parenchyma and blood 
volume. However, our initial screen of efflux transporters included only those expressed 
at the apical membrane of the proximal tubule. Basolaterally expressed efflux 
transporters MRP3 and MRP6 are ideal candidates to facilitate the reabsorption of mesna, 
providing a mechanism of dimesna reduction during passage through the kidney (van de 
Water et al., 2005). Cloning these transporters will enable future screening of their 
dimesna transport capacity. 
5.1.2 Enzymatic and Non-Enzymatic Mechanisms of Dimesna Metabolism 
The flux of mesna moieties between sulfhydryl (mesna) and disulfides (e.g. 
dimesna, mesna-GSH) allows for nephro- and uroprotection without attenuation of anti-
cancer efficacy (Brock et al., 1981a; Verschraagen et al., 2003). Dimesna had previously 
been shown to undergo GSH- and Cys-mediated reduction (Shanmugarajah et al., 2009; 
Verschraagen et al., 2004b). In chapter three we provide evidence of non-enzymatic 
reduction of dimesna via bimolecular nucleophilic thiol-disulfide exchange with thiols 
GSH and Cys. Similar to other endogenous and therapeutic thiols, the redox potential of 
mesna/dimesna favours oxidation to the more stable disulfide species dimesna (Jocelyn, 
1972; Millis et al., 1993). Detailed kinetic analysis of reactions of Cys with dimesna and 
GSH with dimesna revealed initial rapid reduction of dimesna by Cys, but an equilibrium 
constant favouring dimesna over CySSyC. In contrast, the initial formation of mesna-
GSH disulfide was slower than that of cysteine; however, oxidized glutathione was a 
more favoured product, increasing the relative concentration of mesna at equilibrium. 
Thus, despite micromolar concentrations of thiols available to reduce dimesna in the 
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plasma, the presence of cysteine at concentrations 100-fold greater than glutathione 
facilitate the existence of dimesna as the predominant species in plasma. 
Similar to endogenous disulfides, dimesna may also undergo enzyme-catalyzed 
reduction by the thioredoxin and glutaredoxin systems. Our work clearly demonstrates a 
dose-dependent increase in enzymatic activity of the thioredoxin system in the presence 
of dimesna, confirming a prior report of the systems possible involvement (Verschraagen 
et al., 2004b). No activity of the glutaredoxin system was observed in the presence of 
dimesna alone. However, addition of reduced GSH significantly increased enzymatic 
activity. This has been hypothesized to occur via the formation of glutathione-mesna 
mixed disulfide and subsequent reduction by the γ-glutamylcysteine-specific active site 
of glutaredoxin (Meister & Anderson, 1983; Verschraagen et al., 2004b). This hypothesis 
may be directly tested by addition of custom synthesized glutathione-mesna disulfide to 
the glutaredoxin system. Additionally, and perhaps more simply, the presence of mixed 
disulfide species in reaction mixtures may be quantified by liquid chromatography-mass 
spectrometry (LC-MS). Use of LC-MS will also serve to confirm concentrations of 
therapeutically important mixed disulfide mesna metabolites predicted by modeling of 
thiol-disulfide exchange reactions. 
In addition to the formation of low molecular-weight disulfides, mesna also 
readily exchanges with endogenous thiols bound to Cys34-albumin. Previous work by our 
laboratory has shown that the thiol-disulfide exchange of mesna with Cys34-albumin can 
be used to increase the free fraction of plasma total homocysteine (tHcy) (Urquhart et al., 
2006). Homocysteine is a graded, independent risk factor the atherosclerosis and 
subsequent cardiovascular disease (Chao et al., 1999; Graham et al., 1997; Nygard et al., 
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1997; Wald et al., 2002). The standard treatment for hyperhomocysteinemia (plasma 
tHcy > 15 µmol/L) is oral supplementation of the vitamin cofactors of homocysteine 
metabolism; pyridoxine, folic acid, and vitamin B12. This treatment can successfully 
lower tHcy concentrations in the vast majority of patients with normal renal function 
(Ubbink et al., 1993; Ubbink et al., 1994). Amongst those with diminished renal function 
however, oral vitamin supplementation has had limited success (Bostom et al., 1995; 
Bostom et al., 1996; Elian & Hoffer, 2002; House & Donnelly, 1999; Spence et al., 
1999). 
The use of thiol exchange agents to increase the free fraction of tHcy and thereby 
increase its dialytic clearance represents an alternative approach to the treatment of 
hyperhomocysteinemia in end-stage renal disease (ESRD). The results outlined in chapter 
three provide a mechanistic explanation of mesna’s greater reduction of CySSyC and 
homocystine than oxidized glutathione (GSSG) in vitro (Pendyala et al., 2000), and 
clinical observations of dramatic Cys and Hcy depletion with only a modest decline in 
GSH during mesna therapy (Pendyala et al., 2000; Lauterburg et al., 1994; Stofer-Vogel 
et al., 1993; Smith et al., 2003). The calculated redox potential of dimesna/mesna further 
supports the development of mesna as a therapeutic thiol exchange agent for lowering 
tHcy without depletion of the endogenous antioxidant GSH. 
5.1.3 Mesna for the Treatment of Hyperhomocysteinemia in Hemodialysis Patients 
Our laboratory has previously demonstrated that a single, predialysis, 5 mg/kg 
intravenous bolus of mesna can significantly increase the dialytic clearance of tHcy 
(Urquhart et al., 2007b). In addition, plasma tHcy remained significantly lower two days 
after mesna administration. Despite these initial positive findings, prolonged 
243 
 
administration of 5 mg/kg mesna failed to normalize elevated plasma tHcy in a 
randomized, placebo-controlled trial (Urquhart et al., 2008). Similar to the progress of 
these initial studies, in chapter four we demonstrate that a dose of 12 mg/kg had a 
significant tHcy-lowering effect at one week, but no effect following four weeks of 
treatment. 
This apparent loss of efficacy may be explained by a change in equilibrium of 
plasma thiols in the presence of mesna at steady-state dosing. With successive doses of 
mesna, fewer Hcy-Cys34-albumin sites are available for thiol exchange. Free, sulfhydryl 
Hcy may then be sequestered to plasma protein non-specifically, preventing its dialytic 
clearance. This alteration in protein binding at equilibrium can be evaluated in future 
studies using our established in vitro thiol exchange assay by ‘preloading’ of uremic 
plasma with mesna (Urquhart et al., 2006). 
Results of our in vivo drug interaction study in subject with normal renal 
functions suggest mesna moieties are in flux between the total body water and kidney 
parenchyma. Coupled with its reductive capacity, this suggests the kidney may contribute 
to the maintenance of the sulfhydryl mesna fraction of total mesna within the plasma. 
Thus, the presence of functional renal transporters enables more efficient, continuous, 
thiol exchange. Studies evaluating the activity of organic anion transporters of uremic 
rats suggests renal transporter function may be impaired in chronic renal failure (Aoyama 
et al., 2003; Deguchi et al., 2004; Ji et al., 2002). Whether the function of these 
transporters is impaired in chronic renal failure or essential to the equilibrium of mesna 
and dimesna within the plasma remains to be determined. 
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The efficacy of thiol exchange to lower tHcy by increasing its clearance may also 
be attenuated by a concurrent increase in production. Plasma tHcy concentrations are 
tightly controlled by negative feedback via the reversible enzyme S-adenosyl-
homocysteine hydrolase (SAHH) (Perna et al., 1995; Perna et al., 2001). Its substrate, S-
adenosyl-homocysteine is a potent, competitive inhibitor of S-adenosylmethionine 
mediated methylation, resulting in a decrease in Hcy production and cellular methylation 
status. Prior work by our laboratory has shown decreased export of Hcy by erythrocytes 
and peripheral-blood mononuclear cells (PBMCs) isolated from patients with ESRD 
(Cutler et al., 2006; Urquhart et al., 2002). Alleviation of hyperhomocysteinemia by 
increased clearance may result in improved methylation status and compensation of Hcy 
production, until the rate of Hcy removal is at equilibrium with transmethylation. Thus, it 
is possible that the increased Hcy clearance provided by doses of mesna used thus far 
have yet to correct the methylation status of cells, and subsequently normalize plasma 
tHcy. Future, short-term dose-escalation studies of mesna may benefit from monitoring 
PBMC methylation status as an indicator of long-term efficacy. 
The etiology of hyperhomocysteinemia in ESRD remains to be determined. Many 
studies point to a decline in metabolic clearance as the cause.  Although plasma tHcy is 
inversely correlated to glomerular filtration rate, less than 1% of Hcy is excreted and no 
loss of plasma tHcy is seen between arterial and venous blood flow through the kidney 
(van Guldener et al., 1998).  Homocysteine loading in dialysis patients produced an area 
under the concentration-time curve (AUC) that was four-fold greater than healthy 
controls (Guttormsen et al., 1997).  This suggests extra-renal inhibition of Hcy 
metabolism as the cause of hyperhomocysteinemia in ESRD. An eloquent study by Stam 
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et al. using a stable isotope of methionine demonstrated that re-methylation and 
transsulfuration pathways of Hcy catabolism are 28% and 26% lower than healthy 
controls, respectively (Stam et al., 2004). 
Mesna has been shown to effectively lower plasma tHcy in dialysis patients by a 
mechanism independent of B12 status and may provide an important adjunct to vitamin 
therapy for the normalization of plasma tHcy (Urquhart et al., 2007b). A number of 
groups have reported the ability of pharmacological parenteral vitamin B12 doses to 
significantly lower plasma tHcy concentrations in most dialysis patients (Elian & Hoffer, 
2002; Hoffer et al., 2000; Hoffer & Elian, 2004; Kaplan et al., 2001; Obeid et al., 2005; 
Sombolos et al., 2002). Administration of parenteral doses of B12 and oral vitamins to 
provide the necessary cofactors to restore Hcy re-methylation, combined with mesna 
during hemodialysis to increase Hcy excretion, may effectively normalize elevated tHcy 
in ESRD. 
 
5.2 Conclusions 
 The unique pharmacological properties of mesna and dimesna have led to their 
continued development for new therapeutic uses over the past 45 years. The remarkable 
chemoprotection provided by mesna and its prodrug and primary metabolite, dimesna, 
without detriment to the efficacy of chemotherapy can be attributed to the redox 
equilibrium and differential transport of these drugs. Recent work by our laboratory has 
further expanded the application of mesna for the lowering of a known risk factor of 
atherosclerosis and thrombosis in ESRD with the hope of eventually improving patient 
outcome.
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